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General introduction 
Colorectal cancer (CRC) is one of the most common cancer types worldwide1. 
In Europe 436.000 new CRC cases were diagnosed and 212.000 patients died 
of this disease in 20082. CRC occurs sporadically (70%), in families (25%) and 
as the inherited colon cancer syndromes Lynch syndrome/Hereditary Non-
Polyposis Colon Cancer (HNPCC), Familial Adenomatous Polyposis (FAP) and 
MUTYH-associated polyposis in approximately 5% of cases3.  
CRC can be treated and often cured by surgery when localized to the 
submucosa or muscularis propria of the bowel (stage I)1. Importantly, stage II 
CRC patients (cancer progressed into subserosa or perforating the visceral 
peritoneum) undergo surgery alone, despite the recognition that a subgroup 
with a poor prognosis would probably benefit from adjuvant chemotherapy. 
Within stage III (lymph node metastases) and stage IV (distant organ 
metastases) CRC, adjuvant chemotherapeutic drugs such as fluoropyrimidines, 
irinotecan and oxaliplatin are now used as part of standard care and have been 
shown to improve survival significantly4. Although the anatomical based staging 
system predicts the survival accurately, variation in the course of the disease 
and response to treatment among individuals within the same stage exists. 
Emerging understanding of the underlying biology of CRC is expected to 
identify tumor specific molecular markers that improve risk assessment and 
therapeutic options within different stages of CRC5. 
The last decades, comprehensive analysis of the CRC (epi)genome has 
provided novel information on the biology underlying CRC carcinogenesis. 
These studies revealed that cancer cells have acquired genomic instability, 
enabling limitless replicative potential, tissue invasion and metastasis, 
sustained angiogenesis, evasion of apoptosis, self-sufficiency in growth signals 
and insensitivity to anti-growth signaling6-8. The underlying cause of these so-
called hallmarks of cancer are genetic and epigenetic alterations which can be 
subdivided in CRC into three categories: chromosomal instability (CIN), 
microsatellite instability (MSI) and CpG island methylator phenotype (CIMP)9-13. 
CIN is characterised by numerical and/or structural chromosomal 
abnormalities, increased rate of loss of heterozygosity (LOH) and mutations in 
the tumor suppressor genes adenomatous polyposis coli (APC), v-Ki-ras2 
Kirsten rat sarcoma viral oncogene homolog (KRAS) and tumor protein p53 
(TP53)12-14. MSI results from inactivation of the mismatch repair (MMR) system, 
caused by germline mutations in MMR genes mutS homolog 2, colon cancer, 
nonpolyposis type 1 (E. coli) (MSH2), mutS homolog 6 (E. coli) (MSH6) and 
PMS2 postmeiotic segregation increased 2 (S. cerevisiae) (PMS2) in Lynch 
syndrome/HNPCC15 and promoter CpG island methylation of mutL homolog1, 
colon cancer, nonpolyposis type 2 (E.Coli) (MLH1) in sporadic colorectal 
cancer16. CIMP CRCs are characterized by frequent promoter CpG island 
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methylation and subsequent silencing of tumor suppressor genes and DNA 
repair genes and are associated with MSI and v-raf murine sarcoma viral 
oncogene homolog B1 (BRAF) mutations17-19. CRCs are hypothesized to 
develop through one of the three routes: CIN, MSI or CIMP, eventually 
resulting in the inactivation of tumor suppressor genes and activation of 
oncogenes and thereby achieving the hallmarks of cancer16,20. This illustrates 
that CRC is a heterogeneous disease consisting of subgroups with a different 
biology and each subgroup of CRC is associated with more or less specific 
morphological features. For example MSI, BRAF mutated and CIMP CRCs are 
associated with a serrated and/or mucinous morphology21,22, whereas the 
presence of dirty necrosis in malignant glandular lumina is negatively 
correlated with MSI and thought to be primarily present in CRCs with a high 
frequency of APC en TP53 mutations (CIN pathway)23.  
Increased proliferation, which is one of the hallmarks of cancer cells, especially 
at a stage that the tumor has grown beyond a size that can be fed by the 
surrounding micro-vessels, induces hypoxia8,24. Hypoxia is defined as an 
oxygen tension below the physiological level, and occurs frequently in solid 
tumors25. In CRC, the importance of hypoxia has been demonstrated by clinical 
studies in which hypoxia predicts for worse outcome and resistance to 
chemotherapy and radiotherapy26,27. Understanding the underlying biology 
explaining how CRCs will adapt to a hypoxic environment will improve patient 
risk assessment and predict response to chemotherapy28. The coordinated 
cellular response to hypoxia that influences the pattern of gene expression is 
mediated by hypoxia-inducible factors (HIFs) and other cellular pathways such 
as translation regulation, microRNA induction and chromatin remodelling29,30. 
Furthermore, under chronic hypoxic conditions epigenetic changes occur, 
notably a genome-wide adjustment of promoter CpG island methylation, 
suggesting an adaptation to the altered environment thereby promoting and 
maintaining a hypoxia-adapted cellular phenotype, with a potential role in tumor 
development31. 
Regarding HIF’s, there are three homologues of the alpha subunit (HIF-1α, 
HIF-2α, HIF-3α)32. HIF-1α is the best understood isoform and together with 
HIF-2α, both transcription factors are thought to play a significant role in tumor 
neovascularization, enhanced cellular proliferation, decreased apoptosis, and 
development of resistance to chemotherapeutic agents30,33-35. Studying the 
physiology of tumor hypoxia also implies studying the downstream effects of 
HIF. These downstream effects are regulated amongst others by vascular 
endothelial growth factor (VEGF) involved in angiogenesis, glucose transporter 
1 (GLUT1) involved in glycolysis, carbonic anhydrase IX (CA9) regulation of 
pH, TP53 and BCL2/adenovirus E1B 19kDa interacting protein 3 (BNIP3) 
involved in regulation of apoptosis and autophagy36,37.  
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In understanding the mechanisms through which tumor hypoxia can induce a 
more aggressive phenotype, attention should be directed to both the epithelial 
and stromal tumor compartments. This is illustrated by a recent study in breast 
cancer showing that not only the epithelial compartment of the tumor, but also 
the stromal compartment, consisting of (myo)-fibroblasts, endothelial cells, 
smooth muscle cells, adipocytes, inflammatory cells and nerve cells, has 
undergone changes in gene expression. The most prominently altered genes 
included hypoxia-associated genes and this gene expression profile was 
associated with clinical outcome38. Hypoxia-driven cell biological and metabolic 
changes might alter the tumor stroma towards an environment that can 
facilitate cancer progression39. Cancer development depends upon changes in 
the interactions between epithelial cells and their surrounding stroma, leading 
to biological effects along several important pathways so-called “hallmarks of 
cancer”, that collectively constitute malignant growth8. Studying these biological 
processes and correlate it with patient outcome, will besides a better 
understanding of the underlying tumor biology, identify molecular markers that 
could improve therapeutic options within CRC, additional to the traditional 
staging method. 
Aim and outline of thesis 
The identification of prognostic markers for CRC, to determine risk profile and 
to identify patients that need adjuvant therapy respectively, is urgently needed. 
The practice of medicine could benefit from integration of genomic and 
epigenomic information from both the tumor and stroma, to accurately 
determine prognosis and select the best therapies for the longest durable 
responses and the lowest likehood of toxicity.  
The aim of this thesis was to study genetic and epigenetic alterations in relation 
to morphological features and hypoxia in CRC, providing insight in the 
underlying biology of this cancer and possibly yielding relevant novel 
prognostic information. Chapter 2 reviews the current knowledge on the 
epidemiology, diagnosis, treatment and the prognostic and predictive value of 
(epi)genetic markers in CRC. In chapter 3 we classified CRC by computer 
assisted unsupervised hierarchical clustering, based on key genetic and 
epigenetic events in CRC including: CIMP, MSI, and APC-, KRAS-, TP53-, and 
BRAF mutation status, in a series of 160 CRC cases. Subsequently, we 
investigated whether these molecular clusters are associated with 
morphological features, patient characteristics and prognosis. In addition, we 
evaluated the prognostic significance of promoter CpG island methylation of a 
variety of tumor suppressor- and DNA repair genes in CRC patients treated 
with surgery alone, taking into account MSI, BRAF and KRAS mutations 
(chapter 4). Chapter 5 summarizes the current evidence of altered CHFR 
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expression in cancer and discusses its promising role as a prognostic and 
predictive biomarker.  
Promoter CpG island methylation and associated gene expression alterations, 
has been reported to play a role in hypoxia. In chapter 6 we studied the 
baseline protein expression of four hypoxia induced markers (hypoxia-inducible 
factor (HIF)-1α, HIF-2α, carbonic anhydrase 9 (CA9) and glucose transporter 1 
(GLUT1)), in both the epithelial and stromal compartment of CRC’s, and 
evaluated their association with clinicopathological parameters. In chapter 7, 
we investigated whether hypoxia in CRC is related to promoter CpG island 
methylation of a series of genes frequently and functionally methylated 
hallmark of cancer genes. Understanding the mechanisms by which hypoxic 
tumors can overcome cell death signals (one of the hallmarks of cancer) and 
adapt is critical for our understanding of tumor progression and development of 
effective therapeutics in CRC patients with adverse prognostic profiles. 
Therefore in chapter 8, we attempt to elucidate whether changes in the 
epithelial cell compartment of CRC, such as apoptosis and concomitant 
(epi)genetic changes, are related to hypoxia-related changes in the stromal 
compartment. For this purpose, we correlated alterations of TP53 and BNIP3 in 
tumor cells with expression of hypoxia-related proteins HIF-2α and CA9 in 
relation with patient outcome and apoptotic activity in CRCs. Chapter 9 
discusses the major findings and potential clinical applications of our research. 
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Abstract 
Despite therapeutic innovations and increasing education on lifestyle to prevent colorectal cancer 
(CRC), it is still one of the most common cancer types, and for men the second cause of cancer 
death. Lately, much attention has been given to identify molecular markers involved in CRC 
prognosis and treatment with the aim to develop a more accurate classification system based on 
(epi)genetic alterations and, in addition, find markers that could potentially enhance management 
of CRC by predicting treatment response in advance. Although many genetic markers have been 
claimed to have prognostic or predictive influence, results are often inconclusive and, with some 
exception, they are not used in standard practice. Epigenetic alterations have received less 
attention although they are probably even more interesting as they can potentially be reversed 
through drug treatment. This review describes the current knowledge on the prognostic and 
predictive value of genetic, and especially epigenetic markers in CRC. 
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Introduction 
Colorectal cancer (CRC) is one of the most common cancer types worldwide, 
with annual incidence rates of 401,000 in men and 381,000 in women. Both 
environmental and (epi)genetic factors play important roles in CRC aetiology. 
Most CRCs are thought to develop from precursor lesions (adenomas) which 
can readily be detected and removed by use of endoscopic techniques. The 
majority of CRCs are sporadic carcinomas, although a small percentage (<5%) 
are due to well-defined inherited syndromes such as familial adenomatous 
polyposis (FAP) and hereditary non-polyposis colon cancer (HNPCC), currently 
designated as Lynch syndrome. CRC prognosis and treatment are strongly 
related to the extent of tumor spread, which makes accurate staging highly 
important. At this moment, the tumor-node-metastasis (TNM) system is the 
main tool to provide information on prognosis and to determine treatment 
protocols1,2. However, there is considerable variation in the course of the 
disease and the treatment response among individuals within the same stage.  
In recent years, increasing attention has been given to the potential prognostic 
significance of (epi)genetic markers implicated in CRC, but results of studies 
are contradictory1, mainly due to methodological differences and a lack of 
standardization2. In addition to the impact of molecular markers on prognosis, 
studies have also focussed on the use of molecular markers to predict or 
influence treatment outcome. Although some markers seem promising, overall 
results are inconclusive and further studies are necessary before predictive 
markers can be used to influence therapeutic decisions in daily practice. A 
clear distinction should be made between molecular markers that act as 
independent prognostic markers and markers that can predict treatment 
outcome. A biomarker can only be considered as an independent prognostic 
marker if it adds additional information regarding the prognosis to clinical 
characteristics such as TNM-stage and differentiation grade and does not act 
as an intermediate factor between clinical prognostic factors and outcome3. In 
addition, to correctly assess whether a biomarker is an independent prognostic 
factor, it should preferably be studied in an untreated population because 
treatment is a strong prognostic factor that may bias study results. 
Colorectal cancer & prognosis 
Epidemiology 
CRC is the fourth most common cancer type worldwide. It is estimated that 
783,000 new cases are diagnosed each year; a number that has increased 
rapidly since 19754. Fewer than 20% of cases occur before the age of 50, and 
the disease affects men and women almost equally 5. 
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As many as 70% of CRCs are estimated to develop due to environmental or 
lifestyle factors. Theoretically, a large number of cases are therefore avoidable. 
A recent report on diet and cancer concluded that intake of red meat, 
processed meat, alcohol, body fatness (especially abdominal fat) adult attained 
height and low levels of physical activity are convincing risk factors for CRC. 
Intake of calcium and foods containing dietary fibre probably reduces CRC risk. 
There is only limited evidence for the protective effects of intake of fruits, non-
starchy vegetables, and fish; foods containing folate, selenium and vitamin D; 
and for the detrimental effects of cheese and foods containing iron, animal fats 
and sugars6.  
Large survival differences are observed between CRC patients, even between 
patients within a similar disease stage. For men it is the second most common 
cause of cancer death in the European Union5. Five year survival of the 
disease is 90% if it is diagnosed while still localized, but this drops to only 68% 
for regional disease with lymph node involvement and to only 10% if distant 
metastases are present7. 
Clinical diagnosis  
CRC can take many years to develop. Early detection of CRC greatly improves 
the prognosis, however, first symptoms are usually vague, like weight loss and 
fatigue. Local (bowel) symptoms including constipation or diarrhea and bloody 
stools or rectal bleeding are rare and only occur when the tumor has already 
grown to a considerable size.  
Colonoscopy is the golden standard for routine detection of CRC8. It allows for 
the direct inspection of the colorectal mucosa and biopsy sampling or definitive 
treatment by polypectomy during the same session9. Several CRC screening 
options are available. These can be subdivided into two categories: (1) 
structural examinations, which include flexible sigmoidoscopy, colonoscopy, 
double-contrast barium enema, and computed tomographic colonography and 
(2) stool tests, which include tests for occult blood or exfoliated DNA.  
 
Molecular knowledge provides a basis for new screening methods that test 
stool for the presence of DNA alterations that are common in CRC. At present, 
one commercially stool DNA test (sDNA) is available that includes 21 separate 
point mutations in genes commonly mutated in CRC and a marker of DNA 
integrity analysis10. However, additional research is necessary to further 
improve this method11. Molecular testing could also be useful to determine 
CRC risk (e.g. methylation of the SFRP2 gene)12,13. 
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Pathological diagnosis  
CRC is classified according to the WHO histological classification system which 
makes a subdivision into several histological subtypes: mucinous and signet 
ring cell adenocarcinomas, adenosquamous carcinomas, medullary 
carcinomas and undifferentiated carcinomas14.  
The TNM system, as defined by the UICC (International Union against Cancer, 
together with the American Joint Committee on Cancer), is most commonly 
used for pathological staging in routine medical practice15 and is the most 
important prognostic factor at the moment. Increasing depth of bowel wall 
invasion is reflected in the T stage, a scale of T1 (invasion of submucosal 
layer) to T4 (serosal penetration/invasion of adjacent organs). Based on the 
combination of T stage, lymph nodes involved (N) and presence of distant 
metastasis (M), CRCs are grouped in stages from I to IV, with stage I having a 
90% 5-year survival, compared to stage IV having a 5-8% 5-year survival.  
Genetics of colorectal cancer 
Apart from traditional histological classification of CRC, increased cancer 
biology knowledge has led to the idea of classifying CRCs according to 
(epi)genetic aberrations. CRC is a genetic disease in which accumulation of 
mutations in oncogenes and tumor suppressor genes plays an important role. 
In 1990, Fearon and Vogelstein proposed a model for CRC that describes the 
transition from early adenomas to carcinomas as a consequence of a growing 
number of somatic mutations in oncogenes and tumor suppressor genes16,17. In 
the adenoma-carcinoma sequence, several well-described genetic aberrations 
are described, such as APC, KRAS and TP5318-20. Most mutations in APC 
result in a truncated APC protein21 and are considered to occur early in CRC22. 
Loss-of-function mutations in APC result in nuclear β-catenin accumulation, a 
key component of the Wnt signaling transduction pathway23, which modulates 
the expression of downstream Wnt target genes implicated in cell proliferation, 
migration, differentiation and apoptosis22. However, it is highly unlikely that 
these mutations alone are sufficient for the progression of adenomas24. 
Activating KRAS mutations, found in 40-50% of CRCs, abolish GTPase activity 
and as a result, the protein is locked in the active, GTP-bound state. This leads 
to increased and unregulated cellular proliferation and malignant 
transformation. TP53 can induce apoptosis or cell cycle arrest to correct 
occurring defects depending on the severity of the cell damage1. Loss-of-
function of TP53 is seen in approximately 50% of CRCs and is considered a 
late event during the disease17,25. Other common genetic defects implicated in 
colorectal carcinogenesis are BRAF mutations26, allelic loss of chromosome 
18q27, and alterations in DNA mismatch repair genes (MMR) Approximately 
10-15% of sporadic CRCs show defects in DNA MMR leading to an 
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accumulation of alterations in nucleotide repeat sequences; this is defined as 
microsatellite-instability (MSI)28. Most MSI CRCs are believed to arise mainly 
by epigenetic silencing of the MLH1 repair gene29 and are associated with 
specific tumor characteristics such as proximal location, diploid DNA content, 
abundant mucin secretion and poor differentiation28. Since the proposition of 
the adenoma-carcinoma sequence, other aberrations frequently seen in CRC 
have been described and the Fearon and Vogelstein model is constantly being 
modified to take into account these alternative pathways to CRC24,30. However 
only a small proportion of genes has been analyzed and the number of genetic 
alterations that are responsible for the development of CRC is still unknown31.  
Cancer Candidate Genes (CAN) in colorectal cancer 
The recent determination of the human genome sequence provided the 
possibility to examine the cancer genome unbiased by systematically screening 
genetic alterations in cancer instead of focusing on single candidate genes as 
has been the approach until recently. This has led to the identification of a 
panel of cancer candidate genes (CAN genes)31. CAN genes are most likely to 
be involved in the neoplastic process and are therefore interesting for further 
study32. Strikingly, mutation frequencies in the CAN genes were relatively low, 
in the range of 5-15%31. The majority were heterozygous missense mutations 
(81%): 59% of which were C:G to G:C transitions. Moreover, a large part of the 
mutations (44%) were found at 5’-CpG-3’dinucleotides31. There was also 
considerable heterogeneity between mutations from different specimens 
derived from the same tissue. This suggests that single gene alterations reflect 
only a small part of the tumor mutational spectrum. This could perhaps explain 
why it has proven to be difficult to find associations between a single gene 
mutation and prognosis or therapy response31. It also confirms the idea that 
pathways rather than individually mutated genes are responsible for the course 
of tumorigenesis33. Indeed, many mutated CAN genes are involved in 
phosphatidylinositol 3-kinase (PI3K) signaling or in pathways related to cell 
adhesion32.  
Genetic markers and CRC prognosis 
The majority of CRC, about 85%, are characterized by chromosomal instability 
(CIN) which is associated with microsatellite stability (MSS), aneuploidy and 
genetic alterations in genes such as KRAS, APC and TP5334. A recent meta-
analysis suggested a poorer prognosis for CIN tumors, irrespective of 
anatomical location or treatment with chemotherapy35. Because of this, CIN 
could be useful for further stratification after standard pathological staging35. 
Nevertheless, individual study results on the prognostic influence of CIN are 
inconsistent and the 2006 American Society of Clinical Oncology (ASCO) 
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guidelines state that measuring CIN in CRC is nothing more than an 
experimental tool35,36. Indeed, the question remains whether it is really the 
effect of CIN that has been measured in previous studies. Individual genetic 
alterations could possibly act as markers for CIN35. In a number of studies, 
KRAS has been associated with a poorer prognosis, independent of other 
prognostic characteristic such as tumor stage in a number of studies. However, 
other studies were not able to replicate this finding and therefore the clinical 
relevance of these findings is still unclear1,3,37,38. Similarly, inactivation of TP53 
and mutations in BRAF have been associated with a poorer prognosis, but not 
consistently1,3,38-40. Previous studies also suggested that loss of chromosome 
18q is associated with a poor survival in stage II and stage III patients41,42. Gain 
of chromosome 20q has also been associated with a worse patients survival43 
In addition, aneuploid or tetraploid DNA content has been associated with a 
higher tumor stage and distal tumor location44, which are known to cause a 
poor prognosis.  
Other genetic markers not associated with CIN have also been suggested to 
play a role in CRC prognosis. Single Nucleotide Polymorphisms (SNPs) in the 
gene that codes for thymidylate synthase (TS) (TSER polymorphisms) results 
in reduced TS expression and have been associated with a reduced CRC 
risk45. Data on the prognostic role of these polymorphisms are inconsistent45-48 
and independency from tumor stage is only reported in one study46. Over 
expression of TGF-β in the primary tumor and in tumor associated-stroma has 
also been suggested as a prognostic factor in CRC, but results are scarce and 
for overexpression, independency from tumor stage was not reported3,49-51. 
Similarly, epidermal growth factor receptor (EGFR) expression has been 
studied in relation to prognosis, but results are inconsistent and an 
independency of tumor stage has not been proven; a clear relationship 
between EGFR expression and CRC prognosis has therefore not been 
established3,52.  
Although there are many more claims of prognostic significance of other 
genetic markers or gene expression in CRC, the question of which marker is 
strong enough to be applied in daily clinical practice remains unanswered 
because finding consistent associations between genetic markers and CRC 
prognosis has proven to be difficult. In addition, questions have arisen as to 
whether the progression and prognosis of CRC could be attributed to mutations 
alone. Because the frequency of mutations in the CAN genes is often low and 
the majority are missense mutations, it is likely that additional mechanisms 
contribute to tumor progression and prognosis.  
The role of epigenetics 
Epigenetic silencing is a prevalent mechanism that could lead to abnormal 
gene inactivation in cancer53. It has been suggested that aberrant promoter 
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CpG island hypermethylation leading to gene silencing also plays an important 
role in the neoplastic process, and molecular evidence of this concept has 
been accumulating since the late 1990s54,55. Epigenetic alterations may 
cooperate with genetic abnormalities to affect gene function, eventually leading 
to cancer56. Hypermethylation occurs when DNA methyltransferases (DNMTs) 
add a methyl group to cytosine to form methyl-cytosine. In humans, these 
epigenetic alterations include methylation of cytosine located in CpG-islands 
and may be tissue-specific55,57. Methylation within or around the promoter 
region is associated with gene silencing55. Methyl-cytosine-binding proteins and 
histone deacetylases are recruited to modify nucleosomes, forming 
transcriptionally repressive chromatin53. Traditionally, epigenetic events have 
primarily been investigated in classic tumor suppressor genes. In this setting, 
methylation acts as a “second genetic hit” to inactivate the gene53. However, 
more recently, Baylin and co-workers demonstrated that the majority of these 
genes show promoter CpG island hypermethylation in addition to the genetic 
alterations53,58. Most mutations found in the CAN genes were heterozygous 
missense mutations suggesting that these result in haploinsufficiency which is 
augmented by DNA methylation. In many cases involving tumor suppressor 
genes with low mutation rates, hypermethylation is a much more frequent event 
than genetic alterations. This implies that pathway analysis would show that 
CRCs are not that heterogeneous when both genetic and epigenetic alterations 
are taken into account53. 
 
So far, CRCs have been genetically categorized as either CIN or microsatellite 
instable (MIN). In addition to these two categories, a subset of CRCs, 
17%-29%59-61, with a high frequency of CpG-island methylation has recently 
been described as the CpG-island methylator phenotype (CIMP)59,62-64. 
However, the existence of CIMP and role of CIMP in CRC carcinogenesis has 
been controversial, mainly due to lack of a generally accepted standard 
definition and the confounding role of MSI in determining the CIMP 
phenotype60,63,65. Tumors characterized by CIMP have been associated with 
BRAF mutations, older age, advanced tumor stage and proximal location26. 
CRCs with less extensive promoter methylation are proposed to be 
characterized by CIMP-L (CIMP low) and it is hypothesized that these tumors 
are different compared to CIMP-H (CIMP high)26,63. However, evidence is still 
scarce and this hypothesized distinction between CRCs based on the level of 
methylation needs further investigation and definition. The distinct molecular 
genotypes that have been described, CIMP, CIN and MIN, do not seem to be 
mutually exclusive and thus assessing a single molecular phenotype may not 
provide all relevant prognostic information35.  
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Epigenetic markers and CRC prognosis 
The CIMP panel according to Weisenberger et al.59 has been associated with 
poor survival in metastatic MSS CRCs66. However, the influence of this panel 
has not yet been assessed in other stages, and the use of this panel as a 
prognostic factor remains unresolved. One study reported an association 
between CIMP (although defined differently, namely using the panel p16INK4A, 
MINT2 or MDR1) and a worse prognosis among stage III patients treated with 
surgery alone67. In addition, the CIMP panel according to Toyota et al.62 was 
associated with worse survival in stage I-IV CRC patients68. This was not 
observed in another study69 suggesting that other epigenetic markers may be 
responsible for the association. As stated by Ogino and colleagues, additional 
studies are necessary to further examine the prognostic value of methylation 
markers among CRC patients in the different stages66.  
Recently, Chan and colleagues combined information on the methylation of the 
CAN genes with information from gene expression databases to gain more 
insight into the prognostic roles of these genes53. They analyzed eight genes 
that were predicted to have a decreased overall expression in CRC by the 
analysis of microarray data. Two of those genes (PTPRD and RET) were found 
to be associated with clinical characteristics such as metastasis and grade. 
However, a number of other CAN genes which were determined to not have 
altered expression levels related to DNA methylation, no associations with 
clinical characteristics were found53. These results have not yet been validated 
in other, independent populations.  
 
Despite the growing number of studies on molecular genotypes in CRC, many 
questions remain unresolved. For example, what is the prognostic relationship 
of the different genotypes? It is known that they are not mutually exclusive. MIN 
and CIMP appear to be associated, making the conclusion of whether either 
one is an independent prognostic factor even more difficult35. MSI-H has 
consistently been associated with better prognosis and decreased metastasis 
risk70-72, although this is often associated with high frequency of CpG island 
methylation. The presence and role of MSI-L (MSI low) remains controversial. 
Mutations often seen in MSI-H appear to be absent in MSI-L and until now, no 
large differences in clinical or molecular characteristics have been observed 
between MSI-L and MSS patients26. However, reports suggest that MSI-L is 
indeed a unique subtype of CRC which is associated with loss of O6-MGMT73 
and related to a poor prognosis in stage III CRC74. Ward et al. showed that 
DNA methylation in CIMP-associated genes was related to a poor outcome in 
CRC, but this adverse prognostic effect was lost within those methylated 
tumors showing MSI75. There seems to be considerable overlap between CIMP 
and MSI and it has been suggested that MSI-H has a major effect on the 
expression of CIMP60 although more recent results imply that MSI-H in 
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sporadic CRC can be explained by CIMP-H associated MLH1 methylation59. 
These results suggest that MMR deficiency in sporadic CRC is caused by a 
broad epigenetic control defect affecting MLH1 in most CIMP tumors; an 
accurate definition of CIMP could therefore be essential in understanding the 
role of MSI-H59.  
 
At this moment, reports in the literature are too limited to understand the 
interplay between CIN and MIN in CRC prognosis. MSI-H is consistently 
associated with a better prognosis in CRC, but the underlying explanation for 
this finding is not yet clear. It has been suggested that this is due to the fact 
that allelic loss or mutation of 18q, TP53, or KRAS, which are thought to be 
associated with a poor prognosis, are rare in MSI tumors70. However, a recent 
study on the relation between CIN and MIN concluded that the survival benefit 
in MSI-H patients was not dependent of CIN status35,44 thereby questioning this 
explanation. In addition, DNA diploidy seemed to be a stronger prognostic 
factor than MSI in patients treated with 5-FU, and the effect was similar in both 
MSI-H and MSS/MSI-L cases. This could indicate that diploidy may contribute 
to the often reported better survival in MSI-H patients44. Nevertheless, diploidy 
did not seem to be related to treatment response, suggesting that the less 
aggressive behavior of diploid tumors is not the result of a better treatment 
response44. 
Colorectal cancer treatment 
Due to therapeutic innovations, management of advanced CRC has changed 
considerably in recent years76. This has led to an increase in survival, although 
not substantially. The mainstay of treatment is surgery, with primary tumor, 
adjacent bowel and lymph nodes removal77. Although surgery may be 
performed for palliative symptom control in advanced cases, in most 
circumstances it is performed with curative intent. However, with an increasing 
tumor stage, the chance of cure by surgery decreases. For early-stage CRC 
(Stage I) only resection is required, without adjuvant therapy77. Stage III and IV 
CRC patients additionally receive adjuvant or palliative chemotherapy. The 
benefit of adjuvant 5-fluorouracil (5-FU) and leucovorin (LV) has been well 
established in stage III colon cancers, and is the current standard of care78. 
More recently, oxaliplatin-based chemotherapy, added to regimens containing 
5-FU/LV has been shown to further improve disease-free and overall survival in 
these patients79. Other cytostatic agents that have been introduced include 
DNA topoisomerase I inhibitors, such as irinotecan. 
For stage II CRCs, no survival benefit from postoperative chemotherapy in 
patients with standard risk has been shown in randomised clinical trials, but, 
despite the initially good prognosis, 20-30% of these patients will die from CRC 
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within 5 years. Unfavourable tumor features in stage II CRCs, such as serosal 
tumor penetration (T4), tumor perforation, and (extramural) lymphovascular 
invasion appear to be correlated with an increased risk for recurrence. These 
features may identify high-risk disease patients, who might benefit from 
postoperative therapy80. Previously, a survival benefit has been suggested for 
selected stage II tumors after adjuvant chemotherapy81.  
Recently, therapeutic strategies have also involved the use of humanized 
monoclonal antibodies, such as bevacizumab and cetuximab. Bevacizumab is 
a monoclonal antibody directed against vascular endothelial growth factor 
(VEGF); it improves the outcome of first-line chemotherapy (5-FU/LV)82. 
Cetuximab is a monoclonal antibody directed at the EGFR, and is thought to 
inhibit signal transduction through this pathway. It is added to chemotherapy 
with irinotecan (DNA topoisomerase I inhibitor)83. Recently, the European 
Medicine Agency licensed cetuximab and panitumumab, another EGFR-
targeted monoclonal antibody, only for patients with metastatic CRC without 
KRAS mutations after several reports showed an association between KRAS or 
BRAF mutations and clinical resistance to treatment with EGFR antibodies in 
metastatic CRC52,84-88. Nevertheless, even among wildtype KRAS CRC 
patients, response rates for EGFR antibodies are low, ranging from 17% (for 
EGFR antibody monotherapy) to 61% (for EGFR antibody therapy plus 
oxaliplatin-based chemotherapy). These observations suggest that other 
mechanisms are involved in therapy resistance. For example, TSER 
polymorphisms have been implicated as determinants of 5-FU treatment 
response, with several studies suggesting a poor response to chemotherapy 
with the 3R/3R genotype89-92 although others reported a better response with 
this genotype46,93. Other polymorphisms, such as those in MTHFR and GSTP1 
have also been related to treatment response in CRC, but evidence is still 
scarce and inconclusive94. 
Evidence for a role of MSI in predicting treatment outcome is also not 
conclusive. One study has shown that patients with MSI-H did not benefit from 
treatment with 5-FU but MSS or MSI-L tumors did seem to benefit from this 
treatment95. Another study was not able to replicate this finding and even 
observed an opposite effect in MSI-H tumors that had a greater benefit from 5-
FU96. With the current evidence, it is not yet possible to draw any conclusions 
regarding the question of whether MSI-H could be used as a predictive marker 
to distinguish patients that would benefit from 5-FU treatment or not. Given the 
molecular heterogeneity of the MSI genotype, it may be very difficult to use 
MSI-H as a single predictive marker for CRC treatment26. 
In addition to clinical response, pharmacogenetic studies have also focussed 
on the impact of genetic alterations on drug toxicity94,97. While these findings 
are interesting and have led to the first genetic test approved by the U.S. Food 
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and Drug Administration, the UGT1A1 test for the prediction of irinotecan 
toxicity, this topic is beyond the scope of this review.  
Implications of epigenetic markers in colorectal cancer treatment 
A critical difference can be made between gene silencing as a result of 
mutations or aberrant promoter methylation. While mutations are irreversible, 
epigenetic changes are potentially reversible and therefore present potential 
new opportunities for cancer treatment. Because of this, studies on epigenetic 
markers and the prediction of treatment response are gaining increasing 
attention. For example, loss of O6-MGMT function through hypermethylation is 
thought to sensitize cells to the effects of chemotherapy based on alkylating 
mechanisms, since cells have a diminished capacity to repair alkylation 
damage98. Early studies in brain tumors and lymphomas have indeed shown 
that patients with methylated O6-MGMT respond better to alkylation 
treatment55. In addition, over the last few years, new molecular techniques 
have been developed which allow researchers to more easily determine DNA 
methylation. Because of this, DNA-methylation-based technologies have a 
promising future in both clinical diagnostics and therapeutics99. However, 
results on pharmacoepigenomics are still scarce. 
CpG Island methylator phenotype 
The role of aberrant promoter methylation as a predictive marker for treatment 
response is inconsistent. Although not statistically significant, a trend towards 
resistance to chemotherapy among CIMP-H tumors has been observed66. 
Furthermore, patients with advanced CRC and hypermethylation of multiple 
genes, including CIMP-specific genes, have a poor outcome following standard 
5-FU-based chemotherapy100. However, these results could not be replicated 
by another study that showed contrasting data; a survival benefit for CIMP 
patients after 5-FU treatment67.  
Even though the number of studies on the predictive effect of molecular 
genotypes is slowly increasing, a conclusive answer to the question of whether 
they are predictive of treatment effect cannot be given at the moment. Further 
research is needed to resolve this issue. However, although the influence of 
molecular genotypes on treatment response is one of the main focuses of 
current research, other markers are potentially important for the future 
treatment of CRC. 
HDAC2 
Disruption of histone acetylation patterns is common in cancer cells and 
histone modifications that affect chromatin structure are implicated in the 
inactivation of tumor suppressor genes101,102. Recently, truncating mutations in 
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one of the human histone deacetylases, HDAC2, were described in cancer cell 
lines and CRCs with MSI102. Histone deacetylases maintain gene silencing 
through histone deacetylation55 and are potentially clinically relevant as they 
might be responsible for the response to HDAC inhibitors; drugs that show 
promising anticancer activities in clinical trials102,103. Indeed, a recent study 
reported that the presence of a truncating mutation in HDAC2 leads to a loss of 
protein expression and consequently more resistance to the antiproliferative 
and proapoptotic effects of HDAC inhibitors102. This report also suggested that 
HDAC2-deficiency confers resistance to TSA-induced histone acetylation, but 
this could not be confirmed by others104. Furthermore, it has been 
demonstrated that cells lacking HDAC2 are not able to induce APAF1, which 
appears to be the key to apoptosis induced by HDAC inhibitors105. These 
recent findings support the use of HDAC2 mutational status as a guide for the 
prescription of HDAC inhibitors in CRC. However, literature on this topic is still 
limited and more research on the potential use of HDAC2 as a marker in CRC 
is needed. 
Werner (WRN) 
Other epigenetic markers, such as those associated with metastasis, have 
been suggested to act as prognostic or predictive markers106. One of these is 
promoter CpG island methylation of the Werner syndrome gene (WRN), which 
has been associated with longer survival of patients treated with 
chemotherapy107. The WRN gene and its protein are involved in the 
maintenance of telomere structure and initiation of DNA damage response after 
telomere disruption108. As it was observed that patients with WRN germline 
mutations often develop epithelial or mesenchymal tumors, it was suggested 
that the WRN gene had a tumor-suppressor function107. It has been 
demonstrated that WRN is inactivated due to hypermethylation in human 
cancer cells. Inactivation of WRN leads to hypersensitivity to topoisomerase 
inhibitors, such as irinotecan which is often used in the treatment of CRC, and 
DNA-damaging agents107. Indeed, recent studies have observed an increased 
survival in patients with WRN methylation after treatment with a topoisomerase 
inhibitor107. In addition, WRN methylation appears to be associated with 
mucinous differentiation in colorectal tumors independent of MSI or CIMP108. 
Mucinous differentiation is also suggested to be associated with other 
molecular tumor characteristics, including MSI-H, BRAF mutations, KRAS 
mutations and loss of TP53108. This raises questions of whether WRN, in 
addition to its possible role as predictive marker for treatment response, could 
also have a prognostic influence in CRC. Moreover, the observation that WRN 
methylation is associated with increased survival in CRC after treatment with 
irinotecan needs further exploration and confirmation in other larger 
populations before this marker can be used.  
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CHFR 
Recently, CHFR was identified as a mitotic checkpoint gene, located on 
chromosome 12q24.33109. CHFR functions early in the G2/M transition and 
mediates a delay of entry into metaphase in response to mitotic stress induced 
by nocodazole or paclitaxel. CHFR functions as a tumor suppressor and 
several groups have demonstrated that CHFR expression is lost or decreased 
in most human cancers, mostly due to DNA promoter hypermethylation. 
Epigenetic loss of CHFR expression is however rare in primary breast 
cancer110,111. In endometrial and cervical cancer, it has been shown that DNA 
hypermethylation of CHFR predisposes cancer cells to a higher sensitivity to 
taxanes. Cell lines hypermethylated for CHFR with high sensitivity to taxanes 
became resistant after demethylation112,113. It has been suggested that CHFR 
methylation status could act as a new molecular index, allowing for the design 
of personalized treatment in endometrial cancer. In advanced gastric cancer 
however, CHFR hypermethylation is not consistently associated with response 
to docetaxel and paclitaxel, both of which are taxanes114,115. 
While taxanes are not used in the adjuvant treatment setting of CRC, because 
they failed to demonstrate a significant clinical benefit in phase II trials in 
CRC116, frequent hypermethylation of CHFR is detected in CRC. Approximately 
37% of all primary CRCs are hypermethylated for CHFR117,118, raising the 
possibility that CHFR methylation could be used in CRC to identify those 
patients who might benefit from taxanes. 
Although application of these molecular markers is not yet accepted in 
standard patient care, they serve as examples of a shifting paradigm, drawing 
on the notion that awareness of molecular alterations in tumors can be 
harnessed for more selective and effective treatment schedules. It is both 
conceivable and desirable that molecular profiling will more accurately identify 
those patients with a greater chance of benefitting from adjuvant treatment. 
These predictive molecular profiles will help define the best way to integrate 
chemotherapy with biology. 
Future perspectives 
Recently, increasing attention has been given to the role of genetic and 
epigenetic alterations in attempting to answer the question of which CRC 
patients should receive (adjuvant) treatment and which treatment is most 
suitable for an individual patient. Numerous studies have been published in the 
last decade discussing the influence of (epi)genetic markers on CRC prognosis 
and treatment outcome prediction.  
Although epigenetic alterations are heritable in somatic cells, they could 
potentially be reversed by drug treatment; a characteristic that is not shared by 
genetic alterations. This could have significant implications for the treatment of 
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CRC. The recent publications on the use of HDAC inhibitors in clinical trials 
yielding promising results, suggest that the use of epigenetic therapy is 
promising. In addition, epigenetic alterations are frequent in CRC, even more 
frequent than genetic alterations, and recent new molecular techniques enable 
researchers to easily assess methylation status and identify novel epigenetic 
markers. Because of this, it is conceivable that epigenetic markers will 
eventually have a high impact, maybe even higher than to genetic markers, on 
the management of CRC. 
 
Figure 2.1 provides an overview of the current knowledge on (epi)genetic 
markers discussed in this review and their role in prognosis and treatment 
prediction. A more extensive staging system based on (epi)genetic markers will 
have more impact on stage II and III patients, as it is often not clear which 
patients to treat or which treatment to prescribe to these patients. Although 
many studies have led to the overview in Figure 2.1, results are often 
inconsistent and many findings have not yet been replicated in other, 
independent populations. Because of this, it is difficult to draw definitive 
conclusions on the prognostic or predictive role of these (epi)genetic markers.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 Current knowledge on (epi)genetic markers and prognosis / prediction 
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High-throughput technologies and novel approaches 
In the last few years, an increasing number of molecular techniques to detect 
DNA methylation on a larger scale has been reported. Following the 
development of bisulfite sequencing119, rapid progress has been made in the 
characterization of the methylation state of individual cytosines. However, as 
this involves locus-specific amplification, it is challenging to use on a large 
scale120. Bisulfite-conversion based microarrays and high-throughput PCR 
sequencing approaches, and more recently, next-generation bisulfite 
sequencing121 have been developed in an attempt to use this approach on a 
larger scale. In 2002, Suzuki and colleagues described a new microarray-
approach122, a method which was recently adapted by Schuebel et al.53,58,122. 
This approach has proven to be successful in identifying genes silenced by 
hypermethylation which can subsequently be studied for prognostic influence 
as described by Chan and colleagues53. Methylated CpG island amplification 
(MCA) coupled with Representational Difference Analysis (RDA) has been 
described as a tool to identify methylation at multiple loci123. Alternatively, 
immunoprecipitation-based methods (ChIP) can be used for distinguishing 
between methylated and unmethylated fractions120,124,125. Other methods either 
use 5-methylcytosine-specific antibodies (methylated DNA immuno-
precipitation, MeDIP or MDIP) or methyl-binding domain proteins to enrich for 
the methylated fraction of the genome121. Indirect approaches for DNA 
methylation profiling on array platforms have also been developed which are 
based on the high affinity of some proteins to methylated DNA. This technique, 
the methylated-CpG island recovery assay (MIRA), has already been used in a 
genome-wide screen to identify DNA methylation markers125,126. Although many 
methylation-associated gene silencing events in human cancer have been 
studied, little is known about why some CpG islands are methylated in cancer 
whereas others seem resistant to this de novo methylation. In 2003, Feltus and 
colleagues described that not all CpG islands are equally affected127. Using 
DNA pattern recognition and supervised learning techniques, they obtained a 
classification function that could be used to distinguish CpG islands sensitive to 
methylation127. Other techniques also make use of a bioinformatics approach. 
In 2002, several tumor suppressor gene candidates in esophageal squamous 
cell carcinoma were identified using a technique based on functional 
reactivation of epigenetically silenced tumor suppressor genes by 5-aza-2’-
deoxycytidine and TSA in combination with an intuitive algorithm128. Recently, 
next generation sequencing technologies processing millions of sequence 
reads in parallel, have emerged as powerful tools for whole genome profiling of 
epigenetic modifications. Next generation sequencing technologies have 
successfully been combined with ChIP techniques (ChIP-seq)129. These 
studies demonstrate that different genome-wide approaches can successfully 
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be combined in order to gain more insight and knowledge on cancer 
epigenomics.  
Conclusion 
Recent innovations suggest that the current technology could indeed lead to 
the knowledge necessary to enable the implementation of epigenetic therapies 
in everyday practice. However, from a scientific point of view, many questions 
remain unresolved and although epigenetic alterations seem to be promising 
prognostic and predictive markers for CRC, some issues should be taken into 
account when assessing the clinical use of pharmaco(epi)genomics. Despite 
numerous studies on the relevance of molecular markers in oncology, the 
number of clinically useful markers is limited130. Research on molecular 
markers is susceptible to publication bias and false-positive results, due to 
small population sizes and small effect sizes131-133. Often, an initial study shows 
promising results that cannot be replicated in later studies130,131. Moreover, the 
majority of previous studies describe single molecular markers3, even though it 
is suggested that using an approach of combining several markers is more 
likely to identify relevant prognostic factors134. The available evidence on the 
prognostic or predictive influence of molecular markers is limited, even though 
this question has received much attention. It is likely that epigenetic alterations 
play a role in CRC prognosis or treatment response, however, it is not clear to 
what extent, and if this role is independent of other known prognostic factors, 
such as tumor stage. To answer these questions and to maximize the potential 
of the novel technologies, the American Association for Cancer Research 
Human Epigenome Task Force and the Scientific Advisory Board of the 
Epigenome Network of Excellence from the European Union recently urged the 
scientific community to collaborate and join the Alliance for the Human 
Epigenome and Disease (AHEAD) in order to help solve the problem of 
cancer135. AHEAD is aiming to define the patterns of epigenetic regulation 
occurring in different cell states and therefore complements other ongoing 
projects such as ENCODE that aim to define the functional sequences in the 
genome135.  
More research is necessary to assess the prognostic and predictive influence 
of epigenetic markers in CRC and consequently, to determine the clinical use 
of such findings. However, existing technologies provide us with the tools so 
that in time, we will be able to fill all the voids in our current understanding of 
pharmacoepigenomics in CRC and we will be capable to accurately answer the 
questions of which CRC patients are in need of a more aggressive treatment, 
and which treatment is most suitable for an individual patient.    
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Abstract 
The increasing knowledge of (epi)genetic alterations in CRC and the observed variation in the 
course of the disease within the same CRC stage, have led to the recognition that classifying 
CRCs on the basis of molecular events could improve traditional classification. In the current study 
we molecularly classified CRCs using computer assisted unsupervised hierarchical clustering of 
genetic and epigenetic alterations and correlated this with clinicopathological parameters. 
Genetic-(mutations in APC, KRAS, TP53, BRAF, and microsatellite instability), and epigenetic 
(CpG island methylator phenotype, CIMP) alterations were determined in 160 colorectal cancers. 
Morphologic features were refined by inventarisation of differentiation grade, mucinous 
differentiation, dirty necrosis, circumscribed tumour growth, tumour budding and lymphocyte 
infiltration. Unsupervised hierarchical clustering was used to cluster CRCs based on these 
molecular characteristics. Correlations between these clusters, morphology and outcome were 
investigated. 
Unsupervised hierarchical clustering divided CRC’s in CIMP+ (CL2, 22% (36/160)) and CIMP- 
tumors. The latter group could be further subdivided in TP53 mutated tumors (CL3, 37% (59/160)), 
and a group of CIMP- and TP53 wildtype tumors (CL1, 41% (65/160)). CL2 consisted of two 
subgroups of 29% (10/35) microsatellite instable (MSI) and 71% (25/35) microsatellite stable (MSS) 
tumors. There was no consistent relationship between these clusters and morphology, except for 
mucinous differentiation, which was related to right-sided CL2/MSI/TP53 wildtype tumors 
(p=0.023). There was no impact of computerized clustering on survival of CRC patients. In rectum 
tumors on the other hand, a poorer patient survival was noted for CL2 tumors as compared to CL3 
tumors (p=0.01). 
Molecular clustering of colorectal adenocarcinomas shows that CIMP status is the principal 
classifier, and that both CIMP+ and CIMP- tumors are further classified on the basis of TP53 
mutational status. Hierarchical clustering is only modestly related to morphology and outcome, 
which appear to be dependent on additional factors such as microsatellite stability and localization 
in the intestine. Although current molecular clustering provides knowledge in the underlying biology 
of CRC, it did not improve traditional classification with respect to prognostic value. 
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Introduction 
The increasing knowledge of molecular alterations in CRC and the observed 
variation in the course of the disease and treatment response within the same 
CRC stage, have led to the recognition that classifying CRCs on the basis of 
molecular events could improve traditional classification1-4. CRCs are currently 
classified according to traditional clinical and pathological features2. According 
to the WHO histological typing system, adenocarcinoma is by far the most 
prevalent diagnosis (>95%)5. Adenocarcinomas are graded predominantly on 
the basis of the extent of glandular formation, and are classified as low-grade 
(encompassing well and moderately differentiated adenocarcinomas) and high-
grade (including poorly differentiated adenocarcinomas and undifferentiated 
carcinomas)5,6. The tumor-node-metastasis (TNM) system7, as defined by the 
UICC (International Union against Cancer, together with the American Joint 
Committee on Cancer), is the most commonly used staging system, and 
constitutes the most important prognostic factor and adjuvant treatment 
indicator for patients with colorectal cancer in routine medical practice. 
However, this traditional mode of classifying CRC through typing, grading and 
staging does not account for tumor heterogeneity. Each CRC patient has a 
unique disease that has been caused by distinctive biology8,9. The presence or 
absence of specific molecular alterations could predict the response to targeted 
individualised therapy and overall prognosis in contrast to the traditional 
classification.  
The precise incidence and clinical presentation of molecularly defined profiles 
in CRC are subject to ongoing research. With respect to this, genetic instability 
and DNA methylation play a pivotal role. Well characterized forms of genetic 
instability are chromosomal instability (CIN) and microsatellite instability 
(MSI)10,11. CIN includes genetic events occurring through accumulation of 
numerical or structural chromosomal abnormalities (aneuploidy)12. The CIN 
pathway is associated with mutations in key genes involved in the adenoma-
carcinoma sequence of CRC: APC (85%), KRAS (40%) and the tumor 
suppressor gene TP53 (50%)12. MSI results from failure of the mismatch repair 
(MMR) system. In cases of sporadic colorectal cancer, MMR dysfunction is 
strongly associated with bi-allelic DNA promoter methylation of hMLH113. A 
third main pathway in the carcinogenesis of CRC is the CpG island methylator 
phenotype (CIMP) which refers to a subset of tumors with an exceptionally high 
frequency of promoter CpG island methylation of tumor suppressor-and DNA 
repair genes. CIMP+ tumors represent a distinct group of tumors, including the 
majority of cases of sporadic colorectal cancer with MSI and tumors with 
mutations in the BRAF oncogene14.  
A more sophisticated theoretical categorization of CRC in five distinct 
molecular subtypes was proposed by Jass2, based on previous publications of 
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underlying genetic instability and the presence of promoter CpG island 
methylation within CRC. A group of sporadic CRCs was suggested consisting 
of CIMP-high, MSI-high and BRAF mutated tumors, presumed to originate in 
serrated polyps and approximately being present in approximately 12% of all 
sporadic CRCs. A second group representing approximately 8% of sporadic 
CRCs, consisted of CIMP-high, BRAF mutated and MSI-low tumors, also 
originating from serrated polyps. CRC tumors with CIMP-low status, MSS or 
MSI-low with a KRAS mutation, originating from either adenomas or serrated 
polyps formed a third group, with a presumed 20% overall frequency within 
sporadic CRCs. A large group of almost 57% CRCs, named sporadic or FAP-
associated CRCs were designated as a fourth group, containing CIMP- and 
MSS tumors, supposedly being derived from traditional adenomas. The last 
minor group (3% frequency) of CRCs, named Lynch Syndrome associated or 
familial MSI-H tumors, contained CIMP- and MSI-H tumors, also derived from 
traditional adenomas2. More or less characteristic clinicopathological and 
morphologic features have been attributed to each of these suggested CRCs 
subgroups2.  
Studying the association between molecularly defined clusters in CRC and 
their clinicopathological features is important for the improvement of 
therapeutic options within CRC. Therefore, in the light of numerous previous 
efforts that have been undertaken to unravel the complex underlying molecular 
changes in CRC, we classified CRC by computer assisted unsupervised 
hierarchical clustering, based upon well described markers in the genesis of 
CRC including: CIMP, MSI, APC-, KRAS-, TP53-, and BRAF mutation status, 
in a series of 160 CRC cases. Subsequently, we investigated in which way this 
classification was related to patient data, including clinicopathological 
parameters, morphological features (differentiation grade, mucinous 
differentiation, dirty necrosis, circumscribed tumour growth, tumour budding 
and lymphocyte infiltration) and biological behavior in terms of patient 
prognosis. 
Materials and methods 
Patient population 
Patients were entered in two multi-center prospective clinical trials between 
1979 and 1981 in the Netherlands. One trial was designed to compare patient 
survival after treatment of colonic cancer by conventional surgery or the no-
touch isolation technique15. The second trial was conducted to compare 
survival in rectal cancer patients with or without preoperative radiotherapy. In 
the current study, we included only the patients who did not undergo 
preoperative radiotherapy. At the time the trial was conducted, only surgical 
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removal of the tumors was performed, and adjuvant chemotherapy was not yet 
standard practice. Hereby a major advantage is achieved since no bias of 
different adjuvant therapy protocols was introduced. After surgery, tumor 
tissues and lymph nodes were fixed in buffered formalin, sectioned, and 
embedded in paraffin. Experienced pathologists documented the 
histopathological characteristics of the tumors, including tumor stage, 
differentiation grade, size, (lymph-)angioinvasion, perineural invasion and 
lymphnode involvement. Tumor stage was defined according to the TNM 
staging system. 
For both trials, follow up took place every 3 months during the first three years 
and every 6 months between three and five years after initial diagnosis and 
surgery. Standard protocols were followed, with routine blood counts and 
chemistry studies (including CEA levels) at each visit and liver ultrasound, 
chest x-ray and colonoscopy annually, to evaluate both recurrence of disease 
and disease-related death. After the initial five year follow up period, only the 
time and cause of death were registered. Follow-up was complete for all 
patients. In the present study, failure was defined as death due to recurrent 
disease, excluding postoperative mortality within 30 days and non-disease 
related death. 
For molecular analysis, tumor tissues from 160 patients with primary colorectal 
cancer were available. The distribution of age, gender, tumor stage, location 
and type of tumor, frequency of events and mean follow-up time of the patients 
in this study are representative for the patients in the trial and are provided in 
Table 3.1. 
 
 Table 3.1 Clinicopathological characteristics of CRC series. 
  Total 
Age   
   Mean age (SD) 67.7 (11.6) 
Gender  
   Male 75/160 (47%) 
   Female 85/160 (53%) 
Tumor location  
   Right-sided colon 59/160 (37%) 
   Left-sided colon 45/160 (28%) 
   Rectum 56/160 (35%) 
Tumor Grade  
   Well/Moderately 118/141 (84%) 
   Poor 23/141 (16%) 
CRC Stage  
   I 3/160 (2%) 
   II 93/160 (58%) 
   III 47/160 (29%) 
   IV 17/160 (11%) 
Event frequency** 58 (37%) 
Median follow up time 4,7 years 
SD: Standard Deviation, ** colorectal cancer specific death 
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Genomic DNA Isolation 
Genomic DNA was extracted from CRC tissues using PureGene™ Genomic 
DNA Isolation Kit (Gentra Systems) according to the manufacturer’s protocol. 
Methylation-specific PCR 
Promoter CpG island methylation of the following genes: calcium channel, 
voltage-dependent, T type, alpha-1G subunit (CACNA1G ), insulin-like growth 
factor 2 (somatomedin A) (IGF2), neurogenin 1 (NEUROG1), runt-related 
transcription factor 3 (RUNX3) and suppressor of cytokine signaling 1 
(SOCS1), was determined using sodium bisulfite modification of genomic DNA 
using the EZ DNA methylation kit (ZYMO research Co., Orange, CA). 
Methylation Specific PCR (MSP) was performed as described in detail 
elsewhere16,17. In brief, to facilitate MSP analysis on DNA retrieved from 
formalin-fixed, paraffin-embedded tissue, DNA was first amplified with flanking 
PCR primers, that amplify bisulfite modified DNA but do not preferentially 
amplify methylated or unmethylated DNA. The resulting fragment was used as 
a template for the MSP-reaction. All PCRs were performed with a control for 
unmethylated alleles (normal lymphocyte DNA) and a positive control for 
methylated alleles (Sssl methyltransferase (New England Biolabs) treated 
normal lymphocyte DNA) and a negative control without DNA. Each PCR 
reaction was loaded onto a 2% agarose gel, stained with Gelstar® (Cambrex 
Bioscience Rockland Inc, USA) and visualized under UV illumination. Primers 
and PCR conditions are provided in Supplementary Table 3.S1. 
Microsatellite instability 
Microsatellite instability (MSI) was determined by a pentaplex PCR, using the 
mononucleotide MSI markers BAT-26, BAT-25, NR-21, NR-22 and NR-24, as 
previously described18. MSI was defined to be present if ≥3 of 5 markers (BAT-
26, BAT-25, NR-21, NR-22 and NR-24) showed allelic size variants. 
BRAF, KRAS, APC and TP53 mutation analysis 
The common V600E BRAF mutation in exon 15 was analyzed by a semi-
nested PCR and subsequent RFLP analyses as previously described19.  
For KRAS mutation analysis a flanking 179 bp PCR product was amplified 
including codons 12 and 13 as described previously20.  
Since the majority of somatic mutations in APC occur within the MCR, we 
amplified the MCR as four overlapping fragments (codons 1286-1520) in a 
nested PCR strategy. Flank PCR was performed to generate two fragments A 
and B. Fragment A was used as starting material for the amplification of nested 
fragments S1 and S2, and fragment B was used for nested fragments S3 and 
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S4 as previously described21. Mutation analyses of TP53 exons 5-8 was 
performed using a semi-nested PCR approach, (see supplemental Table 3.S2 
for primer sequences). CaCo2 (exon 6, codon 204 non-sense mutation) was 
included as a positive control. Direct sequencing of PCR products was 
performed using the BigDye Terminator v1.1 Cycle Sequencing Kit (Applied 
Biosystems) and analysed on the ABI 3730 DNA Analyzer (Applied 
Biosystems). Mutation detection was performed using Mutation Surveyor DNA 
Variant Analysis Software v3.0 (SoftGenetics LLC, USA). Tumors with silent 
mutations or a common polymorphism were classified as having wild-type 
TP53. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 Illustrations of CRCs with: (A) serrated morphology; (B) mucinous morphology; (C) 
locations of “dirty necrosis”; (D) well differentiated tumour morphology; (E) poorly 
differentiated tumour morphology; (F) circumscribed tumour growth pattern; (G) area 
of tumour budding (black arrows); (H) tumour infiltrating lymphocytes; (I) localisation of 
Crohn-like lymphoid aggregates (black arrows). (A,B,D-G, I) Original magnifications × 
20. (C,H) Original magnifications × 40. 
Morphological characteristics 
Figure 3.1 A-I illustrates the morphological characteristics we determined in our 
study population. Initially we scored several morphological features including: 
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serrated morphology, mucinous differentiation, dirty necrosis, differentiation 
grade, circumscribed tumor growth, tumor budding and lymphocytic infiltration, 
including Crohn-like host response or diffuse tumor infiltrating lymphocytes. 
Serrated morphology was left out of our analyses due to the low observed 
frequency (n=1) in our study-population. Poor differentiation grade was present 
in 16% of cases, mucinous differentiation was present in 16%, dirty tumor 
necrosis in 59%, circumscribed invasion pattern in 35%, 21% showed tumor 
budding at the invasive margins and 23% of all cases showed a clear 
lymphocytic infiltration in the tumor. For details on scoring methods of 
morphologic characteristics see below. 
Differentiation grade 
Tumors were graded by pattern of poorest differentiation, grading was based 
on the retention of glandular differentiation and given a single grade of 
differentiation (well, moderately, poor). The worst grade of tumor seen was 
used for the overall grade. For analysis well and moderately differentiated 
tumors were grouped together. 
Mucinous differentiation 
Tumors with greater than 50% area showing extracellular mucin were classified 
as mucinous. Tumors with less than 50% area showing extracellular mucin 
were classified as having focal mucinous differentiation. Tumours with no 
extracellular mucin were classified as negative for mucinous differentiation. 
Tumor necrosis 
Tumors were assessed for the presence or absence of “dirty necrosis” defined 
by intra-tumoral necrotic debris in tumor glands as well as tumor necrosis, often 
considered a characteristic of colorectal carcinomas. If only a rare focus of 
necrosis was present (<10%) then the tumor was considered negative. 
Tumor budding 
When there was a diffuse growth pattern with a transition from glandular 
structures to single cells or clusters of up to four cells at the invasive margin, 
tumor budding was present22. 
Circumscribed 
Tumors with a so-called “pushing” invasive margin were classified as well 
circumscribed. When the tumor invaded in a diffuse manner with widespread 
penetration of normal tissues, tumors were named non-circumscribed23. 
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Lymphocytic infiltration 
If peritumoral chronic inflammation was present with or without Crohn’s like 
lymphocytic nodules or if tumor infiltrating lymphocytes were present in the 
tumor epithelium, lymphocytic infiltration was scored positive6. 
Data analysis 
CIMP was determined using the panel as suggested by Weisenberger et al.14 
CRCs are defined as CIMP+ when >3/5 analyzed markers (CACNA1G, IGF2, 
NEUROG1, RUNX3, SOCS1) are methylated. 
Unsupervised clustering (using Spotfire DecisionSite® for Functional 
Genomics), based on the similarity of CIMP, MSI, BRAF, APC, KRAS, TP53 
status was performed by using half square Euclidian distance (Wards method 
linkage rule)24,25. Correlations between our computed clusters, morphology 
data and clinicopathological parameters were determined by the Pearson Chi-
Square and Fisher’s exact test as appropriate. To evaluate the relationship 
between the calculated clusters and patient survival, Kaplan-Meier survival 
curves were calculated. The endpoint for analyses was overall survival starting 
from the day of surgery. Independent variables predicting survival were 
evaluated by regression analyses using Cox Regression. The Cox-regression 
model included the variables: CL1, CL2, CL3, age, gender, tumor location, 
differentiation grade and Stage.  All p-values are two sided and p-values <0.05 
were considered statistically significant. SPSS 12.0.1 software was used for 
data analyses. 
Results 
CIMP, MSI, BRAF-, APC-, KRAS- and TP53 mutation status and 
association with tumor location 
A summary of the baseline (epi-)genetic aberrations determined in our study 
population is provided in Table 3.2. Using the Weisenberger criteria to define 
CIMP, 25% (39/156) of CRCs could be classified as CIMP+. This frequency is 
in line with previous publications were the reported frequency of CIMP+ ranged 
between 18% and 25%14,26-29. MSI was detected in 12% (19/158) of our study 
population, which is in accordance with previous reports30. CIMP+ tumors were 
positively correlated with MSI status, p<0.001 (data not shown). BRAF 
mutations were detected in 9% (14/157) of cases, which is in line with the 
reported frequency within CRC by others31,32. CIMP as well as MSI were 
positively correlated with BRAF mutations (p=0.027 and p=0.012, data not 
shown), which is in agreement with current understanding of CIMP+ CRC.  
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50% (73/134) of the tumors had a mutation of the APC gene in the mutation 
cluster of exon 15. Point mutations in exon 1 of the KRAS gene were found in 
26% (40/152) of all cases: 20% (30/152) in codon 12 and 6% (10/152) in codon 
13, respectively. Mutations in exons 5 to 8 of the TP53 gene were present in 
53% (77/146) of all cases. TP53 mutations were positively correlated with APC 
mutations, p=0.021 (data not shown) and not with MSI, CIMP or BRAF 
mutations, likely reflecting tumors within the CIN category. The frequency of 
APC, KRAS and TP53 mutations in our study population are in accordance 
with the frequencies reported by others in CRC3,31-33. 
Regarding baseline clinicopathological features, CIMP+ tumors were more 
often located in the right sided colon (located proximal to the splenic flexure) 
36% (20/56), and rectal tumors 26% (14/55), compared to left sided colon 
tumors (located distal to the splenic flexure) 11% (5/45), p=0.01 (Table 3.2). 
Furthermore MSI was positively correlated with right sided tumor location, 26% 
(16/61) of right-sided colon tumors were MSI tumors, compared to 4% (2/51) in 
the left sided colon and 2% (1/57) in the rectum (p<0.001). BRAF-, APC-, 
KRAS- and TP53 mutations did not correlate with tumor location (Table 3.2). 
Molecular clusters and associations with clinicopathological 
characteristics 
Unsupervised hierarchical clustering, based on (epi)genetic changes including 
CIMP, MSI, BRAF-, APC-, KRAS, and TP53 mutations, resulted in three main 
clusters (CL1, CL2 and CL3, Figure 3.2, Table 3.2), which were reproducible 
with a similar linkage distance, independent of the sequence of input variables 
and stage of disease (data not shown). CL2 was characterized by CIMP+, and 
accounted for 22% (36/160) of CRC’s. The remaining 78% of CIMP- tumors 
were subdivided into TP53 mutated tumors in CL3, comprising 37% (59/160) of 
cases, and a remaining subset of TP53 wildtype tumors representing CL1, 
containing 41% (65/160) of cases, respectively p<0.001 and p<0.001 (Figure 
3.3A). Overall, MSI was more prevalent in CL2 tumors 29% (10/35), than in 
CL1 6% (4/64) or CL3 9% (5/59), p<0.01 (Figure 3.3A). CL3 tumors more often 
harbored APC mutations (71%, 35/49), as compared to CL1 (45%, 23/51) and 
CL2 (50%, 17/34), p=0.021, (Figure 3.3A). To the contrary, BRAF and KRAS 
mutations were more or less equally distributed among the three clusters and 
thus did not give rise to separate clusters (Figure 3.3A). Furthermore, there 
was no consistent relationship between computerized clustering, morphology 
and other clinicopathological variables (Figure 3.3B, Table 3.2). Figure 3.3B 
illustrates the distribution of mucinous differentiation, dirty necrosis, 
differentiation grade, circumscribed tumor growth, tumor budding and 
lymphocyte infiltration among the three (epi)-genetic clusters.  
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Figure 3.2 CRCs clusters CL1 (41%, 65/160), CL2 (22%, 36/160), CL3 (37%, 59/160) obtained 
by unsupervised hierarchical clustering of CIMP, MSI, BRAF/KRAS/APC and TP53 
mutation status. (Black box indicates positive, white box indicates negative, grey 
box indicates missing value). 
 
 
Interestingly, CIMP+ tumors of CL2 could be subcategorized on the basis of 
MSI status and TP53 mutation status as follows. CL2 consisted of 29% (10/35) 
being MSI, a larger group of 71% (25/35) being MSS. Within CL2, MSI tumors 
more often were localized in the right hemicolon 90% (9/10) than in the rectum 
10% (1/10) or left-sided colon 0%, p<0.01 (Figure 3.3C). There was no 
consistent relationship between computerized clustering and morphology, 
except for right-sided MSI tumors in CL2 which more often showed mucinous 
differentiation 44% (4/9), compared to 0% (0/9) in rectum tumors, p=0.023 
(data not shown). Although not significant 20% (3/15) of TP53 mutated tumors 
were MSI and 80% (12/15) MSS, p=0.46 (data not shown). Furthermore, within 
CL2 tumors, TP53 status seems to be related with tumor localization in the 
bowel: 33% (5/15) of TP53 mutated cases were right-sided colon tumors 
compared to 54% (8/15) of TP53 mutated cases being rectum tumors 
(borderline significance p=0.06, Figure 3.3C).  
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Figure 3.3 (A) Percentages of CIMP+, MSI, BRAF/KRAS/APC/TP53 mutated tumors within the 
three clusters CL1, CL2 and CL3 (bars indicate percentage of positive cases 
within each cluster). 
 (B) Percentages of positive scoring of morphology markers: differentiation grade, 
mucinous differentiation, dirty necrosis, circumscribed tumour growth, tumour 
budding and lymphocyte infiltration within CL1, CL2 and CL3 (bars indicate 
percentage of positive cases within each cluster). 
 (C) Within CL2 tumors distribution of MSI and TP53 mutations, according to site of 
origin, respectively right-sided colon, left-sided colon and rectum (bars indicate 
percentage of positive cases). 
  * indicates significant p-values 
0
10
20
30
40
50
60
70
80
90
100
CL1 CL2 CL3
CIMP+
MSI
BRAF-Mt
KRAS-Mt
APC-Mt
TP53-Mt
A
*
*
*
*
0
10
20
30
40
50
60
70
CL1 CL2 CL3
Mucinous
Necrosis
Poorly Dif.
Circum.
Budding
Lymphocytes
0
10
20
30
40
50
60
70
80
90
MSI TP53 mutation
CL2
Right-sided colon
Left-sided colon
Rectum
B
C
*
56Chapter 3 
CIMP- tumors were further subdivided depending on TP53 mutational status, 
into CL1 TP53 wildtype tumors and CL3 TP53 mutated tumors respectively. 
Overall, within CL3, TP53 mutated tumors were equally distributed among 
right-sided colon 32% (17/54), left-sided colon 37% (20/54) and rectum 32% 
(17/54) (data not shown). Within CL3 we could not identify distinct patterns of 
morphology between (epi)genetic aberrations. As opposed to CL3 and CL2, 
CL1 represented a remaining group (41%), of CIMP- and TP53 wild type 
tumors, which were not characterized by a single main (epi)-genetic aberration, 
as illustrated in Figure 3.3A. Within CL1, APC mutations (45%) and KRAS 
mutations (30%) were frequently present, in contrast to MSI, CIMP+ and TP53 
mutations, which showed an overall low frequency (<10%). Similar to cluster 
CL3, within CL1 we could not identify differences between (epi)-genetic 
aberrations and clinicopathological variables. 
Subsequently we verified whether a particular cluster did relate to patient 
survival. Overall and after stratification for tumor stage, there was no impact of 
computerized clustering on survival in colon tumors (Figure 3.4A-D), p=0.24, 
p=0.35, p=0.45, p=0.39, respectively. Furthermore if we stratified for tumor 
location, no survival differences between the clusters were observed within 
proximal and distal colon tumors (Figure 3.4E,F, p=0.82 and p=0.98, 
respectively). In rectal tumors (n=56) on the other hand, a poorer prognosis 
was noted for CL2 tumors as compared to CL3 and CL1 tumors (Figure 3.4G, 
p=0.01). CL2 tumors, being CIMP+, showed lower patient survival rates 
compared to CL3 lesions, containing TP53 mutations. This observation could 
not be confirmed in a multivariate Cox regression model (Table 3.3). Although 
CL2 tumors showed a HR of 2.35 (CI: 0.77-8.32), no statistical significance was 
reached, p=0.13. Probably the effect of CL2 is overruled by tumor stage IV, 
showing a HR=12.62 (CI: 2.75-58.0), p<0.001. 
 
Table 3.3 Cox proportional hazard model in rectum tumors (n=49). 
 Event: CRC mortality 
HR (95%CI) 
p-value 
Clusters 
   CL2* 
   CL3*    
 
2.53 (0.77-8.31) 
0.79 (0.20-3.16) 
 
0.13 
0.74 
Age    (years) 1.03 (0.98-1.09) 0.26 
Gender (female**) 1.59 (0.50-4.98) 0.43 
Differentiation grade  (poor#) 1.92 (0.54-6.78) 0.31 
Stage 
   III = 
   IV = 
 
1.17 (0.38-3.63) 
12.62 (2.75-58.0) 
 
0.78 
<0.001 
HR: Hazard Ratio=Relative Risk. *Reference group = CL1; **Reference group = Man, #Reference 
group = Well/moderate,  =Reference group = Stage II. 
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Figure 3.4 (A) Survival curves overall population of CL1 (n=65) versus CL2 (n=36) and CL3 
(n=59), p=0.24; (B) Survival curves within Stage II of CL1 (n=38) versus CL2 (n=16) 
and CL3 (n=39), p=0.35; (C) Survival curves within Stage III of CL1 (n=21) versus CL2 
(n=16) and CL3 (n=9), p=0.45; (D) Survival curves within Stage IV of CL1 (n=5) versus 
CL2 (n=4) and CL3 (n=8), p=0.39; (E) Survival curves within proximal colon tumors of 
CL1 (n=20) versus CL2 (n=18) and CL3 (n=21), p=0.82; (F) Survival curves within 
distal colon tumors of CL1 (n=19) versus CL2 (n=5) and CL3 (n=21), p=0.98; (G) 
Survival curves within rectal tumors of CL1 (n=26) versus CL2 (n=13) and CL3 (n=17), 
p=0.012.  
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Discussion 
Studying the association between molecular clusters in CRC and their 
clinicopathological features may lead tot a better understanding of the disease. 
Therefore, in the light of numerous previous efforts that have been undertaken 
to unravel the complex underlying molecular changes in CRC, we molecularly 
classified CRC using computer assisted unsupervised hierarchical clustering of 
genetic and epigenetic alterations and correlated this with clinicopathological 
parameters. 
Computer assisted clustering divided CRC’s in CIMP+ (22%) and CIMP- (78%) 
tumors. The latter group could be further subdivided in TP53 mutated tumors 
(37%), and TP53 wildtype tumors (41%). The cluster of CIMP+ tumors 
consisted of two subgroups: 29% microsatellite instable (MSI) and 71% 
microsatellite stable (MSS) tumors. A subdivision of CIMP+ tumors, has 
already been suggested by Jass et al. and others: CIMP1 (MSI associated) and 
CIMP2 (non-MSI associated)2,34,35. Recently it was suggested that in CRC, 
DNA methylation epigenotypes do exist, a high-methylation epigenotype which 
significantly correlates with MSI, right-sided tumor location and a high 
frequency of mucinous differentiation, and an intermediate-epigenotype which 
significantly correlates with distal tumor location, high TP53 expression and a 
low frequency of mucinous differentiation36,37. This subdivision is in 
concordance with CIMP+, right-sided colon tumors in our population, being MSI 
and more often displaying mucinous differentiation, and CIMP+ tumors in the 
rectum, which were more often TP53 mutated, compared to those located in 
the right-sided colon. It has been shown that right-sided colon and distal 
colorectal cancers show distinct gene-specific methylation profiles and clinical 
and molecular characteristics38. Although there is scarce literature specifically 
on the subject of (epi)-genetic profiles in the rectum compared to those in the 
right-sided colon, it seems that CIMP exists in both MSI, right-sided tumors and 
MSS distal (rectum) tumors. CIMP has been postulated to explain silencing of 
the MLH1 gene in right-sided CRC with MSI-High39. The precise role or target 
genes/-pathways of CIMP in distal MSS tumors is unclear. Probably distal 
CIMP+ tumors originate via different pathways compared to proximal CIMP+ 
tumors. As already stated, CIMP+ tumors in the rectum seem to originate in a 
background of CIN since they more often contain TP53 mutations and are 
MSS36. Recently it was shown that 71% of MSS tumors with CIMP+ status 
have APC mutations, suggesting an interrelation with the CIN pathway40.  
Our study suggests that TP53 is the second most important classifier for CRCs 
after CIMP. Within CL3, 98% of tumors harboured a TP53 mutation (p<0.001), 
and 71% an APC mutation (p=0.021) all being CIMP-. Sweeney et al showed in 
917 CRCs, that TP53 and APC mutated tumors formed a distinct cluster within 
CIMP- CRCs40. Jass et al., also suggested the existence of a distinct CRC 
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group consisting of CIMP-/MSS, APC/TP53 mutated tumors, which overlaps 
with CL3 tumors in our study population. Moreover, Jass et all suggested that 
these tumors have characteristic morphological features, namely dirty tumor 
necrosis and tumor budding. We did not find a correlation with any specific 
morphological feature, and in line with our findings the impact of APC and 
TP53 mutations on clinical outcome has been shown to be far from conclusive 
in other studies41,42. 
Overall there was a poor relation between our molecular clusters and 
morphological features. Only mucinous differentiation was associated with a 
subgroup of CIMP+, MSI, right-sided tumors. On the other hand, dirty necrosis, 
circumscribed tumor growth, tumor budding and lymphocyte infiltration did not 
show a relation with our molecular clusters. Several explanations are possible 
for this poor correlation. In our population, 43% of well differentiated tumors 
showed mucinous differentiation compared to 15% in moderately and 12% in 
poorly differentiated tumors (p=0.016, data not shown). Furthermore, none of 
well differentiated tumors showed tumor budding compared to 22% in 
moderately and 24% in poorly differentiated tumors (p=0.13, data not shown). 
These results indicate that some morphological parameters are tightly 
associated with the differentiation grade of a tumor. The poor correlation 
between our molecularly defined clusters and morphological features (other 
than mucinous differentiation) can be explained in part by differentiation grade: 
in a tumor with a higher level of differentiation, probably a single dominant gene 
is still able to dictate its morphology. To the contrary, in moderately and poorly 
differentiated tumors, a cumulative increase in epi-genetic aberrations makes it 
difficult for a single gene to dominate and dictate tumor morphology. Probably 
this explains why mucinous differentiation, strongly coupled to a better 
differentiation grade, can be related to a single genetic aberration like MSI. 
Along similar lines, this explains why morphological features as tumor budding, 
circumscribed tumor growth and dirty tumor necrosis, which are closely 
connected to a poorer differentiation grade, are not related to single epi-genetic 
aberrations. 
We could not demonstrate an impact of computerized clustering on survival of 
CRC patients. Only in rectum tumors, a poorer patient survival was noted for 
CL2 tumors as compared to CL3 tumors. This was observed in a relatively 
small number of rectal tumors and could therefore not be confirmed in 
multivariate analysis taking into account other established prognostic factors 
such as tumor localization, age, gender and tumor stage. Few studies have 
evaluated CIMP+ as a prognostic marker in distal tumors, in particular rectal 
cancer43. De Maat and colleagues reported the quantitative MINT locus 
methylation profile (=surrogate marker for CIMP) and its association with local 
recurrence in rectal cancers44. Based on the methylation profile of MINT3 and 
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MINT17 they were able to subdivide patients in to groups with an increased risk 
for local recurrence.  
Although current molecular clustering provides knowledge in the underlying 
biology of CRC and partly confirms the molecular classification proposed by 
Jass et al. and others, our computed molecular clusters did not have strong 
clinicopathological correlations, and therefore could not improve traditional 
classification with respect to prognostic power. Maybe this was due to the 
relatively small population size, or the fact that we included a lot of single 
genetic aberrations compared to a few epigenetic aberrations. The overall 
frequency of genetic aberrations like mutations in APC, KRAS and TP53 in 
CRC is relatively low, and additional mechanism such as epigenetic 
aberrations contribute to tumor progression and prognosis45. Another 
explanation for the lack of prognostic power for our molecular clusters, could be 
the fact that we did not include chromosomal aberrations, which are associated 
with a poorer patient survival in CRC46,47. Significantly, recent advances in 
technology enable researchers to determine the genetic and epigenetic 
alterations in cancers on a genome-wide scale9,48-50. It reveals true biomarkers 
that enable monitoring of individual tumor progression, tailoring response to 
therapeutic treatment, and identification of residual disease at a level 
previously undetectable by current methods51,52. Future research should point 
out whether these genome wide screening methods are able to identify new 
molecular markers that improve traditional classification.  
In summary, computer assisted classification of CRCs shows that CIMP status 
is the principal classifier, and that both CIMP+ and CIMP- tumors are further 
classified on the basis of TP53 mutational status. Hierarchical molecular 
clustering is only modestly related to morphology and outcome. However, there 
was evidence that some clusters represent biologically distinct subgroups, 
which appear to be dependent on additional factors such as microsatellite 
stability and localization in the intestine. CIMP+ CRC appears to comprise two 
subsets; one localized in the right-sided colon, with MSI and mucinous 
differentiation, the other occurring in the rectum, being MSS. 
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Abstract 
Data on the prognostic significance of promoter CpG island methylation in colorectal cancer (CRC) 
are conflicting, possibly due to associations between methylation and other factors affecting 
survival such as genetic alterations and use of adjuvant therapy. Here we examine the prognostic 
impact of promoter methylation in CRC patients treated with surgery alone in the context of 
microsatellite instability (MSI), BRAF- and KRAS mutations. 
173 CRCs were analyzed for promoter methylation of 19 tumor suppressor- and DNA repair genes, 
the CpG island methylator phenotype (CIMP), MSI, the exon 15 V600E BRAF mutation and KRAS 
codon 12 and 13 mutations. 
Unsupervised hierarchical clustering based on methylation status of 19 genes revealed three 
subgroups: cluster 1 (CL1, 57% (98/173) of CRCs), cluster 2 (CL2, 25% (43/173) of CRCs) and 
cluster 3 (CL3, 18% (32/173) of CRCs). CL3 had the highest methylation index (0.25, 0.49 and 
0.69 respectively, p=<0.01) and was strongly associated with CIMP (p<0.01). After stratification for 
tumor stage, MSI and BRAF status, no statistically significant differences in survival between CL1, 
CL2 and CL3 nor between CIMP and non-CIMP CRCs were detected. Analyzing genes separately 
revealed that CHFR promoter methylation was associated with a poor prognosis in stage II, MSS, 
BRAF wild-type CRCs: HR=3.89 (95% CI =1.58-9.60, p=0.003) and HR=2.21 (95% CI=1.09-4.48, 
p=0.03) in a second population-based study (n=151).  
CHFR promoter CpG island methylation, which is associated with MSI, also occurs frequently in 
MSS CRCs and is a promising prognostic marker in stage II, MSS, BRAF wild-type CRCs. 
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Introduction 
Accurate staging of colorectal cancer (CRC) is essential for optimal disease 
management. Although patients with the same stage can demonstrate 
considerable variation in outcome, the TNM staging system remains the gold 
standard for predicting prognosis and guiding clinical management of CRC1.  
Adjuvant chemotherapy is recommended for all stage III CRC patients. In 
Europe, the majority of stage II CRC patients undergo surgery alone, despite 
the recognition that a subgroup with a poor prognosis would probably benefit 
from adjuvant chemotherapy. Molecular classification of CRC might aid in 
selecting CRC patients who could benefit from adjuvant therapy.  
CRC is characterized by (epi)genetic alterations of genes controlling the 
hallmarks of cancer2,3-5. Frequently observed alterations affecting these 
pathways include chromosomal instability (CIN), microsatellite instability (MSI), 
coding sequence mutations in APC, TP53, KRAS and PI3KCA3-5 and promoter 
CpG island hypermethylation. A distinct subset of CRCs, characterized a 
greater degree of promoter CpG island methylation, is associated with proximal 
location, poor differentiation, MSI and BRAF mutations6-11 and is referred to as 
the CpG island methylator phenotype (CIMP)10,12.  
CIMP has previously been associated with CRC prognosis. However, 
published reports are inconsistent, perhaps due to confounding factors such as 
MSI, BRAF and KRAS mutations, variations in use of adjuvant 
chemotherapy13-16, and methodological differences, such as different CIMP 
definitions.  
The aim of this study was to evaluate the role of CIMP and frequently 
methylated promoter CpG islands on prognosis of CRC, eliminating the 
influence of genetic alterations and adjuvant chemotherapy. 
Materials and methods 
Study population 
CRC patients were entered in two multi-center prospective clinical trials 
between 1979 and 1981 in the Netherlands. One trial was designed to compare 
patient survival after treatment of colon cancer by conventional surgery or the 
no-touch isolation technique17. The second trial was conducted to compare 
survival in rectal cancer patients with or without preoperative radiotherapy, of 
which we included only the patients in the no preoperative radiotherapy arm. At 
the time the trial was conducted, adjuvant chemotherapy was not yet standard 
practice. Tumor stage was defined according to the UICC-TNM staging system 
and American Joint Committee on Cancer classifications (AJCC), Cancer 
Staging Sixth Edition18,19. For both trials, follow up took place every 3 months 
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during the first three years and every 6 months between three and five years 
after initial diagnosis and surgery. Standard protocols were followed, with 
routine blood counts and chemistry studies (including CEA levels) at each visit 
and liver ultrasound, chest x-ray and colonoscopy annually, to evaluate 
recurrence of disease and disease-related death. After five years of follow up, 
only time and cause of death were registered. Follow-up was complete for all 
patients. Failure was defined as death due to recurrent disease, excluding 
postoperative mortality within 30 days and non-disease related death. For 
molecular analyses, tumor tissues from 173 patients with primary CRC were 
available.  
Independent, validation population of CRCs 
A second, independent population of 734 CRC cases, derived from the 
prospective Netherlands Cohort Study on diet and cancer which started in 1986 
with the enrolment of 120,852 healthy individuals between 55 and 69 years old 
from 204 municipalities throughout the Netherlands, was used to validate 
survival data. From 1989 until 1994, 925 incident CRC cases (ICD-O:153.0-
154.1) were identified by computerized linkage with the Netherlands Cancer 
Registry and PALGA, a nationwide network and registry of histopathology and 
cytopathology20. Information on tumor localization, tumor staging, differentiation 
grade and incidence date was available through the Netherlands Cancer 
Registry. Vital status until May 2005 was retrieved from the Central Bureau of 
Genealogy and the municipal population registries and could be obtained for all 
cases. Causes of death were retrieved through linkage with Statistics 
Netherlands. Paraffin-embedded tumor tissue was collected from 54 pathology 
registries; tissue blocks for 734 (90%) of the CRC cases contained sufficient 
DNA for analyses. Details of this cohort have been described previously21.  
Clinical pathological characteristics are provided for both populations (Table 
4.1). In the validation study more left-sided tumors (43%) (p<0.01) and stage I 
tumors (27%) (p<0.01) were diagnosed and the median follow up time was 
longer in the validation population: 7.6 years compared to 4.8 years. p<0.01). 
However, event frequencies were comparable between both studies, making 
the validation population suitable for validation of prognostic markers. 
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Table 4.1 Clinicopathological characteristics of the CRC populations 
  Study population 
(n=173) 
Validation population 
(n=734) 
p-value 
Age     
   Mean age (SD) 67.80 (11.8) 62.90 (4.1) NS 
Gender    
   Male 82 (47%) 408 (56%) NS 
   Female 91 (53%) 326 (44%)  
Tumor location    
   Right-sided colon 62 (36%) 239 (33%) <0.01 
   Left-sided colon 52 (30%) 310 (43%)  
   Rectum 59 (34%) 176 (24%)  
CRC Stage    
   I 4 (2%) 181 (27%) <0.01 
   II 100 (58%) 236 (35%)  
   III 50 (29%) 185 (28%)  
   IV 19 (11%) 69 (10%)  
   Event frequency** 64 (38%) 302 (41%) NS 
   Median follow up time 4.80 years 7.60 years <0.01 
SD: Standard Deviation, ** colorectal cancer specific death 
 
Promoter CpG island methylation-, MSI- and BRAF and KRAS 
analysis 
Genomic DNA was extracted from CRC tissues using PureGene™ Genomic 
DNA Isolation Kit (Gentra Systems) according to the manufacturer’s protocol. 
Promoter CpG island methylation of genes reported to be methylated in 
colorectal cancer: mutL homolog1, colon cancer, nonpolyposis type 2 (E.Coli) 
(MLH1), cyclin dependent kinase inhibitor 2A (p16INK4 and p14ARF ), O-6-
methylguanine-DNA methyltransferase (MGMT), Ras association (RalGDS/AF-
6) domain family member 1 (RASSF1A), adenomatous polyposis coli (APC), 
helicase-like transcription factor (HLTF ), GATA binding protein 4  (GATA4), 
GATA binding protein 5 (GATA5), checkpoint with forkhead and ring finger 
domains (CHFR), ADAM metallopeptidase domain 23 (ADAM23), Rab32, 
member RAS oncogene family (RAB32), junctophilin (3JPH3), forkhead box L2 
(FOXL2), BCL2-adenovirus E1B 19kDA interacting protein 3 (BNIP3) 
,neuralized homolog (Drosophila) (NEURL), calcium channel, voltage 
dependent, alpha2-delta subunit 1 (CACNA2), thrombospondin 1 (THBS1), 
tissue factor pathway inhibitor 2 (TFPI2) and the CIMP genes calcium channel, 
voltage-dependent, T type, alpha-1G subunit (CACNA1G ), insulin-like growth 
factor 2 (somatomedin A) (IGF2), neurogenin 1 (NEUROG1), runt-related 
transcription factor 3 (RUNX3) and suppressor of cytokine signaling 1 (SOCS1) 
was determined using sodium bisulfite modification of genomic DNA (EZ DNA 
methylation kit, ZYMO research Co., Orange, CA). To facilitate MSP analysis 
on DNA retrieved from formalin-fixed, paraffin-embedded tissue, nested 
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Methylation Specific PCR (MSP) was performed as described elsewhere22,23. 
Primers and PCR conditions are provided in Supplementary Table 4.S3. 
Microsatellite instability (MSI) was determined by a pentaplex PCR, using the 
mononucleotide MSI markers BAT-26, BAT-25, NR-21, NR-22 and NR-24, as 
previously described24. MSI was defined positive when three or more of five 
markers (BAT-26, BAT-25, NR-21, NR-22 and NR-24) showed allelic size 
variants.  
The common V600E BRAF mutation in exon 15 was analyzed by semi-nested 
PCR and subsequent RFLP analysis, KRAS mutations were analyzed as 
described previously25,26.  
Data analysis 
CIMP was analysed using the marker panel proposed by Weisenberger et al.11. 
CRCs were defined as CIMP when >3/5 analyzed markers (CACNA1G, IGF2, 
NEUROG1, RUNX3, SOCS1) were methylated. Unsupervised clustering 
(Spotfire DecisionSite® for Functional Genomics), based on the similarity of 
methylation of 19 CpG islands that have been reported to be methylated in 
colorectal cancer (CIMP genes excluded), was performed by using half square 
euclidian distance (Wards method linkage rule)27,28. Methylation Index 
(MI=number of methylated promoter CpG islands divided by number of 
promoter CpG islands successfully analyzed) was calculated using the 
promoter CpG islands of 19 tumor suppressor- and DNA repair genes as well 
as the CIMP panel. Standard Error of Skewness was used as a test of 
symmetry for the distribution of CRC cases according to the number of 
methylated CIMP genes and number of methylated cluster genes, symmetry 
was rejected if the ratio was less than -2 or greater than +2. Differences 
between methylation-, clinicopathological- and molecular characteristics were 
determined by the Pearson Chi-Square and Fisher’s exact test where 
appropriate. Kaplan-Meier curves were used to evaluate the relationship 
between promoter CpG island methylation and patient survival in the overall 
population and stratified for tumor stage, MSI and BRAF mutation status. 
Statistical differences between groups were assessed by use of the log-rank 
test. The endpoint for analyses was overall survival starting from the day of 
surgery until the time of death due to CRC. Independent variables predicting 
survival were evaluated in a multivariate model using Cox Regression 
analyses. The Cox-regression model including CIMP, CL1, CL2, CL3, CHFR 
promoter CpG island methylation, age, gender, tumor location, differentiation 
grade and TNM Stage was used to assess the prognostic influence of these 
variables. All p values (two sided) <0.05 were considered statistically 
significant. SPSS 15.0 and Stata 10.0 were used for data analyses. 
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Results 
(Epi)genetic characterization of CRCs  
MSI, BRAF and KRAS mutations were detected in 11% (19/169), 9% (14/161) 
and 26% (41/157) of CRCs of the study population respectively (Table 4.S1), 
which is in accordance with previously reported frequencies4,5,29.  
The methylation frequency for CIMP genes ranged from 13% to 61%: IGF2 
(13% (20/154)), CACNA1G 18% (30/170)), RUNX3 (32% (52/163)), NEUROG1 
42% (70/165) and SOCS1 (61% (103/170)) (Figure 4.1A). 23% (39/168) of 
CRCs were classified as CIMP (Table 4.S2). This is consistent with previous 
publications with reported frequencies of CIMP between 18-25%11,30,31. The 
distribution of the number of CIMP markers methylated for each tumor 
resembles a normal distribution (Figure 4.1C, standard error of skewness 
0.187).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 (A) Methylation frequencies of the five CIMP genes among the study-population (black 
bars indicate percentages). (B) Methylation frequencies of 19 cluster genes among the 
study-population (black bars indicate percentages). (C) Distribution of colon cancer 
cases according to the number of methylated CIMP genes (black bars indicate number 
of cases). (D) Distribution of colon cancer cases according to the number of 
methylated cluster genes (black bars indicate number of cases CIMP-, white bars 
indicate number of cases CIMP+).  
 
We sought to more broadly examine the methylation of CpG islands in CRC, to 
determine whether the 5 genes used to define CIMP optimally separated 
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methylation in 19 additional tumor suppressor genes ranged from 5% (THBS1) 
to 87% (TFPI2) (Figure 4.1B and Table 4.S1). We compared the distribution of 
tumors according to the methylation status of the 19 additional genes (Figure 
4.1D). This resembles a normal distribution with a standard error of skewness 
0.185, and reveals that CRCs with a high number of methylated genes are 
predominantly characterized by CIMP (white bars). This suggests that the 
Weisenberger CIMP markers are sensitive but not completely specific in 
identifying CRCs with a high frequency of promoter CpG island methylation.  
We assessed whether subgroups of CRCs could be identified using 
methylation patterns of the 19 non-CIMP genes. Unsupervised hierarchical 
cluster analysis identified three clusters of CRCs, CL1 (57% (98/173)), CL2 
(25% (43/173)) and CL3 (18% (32/173)) (Figure 4.2, Table 4.S2). CL3 showed 
the highest number of methylated genes (MI) (mean MI, CL1=0.25, CL2=0.49, 
CL3=0.69, p=<0.001). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2 CRCs clusters CL1 (57%), CL2 (25%), CL3 (18%) obtained by unsupervised 
hierarchical clustering of promoter CpG island methylation of MLH1, p16INK4A, 
p14ARF, MGMT, RASSF1A, APC, HLTF, GATA4, GATA5, CHFR, ADAM23, 
RAB32, JPH3, FOXL2, BNIP3, NEURL, CACNA2, THBS1, TFPI2. 
 Black box indicates methylated gene, white box indicates unmethylated gene, grey 
box indicates failed PCR. After clustering, identification of patients was done for 
individual CIMP markers (CACNA1G, IGF2, NEUROG1, RUNX3 and SOCS1), 
CIMP, MSI, BRAF- and KRAS mutations as visualized. Black box indicates positive, 
white box indicates negative, grey box indicates missing value. 
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Associations between genetic, epigenetic and clinicopathological 
characteristics 
CIMP was highly associated with promoter CpG island methylation of 16/19 
additional genes. Furthermore, CRCs grouped in CL3 were most often 
classified as CIMP (p<0.01) (Figure 4.2, Table 4.2). CIMP was associated with 
MSI, BRAF mutations and CL3 (p<0.01, p=0.05 and p<0.01 respectively) 
(Table 4.2). 69% (26/38) of CIMP CRCs and 60% (18/30) of CL3 CRCs are 
MSS (Table 4.2). Mutations in KRAS were neither associated with CIMP nor 
with the identified clusters (data not shown).  
 
Table 4.2 Correlations between CIMP, CL1, CL2 and CL3 and MSI and BRAF mutation in the 
study population. 
 MSI MSS BRAF M BRAF WT CIMP 
CIMP 
 
12/19 
(63%) 
26/145 
(18%) 
7/14 
(50%) 
32/143 
(22%) 
 
  <0.01  <0.05  
CL1 
 
3/19 
(16%) 
94/150 
(63%) 
5/14 
(36%) 
83/147 
(57%) 
6/39 
(15%) 
CL2 
 
4/19 
(21%) 
38/150 
(25%) 
3/14 
(21%) 
39/147 
(27%) 
8/39 
(21%) 
CL3 
 
12/19 
(63%) 
18/150 
(12%) 
6/14 
(43%) 
25/147 
(17%) 
25/39 
(64%) 
  <0.01  0.06 <0.01 
CIMP: CpG island methylation phenotype using the markers of Weisenberger et al.1, CL1,CL2 and 
CL3: groups of CRCs identified by unsupervised hierarchical clustering based on methylation 
patterns of 19 tumor suppressor and DNA repair genes, MSI: microsatellite instability, MSS: 
microsatellite stability, M: Mutant, WT: Wild-type. 
 
As expected, CIMP and MSI were associated with right-sided tumor location, 
as were CL3 CRCs (p=<0.01, p=<0.01 and p=<0.01 respectively, Tables 4.S1 
and S2). We did not observe previously reported association between sex, age 
and CIMP or with our newly defined CL3 tumors. 
The primary aim of this study was to evaluate the prognostic influence of 
promoter CpG island methylation using CIMP- and to extend this analysis to 
include 19 additional tumor suppressor- and DNA repair genes. As tumor 
stage, MSI, BRAF- and KRAS mutations have in some reports influenced 
survival, we analyzed whether these alterations were of prognostic significance 
in the study population. As expected, disease outcome was significantly 
influenced by tumor stage, with stage I having an improved overall survival 
(p<0.01) compared to other tumor stages. We also observed that wild-type 
BRAF tumors showed an improved overall survival compared to BRAF mutated 
tumors (p=0.04). MSI seems associated with improved overall survival as 
compared to MSS within CRC Stage II, although this association is not 
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statistically significant (p=0.07). KRAS mutations were of no prognostic value, 
neither in the overall population, nor in the separate stages (data not shown). 
Therefore, survival analyses were also stratified for stage, MSI status and 
BRAF mutation status.  
No statistically significant survival differences between CIMP and non-CIMP 
CRCs were observed in the overall study population (Figure 4.3A) or when 
specifically examining Stage II (Figure 4.3C,) or Stage III (data not shown) 
MSS, BRAF wild type CRCs. The same was observed for CL1, CL2 and CL3 
CRCs (data not shown). Examining the validation population showed that 
overall CIMP was borderline statistically significantly associated with prognosis 
(Figure 4.3B, p=0.02). This finding was lost within Stage II (Figure 4.3D) and 
Stage III (data not shown) MSS, BRAF wild type CRCs. We next sought to 
determine whether one possible explanation for additional variation in previous 
studies was that specific CpG island methylation, underlying any prognostic 
importance, was imperfectly associated with CIMP. When analyzing all 19 (or 
24 if including CIMP) genes, only APC and CHFR methylation, although the 
latter was positively associated with MSI (p=0.02) and CIMP (p<0.01, Table 
4.S4), were associated with a worse prognosis in stage II MSS, BRAF wild-type 
CRCs (HR= 2.63 (95% CI=1.21-5.68, p=0.01) and HR=2.59 (95% CI=1.16-
5.76, p= 0.02) respectively) (Table 4.S5 and Figure 4.3G). For stage III MSS 
BRAF wildtype CRCs, associations with worse prognosis were found for 
RASSF1A, THBS1 and CACNA1G (HR=3.89 (95% CI 1.23-12.3, p=0.02; 
HR=26.5 (95% CI=1.66-423, p=0.02) and HR=5.62 (95% CI=1.49-21.3, 
p=0.01)) (Table 4.S5). These effects were not observed in the overall study 
population (Table 4.S5). Since the small numbers of cases and the number of 
comparisons examined to find significance raises concerns, we validated these 
results in an independent validation population. This only confirmed a 
statistically significant association with prognosis for CHFR methylation in 
stage II, MSS, BRAF wild-type CRCs (Figure 4.3F-3H). The Cox-regression 
multivariate model within the study population of MSS, BRAF wild-type, stage II 
CRCs shows that CHFR methylation was associated with a poor prognosis 
(HR=3.89 (95% CI =1.58-9.60), p=<0.01 and was, in this study, a better 
predictor of survival than differentiation grade (HR 1.52 (95% CI =0.69-3.36), 
p=0.30) (Table 4.3). Multivariate analysis in the independent, population-based 
validation cohort of 151 stage II, MSS, BRAF wildtype CRCs confirmed that 
CHFR methylation is associated with a worse prognosis in this specific 
subgroup of CRCs (n=151, HR=2.21 (95% CI =1.09-4.48, p=0.03) (Table 4.3). 
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Figure 4.3 Survival curves overall population of (A) CIMP- (n=124) versus CIMP+ (n=38), 
p=0.381; of validation series (B) CIMP- (n=436) versus CIMP+ (n=167), p=0.016. 
Survival curves in stage II, MSS and BRAF wild-type tumors of (C) CIMP+ (n=12) and 
CIMP- (n=61), p=0.158; of validation series (D) CIMP+ (n=23) and CIMP- (n=113), 
p=0.701. Survival curves overall population of (E) CHFR unmethylated (n=89) versus 
CHFR methylated (n=71), p=0.259; of validation series (F) CHFR unmethylated 
(n=319) versus CHFR methylated (n=280), p=0.078. Survival curves in stage II, MSS 
and BRAF wild-type tumors of (G) CHFR unmethylated (n=43) and CHFR methylated 
(n=30) CRCs, p=0.016; of validation series (H) CHFR unmethylated (n=85) and CHFR 
methylated (n=50) CRCs, p=0.049. 
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Table 4.3 Cox proportional hazard models for MSS, BRAF wild-type, stage II CRCs 
 Study population (n=66) Validation population (n=151) 
 CRC mortality 
HR (95% CI) 
p value CRC mortality   
HR (95% CI) 
p-value 
CHFR   M*   3.89 (1.58-9.60) <0.01 2.21 (1.09-4.48) 0.03 
Age    ( years)  1.02 (0.97-1.07)   0.41 1.02 (0.94-1.11) 0.43 
Gender ( female**) 0.53 (0.23-1.27)   0.16 1.32 (0.66-2.63) 0.62 
Tumor location  
   Left-sided Colon+ 
   Rectum+ 
 
0.52 (0.20-1.38) 
0.29 (0.09-0.93) 
 
  0.19 
  0.04 
 
1.19 (0.51-2.78) 
1.89 (0.64-5.52) 
 
0.69 
0.25 
Differentiation grade  (poor#) 1.52 (0.69-3.36)   0.30 0.70 (0.21-2.36) 0.56 
*Reference group = CHFR unmethylated cases; **Reference group = male, +Reference group = 
Right-sided colon, #Reference group = Well/moderate. HR: Hazard Ratio=Relative Risk, M : 
Methylated. 
 
Discussion  
Data on the prognostic significance of promoter CpG island methylation, and 
CIMP in particular, are conflicting in CRC13-16. These inconsistencies might be 
caused by factors affecting the course of the disease, such as genetic 
alterations, adjuvant therapy and differences in methodological study 
approaches. Here we analysed the prognostic value of promoter CpG island 
methylation in CRCs from patients not treated with (neo)adjuvant therapy 
taking into account the confounding role of clinicopathological and genetic (MSI 
and BRAF) characteristics. Previously reported associations between CIMP 
and proximal tumor location, MSI and BRAF mutations10,11,16 as well as the 
identification of 3 subgroups of CRCs9,32 based on promoter methylation 
profiles could be confirmed. In addition, the prognostic role of tumor stage, MSI 
and BRAF33,34 could be confirmed in the study and the validation series.  
In the study series, neither CIMP nor CL3 classification were statistically 
significantly associated with prognosis, neither overall nor when stratified for 
stage or microsatellite status. These conclusions are valid for the subgroups of 
CRC defined by analyzing CIMP with the markers proposed by Weisenberger 
et al.11 and also for unsupervised clustering of the methylation data for the 19 
CpG islands that we added to the analysis. Since also other CIMP definitions 
have been used, caution with generalizing these conclusions is warranted. 
However, these data confirm the concept that based on CpG island 
methylation, 3 subgroups of CRC can be identified, independently of the 
specific markers used. The subgroup characterized by extensive promoter CpG 
island methylation is strongly, although not perfectly, associated with CIMP and 
its reported clinicopathological characteristics. The borderline overall 
statistically significant prognostic effect of CIMP in the validation series 
indicates that the prognostic role of CIMP in CRC is still unclear and that large, 
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independent studies are needed to answer this question. In addition, until the 
underlying biological cause for CIMP is being identified, an accurate definition 
remains hard to establish. Our evidence for imperfect correlation of highly 
methylated tumors using the independent 19 genes with CIMP illustrates this.  
After stratification for established confounders including age, gender, tumor 
location, differentiation grade, TNM Stage, MSI and BRAF mutation status, 
promoter methylation of only 1 of 24 genes, namely CHFR,  was statistically 
significantly associated with a poor prognosis in stage II MSS CRCs in the 
study population (HR=3.89 (95% CI =1.58-9.602), p=0.003) and the validation 
series (HR=2.21 (95% CI=1.09-4.48, p=0.03). Because of the assumption that 
many biomarker data are false35 and the fact that we studied many variables, 
our validation of the effect of CHFR promoter CpG island methylation in an 
independent prospective cohort study as well as pilot data recently published 
by an independent team pointing to the same conclusion36, underscores the 
potential of CHFR promoter CpG island methylation as a prognostic marker in 
colorectal cancer.  
A dominant effect of MSI over DNA methylation regarding prognosis has been 
shown previously in CRC by Ward et al., for a ‘CIMP’-like’ phenotype37. The 
mechanisms underlying this paradox are still not clear. An explanation could be 
the increased lymphocytic infiltrate that is observed in MSI CRCs38 or the 
extend of instability making MSI tumor cells less fit to metastasize39,40. The 
prognostic effect of CHFR in MSS stage II CRCs is surprising, as we previously 
reported a strong association between CHFR promoter CpG island 
methylation, MSI and MLH1 promoter methylation in CRC41. However, since a 
significant subset of MSS CRCs also have CHFR promoter methylation, this 
could be of clinical relevance.  
CHFR is a tumor suppressor gene which is inactivated by promoter CpG island 
methylation in a variety of solid tumors 41-45. It encodes an ubiquitin ligase that 
regulates both entry into metaphase and chromosome segregation later in 
mitosis to maintain genomic stability46,47. CHFR inactivation has been 
hypothesized to be associated with chromosomal instability, although 
conflicting data have been reported48-50. Although both CHFR and MLH1 
contribute to genomic integrity, they function through different mechanisms. 
CHFR deficiency triggers mild CIN and hMLH1 deficiency leading to MSI51. 
Recent data from Oh et al 200952 indicate that, in vitro, CHFR binds and 
downregulates HDAC1 thereby downregulating the Cdk inhibitor p21CIP/WAF1 
and the metastasis suppressors KAI1 and E-cadherin. This eventually results in 
cell cycle arrest and a less invasive phenotype. In addition to a potential role for 
CHFR as prognostic biomarker, CHFR promoter methylation has been 
proposed as biomarker for response to microtubule inhibitor taxanes in 
endometrial-53 cervical-53, oral-54 and gastric cancer55. Although taxanes are not 
implemented in CRC treatment because they failed to demonstrate a significant 
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clinical benefit in Phase II trials56,57, CRCs with CHFR promoter methylation 
might benefit from taxanes.  
In summary, although our study failed to demonstrate a consistent prognostic 
effect of CIMP, we identified promoter CpG island methylation of CHFR as a 
prognostic biomarker in stage II, MSS, BRAF wild-type CRCs in two 
independent populations.  
Future large-scale validation studies and randomized clinical trials are needed 
to study the clinical value CHFR methylation in CRC. 
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Introduction 
Novel insights in the biology of cancers have revealed a variety of promising 
biomarkers for early detection of cancer and for predicting prognosis and 
response to therapy. Despite these insights and a revolution in biotechnology, 
only few biomarkers are implemented in current daily practice. Examples of 
operational biomarkers are testing for KRAS mutation and expression of EGFR 
to predict response to monoclonal antibodies against EGFR in lung1 and 
metastatic colon cancer2. However, EGFR antibodies are most frequently used 
as second or third line therapy and the number of patients that might benefit 
from this treatment is small. The great majority of patients still receive standard 
first line therapy. For this reason the use of chemotherapeutic agents is still 
very inefficient and too many patients experience unneeded toxicity.  
In this review, we raise attention to a biomarker for which multiple lines of 
evidence are emerging: checkpoint with FHA and ring finger (CHFR). CHFR is 
a mitotic checkpoint- and tumor suppressor gene and is inactivated in a 
diversity of solid malignancies. Here we summarize the current evidence of 
altered CHFR expression in cancer and discuss its promising role as a 
prognostic and predictive biomarker. 
CHFR: an important regulator of cell cycle progression 
One of the hallmarks of cancer is loss of chromosomal instability, mostly due to 
dysfunction of one or more cell cycle checkpoints. The spindle assembly 
checkpoint is a key player in controlling chromosomal integrity by sensing 
microtubule kinetochore attachment and allowing promotion of mitosis only 
when chromosomes are attached properly.   
Checkpoint with FHA and RING finger domain, CHFR, is an early mitotic 
checkpoint gene, which is more frequently inactivated in cancer than all mitotic 
checkpoint control genes together3. In case of microtubule- and radiation 
damaging stress CHFR is able to reversibly delay passage into mitosis before 
chromosome condensation has taken place4,5. CHFR localizes in the nucleus 
and becomes phosphorylated by protein kinase B (PBK/AKT), a member of the 
PI3K signaling pathway6. The nuclear distribution, mobility and function of 
CHFR is modulated by interaction with promyelocytic leukemia protein (PML) 
bodies7,8. PML bodies are involved in various cellular processes such as 
cellular senescence, apoptosis and maintenance of chromosomal stability and 
also the function of CHFR is dependent upon the interaction with PML bodies7. 
CHFR is an E3 ubiquitinin ligase which contains a FHA domain and a RING 
finger domain (Figure 5.1). The function of the FHA domain is largely unknown 
but is thought to mediate binding to phosphorylated proteins9 and is 
responsible for the anti-proliferative effect of CHFR. The RING finger domain is 
 Emerging evidence for CHFR as a cancer biomarker95 
able to ubiquitinate substrates such as polo-like kinase 1 (PLK1), Aurora A, 
MAD2 and CHFR itself9. By degradation of PLK1 CHFR inhibits the formation 
of the cyclin B1-Cdk kinase complex, which will result in a cell cycle arrest10. 
While evidence for degradation of PLK1 by CHFR in vivo is weak, 
ubiquitination of pro-mitotic protein Aurora A and thereby maintaining 
chromosomal stability is clearly shown in vitro and in vivo11. The same 
accounts for ubiquitination of MAD2, which enables CHFR to control proper 
spindle attachment to kinetochores and thereby delays mitotic 
progression12,13,14. The interaction between CHFR and Aurora A and MAD2 is 
accomplished by the cysteine rich domain of CHFR11,12,15. Inside this cysteine 
rich region a RAR-binding zinc-finger (PBZ) is situated which is able to bind 
poly-(ADP-ribose)polymerases, important for checkpoint regulation and DNA 
damage response16.  
More recently it was shown that CHFR also interacts with histone deacetylase 
HDAC117. HDAC1 is able to repress p21 and by inhibiting the deacetylase 
activity of HDAC1 CHFR restores the p21-G1 checkpoint17-19. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1 CHFR gene and protein. Schematic representation of promoter CpG island 
methylation, mutation and polymorphisms with functional significance of: 
 A) CHFR gene encompassing 18 exons. CpG island is enlarged with CpG 
dinucleotides as vertical lines. TSS: transcription start site * mutation. # polymorphism.  
 B) CHFR protein consisting of 664 aminoacids. FHA: forhead-associated domain. 
RING: ringfinger  domain. CR: cysteine rich domain. PBZ: RAR-binding zinc-finger 
domain. Mutations in black, polymorphism in gray. 
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CHFR is frequently inactivated in cancer 
Although many cancer cells have an impaired or unregulated spindle 
checkpoint, mutations of mitotic checkpoint genes are rare. Lack of expression 
of CHFR in cancer cells was first described by Scolnick et al.3 in one 
neuroblastoma and two colorectal cancer cell lines. Nonfunctional CHFR in 
these cell lines resulted in a high mitotic index when exposed to microtubule 
stress compared to wild-type cancer cells, which was restored by reintroduction 
of functional CHFR. A role for CHFR in tumor suppression became clear when 
CHFR deficient mice spontaneously developed malignant tumors11. CHFR 
knockout mice are viable and develop without defects but display invasive 
lymphomas and solid tumors (lung, liver, gastrointestinal) after 40 weeks. 
Furthermore, CHFR deficient mice show defects in chromosome segregation 
and aneuploidy. Also in a breast cancer cell line model decreased CHFR 
expression led to an accelerated growth rate, enhanced invasiveness, and 
amplified colony formation20. Since then, disrupted CHFR expression has been 
described in multiple cancer tissues (Table 5.1). 
The tumor suppressor role of CHFR is not entirely clear. Due to its checkpoint 
function CHFR was thought to participate in the acquisition of chromosomal 
defects and a chromosomal instability phenotype. Although this was observed 
in previously described cell lines models, in primary colorectal- and breast 
cancer tissue this could not be observed25. To the contrary, CHFR inactivation 
was found to occur most frequently in cancers with microsatellite instability 
(MSI)29 and MLH1 promoter CpG island methylation. Comparable results have 
been observed in gastric cancer55. The mechanism underlying the association 
between CHFR promoter methylation and MSI is unknown but might be 
explained the association with MLH1 promoter methylation and a shared 
underlying DNA methylation defect. Future studies are needed to unravel the 
underlying mechanism, and a significant subset of MSS CRCs also has CHFR 
promoter methylation, which could be of clinical relevance.  
 
Furthermore, a recent study shows an additional role for CHFR in regulating 
expression of pro-inflammatory chemokine interleukin-856. CHFR was able to 
inhibit the NFκB signaling pathway and IL-8, which subsequently resulted in 
decreased angiogenesis and cell migration57-59. Inactivation of CHFR may 
trigger NFκB signaling activity, which results in increased angiogenesis, a 
metastatic phenotype and a poor prognosis. 
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CHFR is inactivated by genetic and epigenetic 
mechanisms 
The original study of Scolnick and Halazonetis describes a sequence variation 
in the cysteine rich domain of CHFR in osteosarcoma cell line U2OS3 (Figure 
5.1). The variation consisted of a G to A transition leading to substitution of Val 
539 with Met and was initially interpreted as potential missense mutation with 
functional impairment but turned out to be a functional polymorphism.36 The 
functional difference between wild-type and variant genotype was further 
studied in a series of 462 colorectal cancer patients and 245 healthy controls60. 
This study showed that the A allele of the GA variant was associated with a 
reduced colorectal cancer risk and absence of distant metastasis. Additional 
studies to identify structural variations in the CHFR coding sequence led to the 
identification of three missense mutations in non-small cell lung cancer 
(NSCLC) that all three were associated with a defective mitotic checkpoint39. 
Two mutations target the FHA en RING finger domain and the third is located 
in the cysteine rich region (Figure 5.1B). These mutations, however, were 
observed in only 3 out of 53 patients and are therefore rare events.  
Loss of the chromosomal region harboring CHFR, 12q24.33, occurs more 
frequently. In esophageal adenocarcinomas, CHFR DNA copy number loss 
occurs in 59% (44/56) of esophageal cancers42 and is associated with reduced 
CHFR expression.  
 
In most cancers, however, CHFR expression is reduced due to promoter CpG 
island methylation (Figure 5.1A). The promoter region of CHFR contains a CpG 
island spanning -905 bp to +783 bp relative to the transcription start site (using 
the lower limit values 500bp for length, 55% for GC content and 0.65 for 
ObsCpG/ExpCpG61). CHFR promoter methylation and subsequent 
transcriptional silencing was first described in esophageal cancer40, of which 
16.3% (7/43) was hypermethylated while this was absent in adjacent normal 
tissues. Later it became clear that CHFR promoter methylation occurs in other 
cancers as well, among which colorectal-, gastric- and lung cancer (Table 5.1). 
Also in breast cancer CHFR becomes inactivated, however, only occasionally 
by promoter CpG island methylation20.  
In most studies CHFR promoter CpG island methylation is assessed by 
methylation- specific PCR (MSP), which is an accurate and sensitive test to 
detect aberrant methylation in the primary tumor. In recent years is has 
become clear that the core region of CpG methylation within the CpG island 
which is biologically and clinically relevant can vary per gene62. For CHFR, 
CpG methylation within region -240 bp to -79 relative to the transcription start 
site is associated with reduced expression and clinical parameters such as 
prognosis29 (Cleven et al, submitted) and therefore identified as core region.   
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CHFR promoter methylation is associated with a poor 
prognosis and good response to microtubule inhibitors 
CHFR promoter CpG island methylation as prognostic marker 
In recent years it has become increasingly apparent that CHFR promoter CpG 
island methylation is associated with a poor prognosis in multiple cancer types. 
For NSCLC two independent groups published the association between CHFR 
promoter CpG island methylation and an increased risk for recurrence and poor 
survival38,51. Also for colorectal cancer a small retrospective study (n=82) 
showed an association between CHFR promoter methylation and an increased 
risk of local recurrence as well as poor prognosis in stage III CRC52. We 
recently showed in a larger series of 173 patients that CHFR promoter 
methylation is an indicator of poor survival in stage II microsatellite stable CRC 
(n=82) and validated these results in an independent prospective cohort study 
(n=151) (Cleven et al, submitted).  
Furthermore, different studies have shown the ability to detect CHFR promoter 
methylation in circulating tumor DNA in patients with non-small cell lung cancer 
(NSCLC)38 and in peritoneal lavage in case of peritoneal metastasis in patients 
with gastric cancer31,32. Peritoneal micrometastases in gastric cancer are 
associated with a poor prognosis but difficult to detect. Testing for CHFR 
promoter methylation in DNA from peritoneal fluid can help to detect63,64 
malignant cells and select patients that might benefit from additional 
chemotherapy.  
Together these studies underscore the potential of CHFR promoter CpG island 
methylation as a prognostic marker. 
CHFR promoter CpG island methylation as predictor of response 
to therapy  
In addition to being a biomarker for poor prognosis in CRC and NSCLC, CHFR 
promoter CpG island methylation has been shown to be a potential predictor of 
response to microtubules inhibitors (Table 5.2).   
Microtubule inhibitors such as docetaxel and paclitaxel disrupt normal 
microtubule dynamics during cell division by binding to the beta-tubulin 
subunits. This will lead to a failure of microtubule separation and apoptosis. 
CHFR is able to block entry into prophase until chromosomal alignment is 
restored, which will lead to decreased effect of taxanes. Cells expressing 
CHFR have shown to be more viable upon treatment with microtubule inhibitors 
compared to cells not expressing CHFR65. 
The association between CHFR expression and a poor sensitivity to 
microtubule inhibitors was first shown by Satoh et al. in gastric cancer cell 
lines30. Docetaxel is the second line therapy for gastric cancer; some patients 
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respond while others are resistant. Therefore, CHFR promoter CpG island 
methylation was hypothesized to be an important determinant of response to 
therapy. Different studies to test this hypothesis have been performed with 
conflicting results. A small study restricted to twelve patients, showed that 
cancers with CHFR promoter CpG island methylation had a better clinical 
response compared to cancers with unmethylated CHFR, of which the majority 
showed progressive disease33. In a larger study (n=41), no clear relationship 
between CHFR promoter CpG island methylation and response to microtubule 
inhibitors was observed66. Clinical response, however, was measured in 
metastatic lesions of which the methylation status of CHFR was not assessed.  
Since then, a potential role for CHFR promoter CpG island methylation in 
predicting response to microtubule inhibitors has been described in other 
cancer types as well. In NSCLC, CHFR promoter CpG island methylation is 
associated with high sensitivity to paclitaxel53. Interestingly, sensitivity to 
paclitaxel is correlated with wild-type EGFR and smoking habit, and the 
combination of the three is a strong predictor of clinical response to paclitaxel 
in NSCLC51,53. 
 
Table 5.2 CHFR as marker of prognosis and response to microtubule inhibitor.  
Cancer 
 
Prognostic markers 
 Method 
 
ref 
Lung cancer Reduced CHFR expression associated with poor prognosis 
(n=157) 
Promoter methylation associated with poor prognosis 
(n=203) 
IHC 
 
MSP 
 
37
 
 
51
 
Colorectal cancer Promoter methylation associated with poor prognosis in 
stage II MSS BRAF wt CRC (n=66). Confirmed in second 
independent series (n=151) 
Promoter methylation associated with reduced recurrence 
free- and overall survival (n=82) 
MSP 
 
 
MSP 
  
52
 
Predictive markers     
Gastric cancer Promoter methylation predicts good response to paclitaxel 
(cell lines n=4) 
No association between CHFR promoter methylation and 
sensitivity paclitaxel  (n=12) 
MSP  30 
 
33
 
Cervical cancer Promoter methylation predicts increased sensitivity to 
paclitaxel  (cell lines, n=6)) 
MSP  43 
Oral squamous cell 
carcinomas 
Silencing CHFR (siRNA) increases taxane sensitivity (cell 
lines) 
siRNA  46 
Lung cancer Promoter methylation associated with good response to 
paclitaxel (n=69) 
Unmethylated CHFR promoter associated with good 
response to EGFR TKIs (n=179) 
MSP  53 
 
38
 
Endometrial Cancer CHFR promoter methylation associated with increased 
sensitivity to paclitaxel (cell lines, n=6) 
MSP  50,54 
IHC: immunohistochemistry, MSP: methylation specific PCR, siRNA: short interference RNA 
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Also in cervical adenocarcinomas, CHFR promoter CpG island methylation is 
proposed as biomarker to predict response to paclitaxel. In cervical 
adenocarcinomas, CHFR promoter CpG island methylation occurs in 14% of 
cases, in sharp contrast to cervical squamous cell carcinomas in which CHFR 
is unmethylated67. Cervical adenocarcinomas respond to paclitaxel in 31% of 
cases, which is only 17% for other cervical cancers. Although this difference 
might involve CHFR promoter methylation, this relationship has only been 
shown in cervical cancer cell lines43. The same accounts for CHFR promoter 
methylation in endometrial cancers treated with paclitaxel, where CHFR 
promoter methylation is associated with increased sensitivity to paclitaxel, but 
is only tested in cell lines50,54. These results emphasize the need for bigger and 
better controlled patient series to investigate the role for CHFR promoter 
methylation as marker of response to taxanes.   
Conclusion 
In the last decade many studies have been performed to investigate CHFR 
promoter CpG island methylation as biomarker to predict prognosis and 
response to microtubule inhibitors in a diversity of cancers. There is compelling 
evidence that CHFR promoter methylation is a promising biomarker that can 
improve the management of multiple tumor types. Large, independent cohort 
studies and clinical trials to validate the prognostic and predictive value of 
CHFR promoter methylation are required and must be compared to established 
clinical markers such as for example the Tumor-Node-Metastasis (TNM) 
classification system. Simon et al. have proposed a less time consuming 
design in which archival material of prospective trials is used to investigate the 
performance of a single biomarker68.  
Still the majority of candidate-biomarkers reported in literature do not reach 
clinical use, mostly because they fail to pass the validation phase. This can be 
explained by heterogeneity of the tumors and a technical inability to 
consistently verify the presence of the biomarker in patient material and the 
lack of specificity for a particular disease⁹. Furthermore, comparison between 
studies is difficult because different methylation detection methods are used 
and different regions within the CpG island are analyzed. It is therefore that a 
standardized method to assess CHFR promoter CpG methylation within the 
core region of the CpG island is needed. MSP is a very accurate, easy to 
handle method that can be used in the majority of laboratories and therefore a 
good method of choice. Especially since the core region of methylation which is 
associated with expression and prognosis has been identified and can also be 
detected by MBD2-affinity sequencing (unpublished results).  
Although work is still in progress, currently available results all point towards 
the same direction, making CHFR promoter CpG island methylation a 
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biomarker with great potential and the development of clinical trials to study its 
predictive and prognostic power a priority. 
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Abstract 
Hypoxia modifies the phenotype of tumors in a way that promotes tumor aggressiveness and 
resistance towards chemotherapy and radiotherapy. However, the expression and influence of 
hypoxia-regulated proteins on tumor biology are not well characterized in colorectal tumors. We 
studied the role of protein expression of hypoxia-inducible factor (HIF)-1α, HIF-2α, carbonic 
anhydrase 9 (CA9) and glucose transporter 1 (GLUT1) in patients with colorectal adeno-
carcinomas. 
Expression of HIF-1α, HIF-2α, CA9 and GLUT1 was quantified by immunohistochemistry in 133 
colorectal adenocarcinomas. The expression of hypoxia markers was correlated with 
clinicopathological variables and overall patient survival.   
Expression of these hypoxia markers was detected in the epithelial compartment of the tumor cells 
as well as in tumor-associated stromal cells. Although tumor cells frequently showed expression of 
one or more of the investigated hypoxia markers, no correlation among these markers or with 
clinical response was found. However, within the tumor stroma, positive correlations between the 
hypoxia markers HIF-2α, CA9 and GLUT1 were observed. Furthermore expression of HIF-2α and 
CA9 in tumor-associated stroma were both associated with a significantly reduced overall survival. 
In the Cox proportional hazard model, stromal HIF-2α expression was an independent prognostic 
factor for survival.  
These observations show, that expression of hypoxia regulated proteins in tumor-associated 
stromal cells, as opposed to their expression in epithelial tumor cells, is associated with poor 
outcome in colorectal cancer. This study suggests that tumor hypoxia may influence tumor-
associated stromal cells in a way that ultimately contributes to patient prognosis. 
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Introduction 
Regulation of tissue oxygen homeostasis is critical for cell function, behavior 
and survival. Lack of oxygen (hypoxia), occurs early and remains a common 
feature of tumors throughout their development. Hypoxic areas in tumors 
contribute to a worse prognosis independent of treatment modality1,2. One of 
the underlying mechanisms proposed to account for this poor prognosis is a 
contribution of hypoxia to the malignant status of tumors through promotion of 
metastasis, angiogenesis, and selection of cells with defects in apoptosis3. In 
colorectal cancer, the importance of hypoxia has been demonstrated by clinical 
studies in which hypoxia predicts for worse outcome and resistance towards 
chemotherapy and radiotherapy4,5.  
The majority of studies investigating hypoxia in human tumors has been carried 
out with oxygen sensing needle electrodes that are capable of direct oxygen 
measurements in tumors6. However, this procedure is invasive and restricted to 
accessible tumor sites7. This has led to the development and testing of 
alternative hypoxia markers including the 2-nitroimidazole compounds 
pimonidazole and EF-5 which undergo reduction upon binding within hypoxic 
cells8. Estimation of hypoxia by these so-called “exogenous” markers is made 
several hours following intravenous administration, by evaluating the degree of 
binding using specific antibodies in biopsies9. In addition, several “endogenous” 
markers have also been proposed. These markers consist of hypoxia regulated 
gene products and include among others hypoxia inducible factor (HIF)-1α, 
HIF-2α, carbonic anhydrase 9 (CA9), glucose transporter 1 (GLUT1), glucose 
transporter 3 (GLUT3), and vascular endothelial growth factor (VEGF)9-17.  
HIF is a heterodimeric transcription factor composed of α and β subunits. HIF-
1β is expressed constitutively and is not sensitive to the hypoxic status of the 
cells, whereas the alpha subunit accumulates rapidly inside the hypoxic cells 
primarily because of the prevention of ubiquitination and subsequent protein 
degradation by the proteasome complex, which usually takes place in normoxic 
cells. There are three homologues of the alpha subunit (HIF-1α, HIF-2α, HIF-
3α)18. HIF-1α and HIF-2α are thought to play a significant role in tumor 
neovascularization, enhanced cellular proliferation, decreased apoptosis, and 
development of drug resistance to chemotherapeutic agents19. In colorectal 
cancer HIF-2α also seems to play an important role in angiogenesis, the 
combined expression of HIF-2α and HIF-1α may play a role in tumor 
progression and prognosis10,20.  
CA9 is a transmembrane glycoprotein and a member of the carbonic 
anhydrase family that is regulated by HIF21. Carbonic anhydrases are zinc 
metalloenzymes that catalyze the reversible conversion of carbon dioxide to 
carbonic acid and are involved in respiration, calcification, acid-base balance, 
the formation of cerebrospinal fluid, saliva, and gastric acid. Increased CA9 
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expression is induced by hypoxia, as was shown in a wide spectrum of tumor 
types including tumors of the uterine cervix, head and neck, lung, bladder, 
breast, esophagus, colon and rectum22-29. CA9 expression has previously been 
demonstrated in colorectal tumors by Saarnio et al. (1998). CA9 staining 
intensity in colorectal tumors was higher in less advanced tumors (Dukes A + 
B)29,30.   
GLUT1 is a member of the glucose transporter family of proteins facilitating 
independent transport of glucose that is also regulated by HIF. Tumors have 
accelerated metabolism and increased requirements for ATP production, 
therefore cancer cells have high rates of glycolysis. Elevated GLUT1 
expression under hypoxic conditions has been described for many cancers, 
including hepatic, pancreatic, breast, esophageal, brain, renal, lung, cutaneous, 
colorectal, endometrial, ovarian and cervical carcinoma31. In a study done by 
Haber et al in colorectal cancer, disease specific mortality was greater in 
patients with high expression of GLUT1 in tumors (>50% of cells were GLUT1 
positive)32. Furthermore, GLUT1 expression in colorectal cancer was shown to 
be associated with a high incidence of lymph node metastasis33. 
The present study was performed to evaluate the expression of hypoxia 
regulated proteins and their association with clinicopathological response in 
colorectal adenocarcinomas. We applied a panel of hypoxia-related 
endogenous immunohistochemical markers on a series of 133 colorectal 
cancer tissues, and correlated their expression with morphologic tumor 
parameters, clinicopathological features and overall patient survival. 
Materials and methods 
Patients 
Patients were entered in two multi-center prospective clinical trials between 
1979 and 1981 in the Netherlands. One trial was designed to compare patient 
survival after treatment of colonic cancer by conventional surgery or the no-
touch isolation technique34. The other trial was conducted to compare survival 
in rectal cancer patients with or without preoperative radiotherapy. At the time 
the trial was conducted, only surgical removal of the tumors was performed, 
and adjuvant chemotherapy was not yet standard practice. Although the results 
from this study can therefore not be extrapolated to current practice, it does 
enable unbiased study of the influence of hypoxic conditions on tumor biology. 
In the current study, we included only the patients who did not undergo 
preoperative radiotherapy. For immunohistochemical analysis tumor tissues 
from 133 patients with primary colorectal cancer were available. The 
distribution of age, gender, tumor stage, location and type of tumor, frequency 
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of events and mean follow-up time of the patients in this study are 
representative for the patients in the trial (see Table 6.1).  
 
Table 6.1 Clinicopathological variables of study population. 
Age  
   <69 years 
   >69 years 
 n=64 (48%) 
 n=69 (52%) 
Sex  
   Male 
   Female 
 n=55 (41%) 
 n=78 (59%) 
Tumor-size  
   <46mm 
   >46mm 
 n=57 (43%) 
 n=76 (57%) 
Tumor location  
   Proximal 
   Distal 
 n=52 (39%) 
 n=81 (61%) 
Tumor  
   Colon 
   Rectum 
 n=91 (68%) 
 n=42 (32%) 
Differentiation  
   Well 
   Moderate/poor 
 n=14   (11%) 
 n=119 (89%) 
TNM  
   1  n=0   (0%) 
   2  n=83 (63%) 
   3  n=35 (26%) 
   4  n=15 (11%) 
Tumortype  
   Exophytic  n=15 (11%) 
   Sessile  n=19 (14%) 
   Ulcerative  n=99 (74%) 
 
 
Follow up took place every 3 months during the first three years and every 6 
months between three and five years after initial diagnosis and surgery. 
Standard protocols were followed, with routine blood counts and chemistry 
studies (including CEA levels) at each visit and liver ultrasound, chest x-ray 
and colonoscopy annually, to evaluate both recurrence of disease and disease-
related death. After the initial five year follow up period, during the next years 
only the time and cause of death were registered. Follow-up was complete for 
all patients. In the present study, failure was defined as death due to recurrent 
disease, excluding postoperative mortality within 30 days and non-disease 
related death.  
After surgery, tumor tissues and lymph nodes were fixed in buffered formalin, 
sectioned, and embedded in paraffin. Experienced pathologists documented 
the histopathological characteristics of the tumors, including tumor stage, 
differentiation grade, size, (lymph-)angioinvasion, perineural invasion and 
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lymphnode involvement. Tumor stage was defined according to the TNM 
staging system. 
Immunohistochemistry 
Formalin fixed, paraffin-embedded tissues consisting of both normal mucosa 
and tumor were used for immunohistochemical staining. Serial sections (4 µm) 
from each patient were stained for HIF-1α, HIF-2α, CA9 and GLUT1 after 
deparaffination. Endogenous peroxidase activity was blocked by pre-incubating 
in 0.6% hydrogen peroxide for 20 min.  
The following staining protocols for the different antibodies were used: 
HIF-1α staining: Antigen retrieval was performed by microwave 750 W for 2 
min. followed by 20 min. at 90 W in 1mM TE buffer pH 9.0, followed by 30 min. 
cooling in buffer. Slides were blocked in 25% normal serum for 10 min. 
Sections were incubated overnight (4ºC) with primary antibody HIF-1α (1:120) 
(anti-HIF-1α  monoclonal: 610958 BD, USA).  
HIF-2α staining: Antigen retrieval was performed by microwave treatment (750 
W for 20 min in 1mM TE buffer pH 8.0), followed by 30 min. cooling in buffer. 
Slides were blocked in 25% normal serum for 10 min. Sections were incubated 
with primary antibody HIF-2α (1:500) for 100 min. (anti-HIF2 alpha monoclonal: 
ab8365  AbCam, UK). 
CA9 staining: Slides were blocked in 25% normal serum for 10 min., then 
incubated for 45 min. with primary CA9 antibody MoAb M75 (1:50) (anti-human 
CA9, kindly supplied by Dr. S. Pastorekova) at room temperature27. 
GLUT1 staining: Microwave treatment (750 W for 15 min. in Citrate buffer pH 
6.0), followed by 30 min. cooling in buffer. Slides were blocked in 25% normal 
serum for 10 min. Sections were incubated (1:100) with primary antibody 
GLUT1 (rabbit polyclonal anti-human GLUT1, A3536, DakoCytomation, 
Denmark) for 2 hr. followed by incubation with Swine Anti-Rabbit 
Immunoglobuline/Biotinylated (E0431, DakoCytomation, Denmark) (1:250) for 
30 min. at room temperature, and StreptABComplex/HRP (K0377, 
DakoCytomation, Denmark) (1:200) for 30 min. at room temperature. 
As a negative control for all antibodies, TBS buffer instead of primary antibody 
was used. Visualization was performed using Dako Envision, Peroxidase, 
mouse System (K4001, DAKO, Denmark). For GLUT1, Diaminobenzidine was 
applied for 10 min. The slides were counterstained with hematoxylin and 
mounted. 
Evaluation of staining 
Immunohistochemical staining was evaluated on the basis of 1) localisation in 
tumor epithelial or stromal cells and 2) subcellular localisation. For the tumor 
stroma, only the tumor-associated stromal cells were taken into account, not 
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the tumor infiltrating inflammatory cells or the lamina propia of the normal 
mucosa.  
If nuclear staining was present in >5% of the tumor epithelial cells or tumor-
associated stromal cells, the sample was considered positive for HIF-1α and 
HIF-2α. If membranous staining occurred in >5% of the tumor epithelial cells or 
stromal cells, samples were considered positive for CA9 and GLUT1. Staining 
results were also checked by determining the extent and intensity of staining. 
Because this did not change the categorization, we used the 5% cut-off value 
for further analysis20. 
Data analysis 
For the data analyses we used three groups of expression patterns for HIF-1α, 
HIF-2α, CA9 and GLUT1 expression, namely: 1 Stromal expression (= defined 
as purely stromal or a combination of stromal and epithelial expression), 2 
Epithelial expression (=defined as epithelial only or a combination of stromal 
and epithelial expression), and 3 Negative.  
The correlations between HIF-1α, HIF-2α, CA9, GLUT1 and various 
clinicopathological parameters were determined by the Pearson Chi-Square 
and Fisher’s exact test as appropriate. To evaluate the relationship between 
HIF-1α, HIF-2α, CA9, GLUT1 and patient survival, Kaplan-Meier survival 
curves were calculated. Statistical differences between groups were 
determined by using the Log-rank test. The endpoint for analyses was overall 
survival starting from the day of surgery. Independent variables predicting 
survival were evaluated by the multiple stepwise regression analyses using 
Cox Regression. The Cox-regression model included the variables: sex, age, 
tumor size, tumor location, TNM stage, differentiation grade, HIF-1α, HIF-2α, 
CA9 and GLUT1 (epithelial and stromal expression separately). All p-values 
are two sided and p-values <0.05 were considered statistically significant. 
SPSS 10.0 software was used for data analyses. 
To check for differences between colon and rectum tumors, all survival 
analyses were performed separately for these two categories. 
Results 
We evaluated the staining characteristics of the potential hypoxia markers HIF-
1α, HIF-2α, CA9 and GLUT1 in 133 human colorectal adenocarcinomas. On 
analyzing these four hypoxia associated proteins, it became clear that many 
tumors displayed positive staining in the tumor epithelial cells as well as 
positive staining in tumor- associated stromal cells. We therefore separately 
evaluated the staining patterns of HIF-1α, HIF-2α, CA9 and GLUT1 in tumor 
epithelial cells and tumor-associated stromal cells. All tumors showed 
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immunohistochemical expression of at least one of the analysed hypoxia 
markers. Overall HIF-1α was positive in 43% of cases, whereas 83% of the 
tumors were positive for HIF-2α, 89% of the tumors showed CA9 protein 
expression and GLUT1 expression was positive in 85% of the cases. 
Expression of hypoxia proteins in tumor epithelial cells 
In order to evaluate the association of hypoxia and the clinical outcome of 
colorectal cancer, quantification of the expression of hypoxia markers within the 
tumor epithelial cell compartment was performed. Overall, 29% of the patients 
showed HIF-1α protein expression within the tumor epithelial cells (Figure 
6.2A). In these cells, HIF-1α expression was observed exclusively in the nuclei, 
often in areas surrounding tumor necrosis (Figure 6.1A), a pattern that is typical 
of hypoxia induced expression. Surprisingly, none of the 133 tumors showed 
any staining for HIF-2α in tumor epithelial cells. This lack of expression may be 
associated with the intestinal cell lineage as expression was also not detected 
in any adjacent normal intestinal epithelial cells. Epithelial CA9 expression was 
observed in 78% of all tumors (Figure 6.2C). Expression in the tumor cells was 
restricted to a membranous type of expression (Figure 6.1E) but was typically 
not perinecrotic. GLUT1 was also present in tumor epithelial cells in 83% of the 
cases (Figure 6.2D), where it showed a clear and strong membranous staining, 
typically surrounding areas of tumor necrosis (Figure 6.1G). 
Expression of hypoxia proteins in the tumor-associated stromal 
cells 
Stromal HIF-1α expression was observed in 32% of tumors, of which 18% 
showed  combined staining of tumor epithelium and stroma and 14% showed 
exclusive staining in the stromal cells (Figure 6.2A). Staining was observed 
surrounding areas of tumor necrosis (Figure 6.1B) and was confined to the 
nuclei.  
In contrast with the lack of HIF-2α expression in tumor epithelial cells, HIF-2α 
staining was frequently seen within the tumor stroma, both in tumor-associated 
stromal cells and inflammatory cells (Figure 6.1C and 6.1D). Expression was 
predominantly nuclear, only occasionally accompanied by additional 
cytoplasmic staining. In further analysis, HIF-2α staining of inflammatory cells 
in the tumor stroma was disregarded, because HIF-2α expression in 
inflammatory cells did not influence the effect of HIF-2α expression in tumor-
associated stromal cells on patient outcome (Figure 6.3A). Overall, 83% of the 
tumors showed positive staining for HIF-2α in stromal cells, typically 
surrounding areas of necrosis (Figure 6.2B). In the remaining 17% of the 
tumors where no expression of HIF-2α was observed, some staining was found 
in inflammatory cells in the lamina propria of the normal mucosa. Stromal 
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membranous CA9 expression (Figure 6.1F) was observed in 37% of all tumors. 
Interestingly, of the tumors that lacked CA9 expression in tumor epithelial cells, 
half were positive for CA9 in the stroma (Figure 6.2C). GLUT1 expression was 
only occasionally detected in stromal cells and restricted to a membranous type 
of expression (Figure 6.1H). Stromal cell expression of GLUT1 was present in 
14 % of the cases (Figure 6.2D).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1 Expression patterns of hypoxia regulated proteins in colorectal tumors. black arrow: 
(A, E, G) epithelial tumor cell expression, (B, D, F, H) tumor-associated stromal cell 
expresion, (C) inflammatory cell expression. (A) HIF-1α expression in the nuclei of 
epithelial tumor cells. (B) HIF-1α expression in the nuclei of tumor-associated stromal 
cells. (C) HIF-2α expression in inflammatory cells located within the tumor-associated 
stroma. (D) HIF-2α expression in tumor-associated stromal cells. (E) CA9 expression 
in epithelial tumor cells. (F) CA9 expression in tumor-associated stromal cells. (G) 
Expression of GLUT1 in tumor epithelial cells. (H) GLUT1 expression in tumor-
associated stromal cells. (A, B, D, F and H original magnifications x 40; C, E and G 
original magnifications × 20.) 
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No staining of stromal cells within the lamina propria of surrounding normal 
mucosa was found for any of these hypoxia inducible proteins. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2 Quantification of expression patterns of hypoxia associated proteins in 133 colorectal 
cancers. (A) Quantification of HIF-1α expression patterns. (B) Quantification of HIF-2α 
expression patterns. (C) Quantification of CA9 expression patterns. (D) Quantification 
of GLUT1 expression patterns. 
 
Correlations between HIF-1α, HIF-2α, CA9, GLUT1 and clinico-
pathological variables  
To investigate the functional relevance of HIF-1α and HIF-2α expression, we 
tested the correlations of the expression of these transcription factors with the 
expression of their downstream gene products CA9 and GLUT-1. HIF-1α 
expression showed no correlation with HIF-2α, GLUT1 or CA9 when analyzed 
by either epithelial or stromal expression patterns. This suggests that HIF-1α 
expression is not primarily responsible for induction of CA9 and GLUT1 
expression and that these genes are regulated by factors other than HIF-1α. In 
contrast, a significant correlation was found between HIF-2α and CA9 (p=0.02, 
Table 6.2) within the tumor stroma. Furthermore, GLUT1 and CA9 expression 
within the tumor stroma were significantly correlated (p=0.002, Table 6.2). 
These data suggest that HIF-2α upregulation in tumor stroma may be 
responsible for upregulation of CA9 . 
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Table 6.2 Correlations between stromal expression of HIF-1α, HIF-2α, CA9, GLUT1. 
 HIF-2α  p-value  HIF-1α  p-value 
 Stroma Negative   Stroma Negative  
HIF-1α    GLUT1    
Stroma 37/43 (86%) 6/43 (14%)  Stroma 5/19 (26%) 14/19 (74%)  
Negative 74/90 (82%) 16/90 (18%) 0.6 Negative 38/114 (33%) 76/114 (67%) 0.5 
 HIF-2α    HIF-1α   
 Stroma Negative   Stroma Negative  
GLUT1    CA9    
Stroma  17/19 (89%) 2/19 (11%)  Stroma 18/48 (38%) 30/48 (62%)  
Negative 94/114 (82%) 20/114 (18%) 0.7 Negative 25/85 (29%) 60/85 (71%) 0.3 
 HIF-2α    GLUT1   
 Stroma Negative   Stroma Negative  
CA9    CA9    
Stroma  45/48 (94%) 3/48 (6%)  Stroma  13/48 (27%) 35/48 (73%)  
Negative 66/85 (78%) 19/85 (22%) 0.02 Negative 6/85 (7%) 79/85 (93%) 0.002 
 
 
No significant correlation was found between stromal or epithelial expression of 
HIF-1α, HIF-2α or GLUT1 and any of the following clinicopathological 
characteristics: age, sex, tumor size, location in the colon (proximal, distal), 
differentiation (well, moderately and poorly), TNM stage (2,3 and 4). Only CA9 
epithelial expression showed a significant correlation with TNM stage, with 
reduced CA9 expression in the more advanced tumors. These results suggest 
that the biological responses to hypoxia in colorectal cancer are largely 
independent of these clinicopathological variables. 
Relationship between hypoxia markers and patient survival  
An important objective of our study was to analyze the relationship between 
hypoxia regulated proteins and patient survival. Previous studies in other tumor 
types have indicated that expression of the hypoxia induced proteins 
investigated here correlate with poor overall survival. This is presumed to be 
due to an adverse effect of hypoxia on the tumor cells themselves. Since we 
also observed frequent staining within the tumor stroma, we further 
investigated the potential relationship between stromal hypoxia and overall 
survival.  
HIF1-α expression in tumor-associated stromal cells and epithelial tumor cells 
showed no significant correlation with patient survival. Similarly, CA9 epithelial 
expression had no impact on patient survival. GLUT1 epithelial negative cases 
showed a significantly poorer survival compared to GLUT1 positive epithelial 
cases (p=0.02, Figure 6.3B).   
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Figure 6.3 (A) Survival curve HIF-2α expression including inflammatory cells (IC) p=0.06 
(n=133). (B) Survival curve GLUT1 epithelial expression  p=0.02 (n=133). (C) 
Survival curve HIF-2α (without inflammatory cells) p=0.008 (n=133). (D) Survival 
curve HIF-2α stratified for TNM stage 2 p<0.05 (n=83). (E) Survival curve HIF-2α 
stratified for TNM stage 3 p=0.4 (n=35). (F) Survival curve CA9 p=0.01 (n=133). 
 
 
In contrast to the lack of association between markers of hypoxia in the tumor 
cells and clinical response, we found strong evidence that stromal hypoxia may 
be associated with poor outcome. Patients with stromal HIF-2α expression 
showed a statistically significant poorer survival compared to HIF-2α negative 
patients (p=0.008, Figure 6.3C). This trend was maintained in TNM stage 2 and 
stage 3 (Figure 6.3D and 6.3E). The same trend was observed for stromal CA9 
expression (p=0.01, Figure 6.3F). Patients with stromal GLUT1 expression also 
showed a tendency for poorer overall survival compared to patients negative 
for stromal GLUT1 expression, although this did not reach statistical 
significance. There was no difference in survival between cases with exclusive 
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stromal expression and cases with combined stromal and epithelial expression 
for any of the four applied markers (data not shown). 
Multivariate analysis 
An overall model to test the most relevant prognostic factors for patient 
outcome was performed using a multistep Cox-regression model. After 
stepwise multivariate analysis, stromal HIF-2α positivity (Hazard Ratio (HR) 
4.61), tumor epithelial GLUT1 positivity (HR 0.44), TNM stage 3 (HR 2.74) and 
stage 4 (HR 16.09) and age >69 years (HR 2.09) were statistically significant 
independent prognostic markers. Poorly and moderately differentiated tumors 
had a HR of 3.12 compared to well differentiated tumors, although this did not 
reach statistical significance (p=0.07, Table 6.3). Multivariate analysis restricted 
to stage 2 and 3 cases, revealed stromal HIF-2α positivity as the strongest 
independent prognostic marker, with a HR 4.87 (p=0.01), followed by TNM 
stage 3 (HR 2.29, p=0.01), stromal CA9 expression (HR 1.95, p<0.05), age 
>69 years (HR 1.94, p<0.05) and epithelial GLUT1 expression (HR 0.26, 
p=0.001). 
There were no differences in univariate or multivariate survival analysis 
between colon and rectum tumors. 
 
Table 6.3 Cox proportional hazard model. 
 Event: CRC mortality 
HR (95%CI) 
p-value 
HIF-2α Positive*    4.61 (1.40-15.50) 0.01 
GLUT1 Epithelial†  0.44 (0.22-0.86) 0.02 
TNM 3‡  2.74 (1.42-5.29)   0.003 
 4‡  16.09 (7.00-39.95)   0.000 
Differentiation  Moderately/poorly**  3.12 (0.93-10.48) 0.07 
Age  >69 years††   2.09 (1.16-3.74) 0.01 
CRC, colorectal cancer; HR, Hazard Ratio=Relative Risk. *Reference group = negative HIF-2α 
cases; †Reference group = negative GLUT1 cases; ‡Reference group = TNM stage 2; **Reference 
group = well differentiated; ††Reference group = Age<69 years. 
Discussion  
This is the first comprehensive study analyzing the expression of endogenous 
hypoxia markers HIF-1α, HIF-2α, CA9 and GLUT1 in colorectal cancer. All 133 
tumors in this study showed expression of at least one of the hypoxia-regulated 
proteins, suggesting that all tumors may exhibit at least some degree of 
hypoxia. In contrast to what was initially expected, our data suggest that HIF-1α 
immunostaining does not appear to be a reliable indicator of hypoxia in 
colorectal cancer and furthermore does not correlate with patient outcome. 
Although HIF-1α did display staining characteristics consistent with hypoxia 
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(peri-necrotic staining of cell nuclei), its expression in either stromal or tumor 
cells did not correlate with the expression of its downstream genes CA9 and 
GLUT1.  Consistent with our results, HIF-1α staining was previously reported to 
be positive in 44.8% of patients with colorectal cancer, but had no correlation 
with HIF-2α expression and no prognostic value5. Several explanations for the 
lack of correlation between HIF-1α and CA9 or GLUT1 in the tumor cells are 
possible. HIF-1α is susceptible to degradation after prolonged hypoxia due to 
upregulation of the Prolyl Hydroxylase Domain proteins35. In vitro studies 
suggest that nutrient deprivation may also decrease HIF-1α expression. 
Furthermore, the half-life of CA9 is sufficiently long (>>24hrs) that once formed 
it remains present for many days in the absence of continued HIF-1α 
expression36.  
As for HIF-1α, our data indicate that tumor epithelial cell expression of CA9, 
although frequently occurring, is not related to poorer survival either. In fact, we 
found that epithelial CA9 expression decreased with advancing TNM stage, 
with 78% of CA9 epithelial positive cases in TNM stage 2 compared to 53% of 
CA9 epithelial positive cases in TNM stage 4 (p=0.02). It is well known that in 
colorectal cancer TNM Stage 2 tumors have a better overall survival than 
Stage 4 tumors37. The lack of correlation between HIF-1α and CA9 expression 
in tumor epithelial cells suggests that the CA9 positivity may also be unrelated 
to hypoxia. This is supported by the finding that in cases with only tumor 
epithelial CA9 staining (53%), the expression was usually not perinecrotic. On 
the other hand, tumor epithelial cell expression of GLUT1 in our study was 
typically found in perinecrotic zones, and therefore may indeed be indicative of 
tumor hypoxia. However, GLUT1 epithelial positivity turned out to be a marker 
for good prognosis compared to epithelial negative GLUT1 cases. This is 
somewhat surprising, since GLUT1 expression has been previously reported to 
be associated with a high incidence of lymphnode metastases38. Although 
further analyses is clearly necessary to determine the role for epithelial GLUT1 
expression within different TNM stages of colorectal cancer, our data do not 
support the premise that epithelial GLUT1 expression is a poor prognostic 
factor. Taken together, the immunostaining patterns of these four markers 
within the tumor epithelial cell compartment do not consistently reflect tumor 
hypoxia, and tumor epithelial cell hypoxia does not seem to contribute to a 
poorer patient prognosis in colorectal cancer. 
In direct contrast to these results, our study did indicate that the tumor stroma 
may be frequently hypoxic. We found that 84% of all tumors demonstrated 
staining of HIF-2α within the tumor-associated stromal cells. HIF-2α appears to 
be biologically active in stromal cells because HIF-2α correlated significantly 
with stromal CA9 expression (p=0.02) in these tumors. Most importantly, 
tumors showing stromal HIF-2α expression also had a worse overall survival 
when compared with HIF-2α negative cases. After stratification for other factors 
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in a multivariate analysis (sex, age, TNM stage, differentiation grade, HIF-1α, 
GLUT1 and CA9), stromal HIF-2α expression was a strong (HR 4.61, p=0.01) 
independent unfavorable prognostic factor. The negative impact of HIF-2α 
expression on patient survival in colorectal cancer was recently also described 
by others. However, in this study of curatively resected colorectal carcinoma 
patients, the authors did not study the contribution of the epithelial and stromal 
tumor compartments separately20.  
As might be expected given the correlation between HIF-2α and CA9 in tumor-
associated stromal cells, our data also indicated that stromal CA9 expression 
was associated with a worse overall survival. Furthermore, stromal CA9 
expression proved to be an independent unfavorable prognostic factor in cases 
having stage 2 or 3 colorectal cancer. This finding may not be unique to 
colorectal cancer. In invasive breast cancer, stromal CA9 expression levels 
have been associated with a higher relapse rate and a worse overall survival39.  
Together our data suggest the intriguing possibility that hypoxia within the 
tumor associated stroma may contribute to a poor outcome in patients with 
colorectal cancer who are treated by surgery alone. Although it is commonly 
accepted that the genetic and epigenetic changes in tumor cells are 
responsible for the differences in patient response, there are also data to 
suggest that non-tumor cells may play an important role as well. The induction 
of CA9 by hypoxia could help in maintaining normal intracellular pH, preventing 
apoptosis, and thus provide a survival advantage to the stromal cells, and 
indirectly be of benefit to the adjacent tumor cells. A reduction in extracellular 
pH might also provide an advantage to tumor cells as it helps in breakdown of 
extracellular matrix, migration and invasion of tumor cells, as well as induction 
and expression of growth factors. This explanation is consistent with a report 
from Sivridis et al., who showed that cancer-stromal cell interactions may be 
favoured by the altered microenvironmental conditions of hypoxia and acidity 
40
. The strong association of markers of intratumoral hypoxia and pH within the 
tumor stroma indicates an interesting link between cancer cell metabolism and 
the induction of a supportive stroma that favors cancer cell invasion and 
migration30,31,41-44.   
Recent data have provided further compelling evidence that tumor-associated 
stromal cells are important in cancer growth and metastasis45. In colorectal 
tumors not only epithelial but also stromal elements demonstrate genetic 
instability and that such stromal alterations might influence the genesis of 
sporadic colorectal carcinomas46. Weinberg et al. showed that co-injection of 
carcinoma associated stromal cells (myofibroblasts) promoted the growth of 
invasive breast carcinomas. This effect was mediated in part through increased 
secretion of stromal cell-derived factor-1 (SDF-1). This is particularly interesting 
since SDF-1 and its receptor have been shown to be upregulated by hypoxia47. 
The Weinberg study also indicated that the tumor associated stromal cells 
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could promote angiogenesis by recruiting endothelial progenitor cells (EPC’s) 
into carcinomas48. Stromal cells within the tumor microenvironment have been 
shown to acquire new properties, including the capacity to promote phenotypic 
and genetic progression in adjacent epithelial cells30,49. For example, epigenetic 
changes have been shown to occur in stromal cells of breast cancer during 
tumorigenesis, in a tumor stage- and cell type-specific manner50. Alterations of 
stromal cells may therefore be either a consequence or contributor to an 
abnormal tumor micro-environment. Our study indicates that hypoxia may be a 
potential mechanism influencing the phenotype of tumor stroma, ultimately 
leading to a worse patient prognosis. 
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Abstract 
It is becoming increasingly clear that epigenetic alterations, such as promoter CpG island 
methylation of important cancer related genes, play a crucial role in the cellular responses to 
hypoxia, another hallmark of cancer. This study investigates whether hypoxia in CRC is associated 
with promoter CpG island methylation of genes involved in important tumor biological processes 
such as genomic instability, limitless replication potential, tissue invasion and metastasis, 
insensitivity to anti-growth signals, self-sufficiency in growth signals, sustained angiogenesis and 
evading apoptosis.  
Expression of HIF-1α, HIF-2α, CA9 and GLUT1 was quantified by immunohistochemistry in 173 
colorectal adenocarcinomas. Promoter CpG island methylation was determined using methylation-
specific PCR (MSP) for the following genes: MGMT, CHFR, HLTF, MLH1, RASSF1A (genomic 
instability), p14ARF, p16INK4A (limitless replication potential), ADAM23, TFPI2 (tissue invasion 
and metastasis), APC (insensitivity to anti-growth signals), SOCS1 (self-sufficiency in growth 
signals), THBS1 (sustained angiogenesis), BNIP3, NEURL, RUNX3, RAB32 (evading apoptosis). 
Associations between these variables were determined by T-test of means, Pearson Chi-Square 
and Fisher’s exact test as appropriate. 
Overall we did not find a correlation between mean number of promoter methylated genes and 
expression of hypoxia regulated proteins. However, methylation of individual genes was associated 
with stromal rather than epithelial expression of hypoxia regulated proteins: stromal expression of 
CA9 was more often observed in CHFR and ADAM23 methylated tumors (52% (35/67) and 58% 
(35/60)) compared to tumors unmethylated for these two genes (34% (29/86) and 28% (22/79), 
respectively p=0.03 and p<0.001). Stromal expression of HIF-2α was more often observed in APC 
and SOCS1 methylated tumors (82% (46/56) and 79% (77/98), respectively) compared to tumors 
unmethylated for these two genes (67% (73/109) and 61% (39/64) respectively, p=0.04 and 
p=0.02). Only BNIP3 methylated CRCs showed more often CA9 epithelial expression (87% 
(78/90)) compared to its unmethylated counterpart (73% (50/69), p=0.03). 
Stromal expression of hypoxia regulated proteins HIF-2α and CA9 was associated with promoter 
CpG island methylation of genes involved in important tumor biological processes. Tumors with 
hypoxic features do not appear to show increased overall CpG island promoter methylation, but 
rather harbour specific methylated cancer biology related genes, which could contribute to the 
more aggressive behaviour of these tumors.  
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Introduction 
Hypoxia has been recognized as one of the fundamental features of solid 
tumors like colorectal cancer (CRC). It plays a critical role in various cellular 
and physiologic events, including apoptosis, cell proliferation and 
angiogenesis1-4. Also it is important from a clinical point of view, as hypoxic 
tumors show resistance to radiation therapy and chemotherapy, and a poorer 
prognosis by increasing risk of invasion and metastasis1-4. The cellular 
responses to hypoxia are at least partially orchestrated by activation of the 
hypoxia-inducible factors (HIFs) and its many downstream genes including 
carbonic anhydrase 9 (CA9) and glucose transporter 1 (GLUT1)2. In the 
previous chapter we studied the role of protein expression of HIF-1α, HIF-2α, 
CA9 and GLUT1 in colorectal adenocarcinomas. We concluded that expression 
of hypoxia regulated proteins in tumor associated stroma, as opposed to their 
expression in cancer cells, is associated with poorer outcome, suggesting that 
tumor hypoxia may influence tumor associated stromal cells in a way that 
ultimately effects patient prognosis.  
It is becoming increasingly apparent that epigenetic alterations, such as 
promoter CpG island methylation of important cancer related genes, also play a 
crucial role in the cellular responses to hypoxia5. Hypoxia could be a 
consequence of tumor progression through increased CpG island methylation 
and silencing of important tumor suppressor genes, or conversely, hypoxia 
could induce cancer related epigenetic changes. Such epigenetic changes may 
co-operate with hypoxia induced proteins to contribute to the maintenance of a 
hypoxia-adapted cellular phenotype, which is associated with an aggressive 
tumor behavior5. There are four current opinions on the interaction of 
epigenetics and hypoxia: (1) HIF stabilisation is influenced by the epigenetically 
controlled expression of several HIF-degrading proteins, for example silencing 
of VHL by promoter CpG island hypermethylation in renal cell carcinomas6. (2) 
Epigenetic mechanisms such as histone acetyltransferase enzymes regulate 
HIF binding by maintaining a transcriptionally active chromatin confirmation 
within and around HIF binding regions7. (3) Histone demethylase enzymes are 
direct HIF target genes and therefore play a role in the regulation of 
transcription during the hypoxic response8. (4) Significant global changes in 
histone modifications and promoter CpG island methylation occur in response 
to hypoxic exposure.  
Studying the relation between hypoxia and epigenetic mechanisms should 
address the notion that the extent of promoter CpG island methylation of tumor 
suppressor genes and other important cancer related genes influences the 
ability of a tumor to adapt to hypoxia5,9. An example of this phenomenon is 
found in both CRC and pancreatic cancer, where hypoxic induction of BCL-
2/adenovirus E1B-19 kDA-interacting protein (BNIP3), which is known to 
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promote apoptosis, is blocked by promoter CpG island methylation, thereby 
facilitating the evasion of apoptosis during hypoxia10,11. Previously we observed 
that promoter CpG island methylation of CHFR is related to a poorer survival. 
Loss of function of CHFR causes genomic instability12-14, which is a feature of 
tumor progression leading to increasing hypoxia, but may also contribute to 
intrinsic resistance of tumor cells to hypoxia4. Comparable to promoter CpG 
island methylation of BNIP3, silencing of CHFR could contribute to a more 
efficient adaptation of a tumor to hypoxia, eventually resulting in a more 
aggressive tumor behavior.    
The aim of the current study was to find out whether expression of hypoxia 
regulated proteins in CRC is related to promoter CpG island methylation of 16 
genes which are frequently methylated in CRC, and also involved in main 
pathways of tumor progression, the so-called hallmarks of cancer15 (Table 7.1): 
MGMT, CHFR, HLTF, MLH1, RASSF1A (genomic instability), p14ARF, 
p16INK4A (limitless replication potential), ADAM23, TFPI2 (tssue invasion and 
metastasis), APC (insensitivity to anti-growth signals), SOCS1 (self-sufficiency 
in growth signals), THBS1 (sustained angiogenesis), BNIP3, NEURL, RUNX3, 
RAB32 (evading apoptosis). Methylation status of these genes was determined 
using methylation-specific PCR (MSP) in a series of 173 CRCs. Expression of 
HIF-1α, HIF-2α, CA9 and GLUT1 was quantified by immunohistochemistry in 
this series of CRC’s. Since we previously described the importance of stromal 
expression of hypoxia regulated proteins for patient survival in CRC, in the 
current study we also investigated whether promoter CpG island 
hypermethylation was related to differential expression of hypoxia regulated 
proteins, in either the epithelial or stromal tumor compartments. 
 
Table 7.1 Promoter CpG island hypermethylated genes related to the hallmarks of cancer 
Cancer Hallmarks Promoter CpG island hypermethylated genes Reference 
Genomic instability MGMT, CHFR, HLTF, MLH1, RASSF1A 12-14,40-56 
Limitless replication potential p14ARF, p16INK4A 57-60 
Tissue invasion and metastasis ADAM23, TFPI2 15,61-68  
Insensitivity to anti-growth signals APC 69-71 
Self-sufficiency in growth signals SOCS1 72-74  
Sustained angiogenesis THBS1 75-77 
Evading apoptosis BNIP3, NEURL, RUNX3, RAB32 78-86 10,37-39,87-91 
 
Materials and methods 
Patient population 
Patients were entered in two multi-center prospective clinical trials in the 
Netherlands, between 1979 and 1981. One trial was designed to compare 
patient survival after treatment of colon cancer by conventional surgery or the 
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no-touch isolation technique16. The second trial was conducted to compare 
survival in rectal cancer patients with or without preoperative radiotherapy. In 
the current study, we included only the patients who did not undergo 
preoperative radiotherapy. At the time the trial was conducted, only surgical 
removal of the tumors was performed, and adjuvant chemotherapy was not yet 
standard practice. This study population therefore enables unbiased study of 
the influence of hypoxic conditions on tumor biology.  
Tumor tissues were fixed in buffered formalin, sectioned, and embedded in 
paraffin. Experienced pathologists documented the histopathological 
characteristics of the tumors (see previous chapters). Follow up took place 
every 3 months during the first three years and every 6 months between three 
and five years after initial diagnosis and surgery. Standard protocols were 
followed, with routine blood counts and chemistry studies (including CEA 
levels) at each visit and liver ultrasound, chest x-ray and colonoscopy annually, 
to evaluate recurrence of disease and disease-related death. After five year 
follow up period, only time and cause of death were registered. Follow-up was 
complete for all patients. Failure was defined as death due to recurrent 
disease, excluding postoperative mortality within 30 days and non-disease 
related death.  
For immunohistochemical and molecular analysis, tumor tissues from 173 CRC 
patients were available. The distribution of age, gender, tumor stage, location 
and type of tumor, frequency of events and mean follow-up time of the patients 
in this study are representative for the patients in the trial. 
Immunohistochemistry 
Immunohistochemistry and evaluation of the data was performed as described 
previously17. In brief serial formalin fixed, paraffin-embedded tissues sections 
(4 µm) were stained for HIF-1α, HIF-2α, CA9 and GLUT1. Localisation 
(epithelial or stromal) was scored separately. For the category stromal staining 
only the stromal myofibroblasts were taken into account, not the tumor 
infiltrating inflammatory cells or the lamina propia of the normal mucosa. If 
staining was present in >5% of the tumor stromal cells, the sample was 
considered positive for stromal expression. If membranous staining occurred in 
>5% of the tumor epithelial cells, samples were considered positive for 
epithelial expression18. 
Promoter CpG island methylation analysis 
Genomic DNA was extracted from CRC tissues using PureGene™ Genomic 
DNA Isolation Kit (Gentra Systems) according to the manufacturer’s protocol. 
Promoter CpG island methylation of MLH1 (mutL homolog1, colon cancer, 
nonpolyposis type 2 (E.Coli)), p16INK4A (cyclin dependent kinase inhibitor 2A), 
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p14ARF (cyclin dependent kinase inhibitor 2A), MGMT (O-6-methylguanine-
DNA methyltransferase), RASSF1A (Ras association (RalGDS/AF-6) domain 
family member 1), APC (adenomatous polyposis coli), HLTF (helicase-like 
transcription factor), CHFR (checkpoint with forkhead and ring finger domain), 
ADAM23 (ADAM metallopeptidase domain 23), RAB32 (Rab32, a member 
RAS oncogene family), BNIP3 (BCL2-adenovirus E1B 19kDA interacting 
protein 3), NEURL (neuralized homolog (Drosophila)), THBS1 (thrombospondin 
1), TFPI2 (tissue factor inhibitor 2), RUNX3 (runt-related transcription factor 3) 
and SOCS1 (suppressor of cytokine signaling 1) was determined using sodium 
bisulfite modification of genomic DNA using the EZ DNA methylation kit (ZYMO 
research Co., Orange, CA). Methylation Specific PCR (MSP) was performed as 
described in detail elsewhere19,20. In brief, to facilitate MSP analysis on DNA 
retrieved from formalin-fixed, paraffin-embedded tissue, DNA was first 
amplified with flanking PCR primers that amplify bisulfite modified DNA but do 
not preferentially amplify methylated or unmethylated DNA. The resulting 
fragment was used as a template for the MSP-reaction. All PCRs were 
performed with a control for unmethylated alleles (normal lymphocyte DNA) 
and a positive control for methylated alleles (Sssl methyltransferase (New 
England Biolabs) treated normal lymphocyte DNA) and a negative control 
without DNA. Each PCR reaction was loaded onto a 2% agarose gel, stained 
with Gelstar® (Cambrex Bioscience Rockland Inc, USA) and visualized under 
UV illumination. For primers and PCR conditions see chapter 4. 
Data-analysis 
The Methylation Index (MI=number of methylated promoter CpG islands 
divided by number of promoter CpG islands successfully analyzed) was 
calculated using the promoter CpG islands of 16 genes (Table 7.1). 
Relationships between mean methylation index and expression of HIF-1α, HIF-
2α, CA9, GLUT1 was determined by T-test of means. Correlations between 
HIF-1α, HIF-2α, CA9, GLUT1 and the cancer hallmark genes were determined 
by the Pearson Chi-Square and Fisher’s exact test as appropriate. All p-values 
are two sided and p-values <0.05 were considered statistically significant. 
Patients with unknown and unspecified scores have been omitted from 
analyses for that specific variable. SPSS 15.0 software was used for data 
analyses. 
Results 
Overall, no correlation was observed between epithelial and stromal expression 
of HIF-1α, HIF-2α, CA9 and GLUT1 and the methylation index in these 
subgroups of CRC, which varies between 0.36 and 0.45 (Table 7.2). However 
 Promoter CpG island methylation and hypoxia133 
when categorizing each gene in important tumor biology pathways (Table 7.1), 
we found that promoter CpG island methylation of a least one gene within each 
group was associated with stromal expression of hypoxia regulated proteins 
but not with epithelial expression (Table 7.3). Within the group of genomic 
instability associated genes (MGMT, CHFR, HLTF, MLH1, RASSF1A), stromal 
expression of hypoxia regulated protein CA9 was more often observed in 
CHFR methylated tumors 52% (35/67) compared to unmethylated CHFR 
tumors 34% (29/86), p=0.03. Epithelial expression of hypoxia regulated 
proteins was not related to methylation of genes involved in genomic instability. 
Within the group of methylated genes involved in limitless replication potential 
(p14ARF, p16INK4A), we found a borderline significant correlation that stromal 
expression of HIF-2α was more often observed in p16INK4A methylated 
tumors 80% (56/70) compared to unmethylated p16INK4A tumors 65% (58/89), 
p=0.05. In line with the group of genes involved in genomic instability, epithelial 
expression of hypoxia regulated proteins was not associated with the 
methylation status of genes related to limitless replication potential. Between 
hypoxia regulated proteins and genes involved in tissue invasion and 
metastasis (ADAM23, TFPI2), again stromal expression of hypoxia regulated 
protein CA9 was more often observed in ADAM23 methylated tumors 58% 
(35/60) compared to ADAM23 unmethylated tumors 28% (22/79), p<0.001.  
 
Table 7.2 Mean methylation index (MI) of  MGMT, CHFR, HLTF, MLH1, RASSF1A, p14ARF, 
p16INK4A, ADAM23, TFPI2, APC, SOCS1, THBS1, BNIP3, NEURL, RUNX3, RAB32 
according to positive expression of hypoxia regulated proteins in the overall study 
population. 
 MI p-value   MI p-value 
HIF-1α    HIF-1α   
Stroma 0.38   Epithelial 0.43  
Negative 0.45 0.09  Negative 0.43 0.98 
HIF-2α       
Stroma  0.38      
Negative  0.35 0.39     
CA9    CA9   
Stroma 0.41   Epithelial 0.39  
Negative 0.36 0.19  Negative 0.35 0.45 
GLUT1    GLUT1   
Stroma  0.37   Epithelial 0.40  
Negative 0.40 0.55  Negative 0.40 0.95 
 
 
Likewise APC, which is involved in insensitivity to anti-growth signals, showed 
more often 82% (46/56) HIF-2α stromal expression in methylated tumors 
compared to APC unmethylated tumors 67% (73/109), p=0.04. Furthermore 
within the group of genes involved in self-sufficiency in growth signals, HIF-2α 
stromal expression was more often observed within SOCS1 methylated tumors 
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79% (77/98) compared to their unmethylated counterparts 61% (39/64), 
p=0.04. These results underscore that in particular stromal and not epithelial 
expression of hypoxia regulated proteins is associated with the loss of function 
by promoter CpG island methylation of genes involved in important tumor 
biological processes like genomic instability, tissue invasion and metastasis.  
THBS1 promoter CpG island methylation was an infrequent event within our 
study population (n=8), and furthermore we did not observe a correlation 
between hypoxia regulated proteins and THBS1 methylation involved in 
sustained angiogenesis. Four genes (BNIP3, NEURL, RUNX3, RAB32) were 
related to evading apoptosis, of which only BNIP3 methylated tumors showed 
more often 87% (78/90) CA9 epithelial expression compared to BNIP3 
unmethylated tumors 73% (50/69, p=0.03). Within this group of genes, stromal 
expression of hypoxia regulated proteins was not related to promoter CpG 
island methylation.  
Regarding HIF-1α, neither stromal nor epithelial expression showed correlation 
with promoter CpG island methylation of genes listed in Table 7.3. The results 
for GLUT1 were less clear-cut. Although GLUT1 stromal expression appeared 
to be a feature of THBS1 methylated tumors 43% (3/7) compared to THBS1 
unmethylated tumors 12% (13/105), p=0.06, it was more often observed in 
p16INK4A unmethylated tumors 23% (15/66) compared to p16INK4A 
methylated tumors 8% (5/61), p=0.03. As already stated in chapter 5, these 
findings for GLUT1 should be interpreted with caution, since the frequency of 
stromal GLUT1 expression is very low (n=20) compared to stromal expression 
of HIF-2α (n=119) and CA9 (n=66). 
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Discussion 
The interactions between epigenetic changes in tumors and the phenomenon 
of tumor hypoxia are complex, including HIF-dependent and independent 
mechanisms, and vary from HIF stabilization through epigenetic control of HIF 
degrading proteins, through activity of histone acetyltransferases and histone 
demethylases involved in binding and transcriptional activity of HIF, to global 
epigenetic alterations such as histone modification and promoter CpG island 
methylation.  
In this study, we emphasized on the latter aspect and formulated the 
hypothesis that hypoxia in CRC is related to promoter CpG island methylation 
of genes which play a role in executing important mechanisms of cancer 
progression, the so-called hallmarks of cancer. We studied a panel of hypoxia-
related markers including HIF-1α, HIF-2α, CA9 and GLUT1, and correlated 
their expression with promoter CpG island methylation of 16 genes frequently 
methylated in CRC including: MGMT, CHFR, HLTF, MLH1, RASSF1A  
p14ARF, p16INK4A, ADAM23, TFPI2, APC, SOCS1, THBS1, BNIP3, NEURL, 
RUNX3, RAB32. The results show interesting correlations between hypoxia 
and DNA promoter hypermethylation. Although overall hypoxia was not 
associated with a higher methylation index, stromal expression of hypoxia 
regulated proteins HIF-2α or CA9 was related to methylation of at least one 
gene within almost every group of cancer related biological pathways (Table 
7.1) as follows: CHFR, p=0.03 (genomic instability), p16INK4A, p=0.05 
(limitless replication potential), ADAM23, p<0.001 (tissue invasion and 
metastasis), APC p=0.04 (insensitivity to anti-growth signals), SOCS1, p=0.04 
(self-sufficiency in growth signals). These results have to be interpreted with 
caution, since we studied relatively many genes (n=16) within small subgroups 
of CRCs, possibly resulting in false positive results due to multiple testing. 
Therefore our results should be interpreted accordantly and need further 
validation in additional studies21. Although our data need to be validated, the 
fact that expression of HIF-2α and its downstream gene product CA9 were 
associated with methylation of genes involved in common cancer related 
biological pathways, could reflect a mechanism by which hypoxic tumors, 
behave more aggressively and eventually influence patient prognosis. The 
current data and in vitro studies by others22,23 make it tempting to speculate 
about the sequence of events during hypoxia in which epigenetic mechanisms 
such as promoter CpG island methylation may play a role.  
Conflicting experimental results can be derived from the literature. An inverse 
relationship between the presence of extensive tumor hypoxia and the 
incidence of promoter CpG island methylation was shown in human colorectal 
cell lines, in which exposure to hypoxia for 24 hours induced a reduction of 15-
20% in global promoter CpG island methylation24. In contrast, an altered 
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cellular phenotype in response to chronic hypoxia was demonstrated, with 
significant increases in global levels of promoter CpG island methylation, and 
concomitant increased expression of DNA methyltransferase9. Although the 
effects of hypoxia on epigenetic changes apparently can occur in a bi-
directional mode, with either decrease or increase in promoter CpG island 
methylation, these results nonetheless indicate that epigenetic changes may 
represent an additional level of cellular adaptation to hypoxia, in addition to the 
HIF induced cellular response.   
In theory, three possible scenarios could be put forward to account for the 
relation between tumor hypoxia and epigenetic alterations: firstly, DNA 
promoter hypermethylation and silencing of relevant tumor suppressor or DNA 
repair genes, by interfering with their control functions, can lead to conditions of 
genomic instability, evasion of apoptosis and limitless replication, resulting in 
tumor growth and subsequent hypoxia. Conversely, hypoxia in a growing tumor 
mass could induce epigenetic changes, such as gene silencing through 
methylation. Lastly, promoter hypermethylation of specific genes could offer 
protection against the deleterious effects of hypoxia on tumor cells, thus 
rendering a selective growth advantage in tumors with the appropriate 
methylation status5,9.  
Promoter CpG island methylation of the 16 genes we analyzed in the present 
study has also been detected in early lesions such as hyperplastic polyps and 
adenomas25-27, in which hypoxia does not play any significant role2, suggesting 
that these genes are already methylated before hypoxia has occurred, rather 
than methylation being a consequence of hypoxia. This is in line with the theory 
that by silencing of crucial cancer biology genes, tumors are able to adapt and 
behave more aggressively during hypoxia4,28. Strengthening this theory is the 
fact that within our series of CRCs, promoter CpG island methylation of CHFR 
and stromal expression of HIF-2α and CA9 were both shown to be indicators of 
a more aggressive tumor behavior, since they were both related to a poorer 
patient survival (Chapters 4&6). We concluded that expression of hypoxia 
regulated proteins HIF-2α and CA9 in tumor associated stroma, as opposed to 
their expression in epithelial cancer cells, is associated with poorer outcome, 
suggesting that tumor hypoxia may influence tumor associated stromal cells in 
a way that ultimately effects patient prognosis. The results of the current study 
add to this observation, in that  tumors with stromal expression of HIF-2α and 
CA9, show promoter CpG island methylation of crucial cancer pathway genes 
occurs. As our study is correlative and descriptive in nature, and based on 
patient material, we are unable to pinpoint the precise mechanisms involved. 
There are however some indications from in vitro data, which have also shown 
that tumor stroma is involved in effecting tumor biology, e.g. by downregulation 
of caspases, crucial apoptosis mediators29-32. Interestingly, this downregulation 
was established by promoter CpG island methylation, as it was shown that the 
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DNA-methylation inhibitor 5-azadeoxycytidine could reverse methylation and 
restore caspase expression33. 
Apart from the discussion whether hypoxia should be considered a 
consequence or cause of epigenetic changes such as promoter CpG island 
methylation, the third aspect, protection of tumor cells against hypoxic cell 
damage, is also relevant. It has been shown that hypoxia, through induction of 
cell death, selects for cells with defective cell death regulators such as BNIP3 
and TP53, thus evading apoptosis34. One way of achieving this situation is by 
promoter CpG island methylation and silencing of BNIP3. In the current study 
we found that BNIP3 methylated tumors more often showed CA9 epithelial 
expression (88%), compared to BNIP3 unmethylated tumors (73%), p=0.03. 
Conceivably, the combination of BNIP3 methylation and CA9 epithelial 
expression reflects a synergistic mechanism to evade apoptosis, since CA9 
expression maintains intracellular pH, thereby preventing tumor cell 
apoptosis35. This is in line with the concept that in hypoxic tumors there is a 
selective growth and survival advantage for cells with defects in the apoptotic 
machinery, by silencing of BNIP3 due to promoter CpG island methylation and 
TP53 mutations11,36. Epigenetic silencing of BNIP3 by promoter CpG island 
methylation has been reported in several cancer types and contributes to 
resistance to hypoxia-induced cell death37-39. The exact role of BNIP3 in CRC is 
unknown. In the next chapter we attempt to elucidate whether BNIP3 
methylation and TP53 mutations in tumor cells, are related to patient outcome 
and apoptotic activity in hypoxic CRCs.  
In summary, stromal expression of hypoxia regulated proteins HIF-2α and CA9 
was associated with promoter CpG island methylation of genes that participate 
in all of the major tumor biological pathways that were studied. Tumors with 
hypoxic features do not appear to show increased overall methylation, but 
rather harbour a selection of methylated genes, which could individually 
contribute to the more aggressive behaviour of these tumors. Further clinical 
and biological studies are necessary to validate our data and to unravel the 
precise mechanisms involved. 
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Abstract 
Stromal expression of hypoxia inducible factor 2α (HIF-2α) and Carbonic Anhydrase 9 (CA9) are 
associated with a poorer prognosis in colorectal cancer (CRC). Tumor cell death, regulated by a 
hypoxic stromal microenvironment could be of importance in this respect. Therefore, we correlated 
apoptosis, TP53 mutational status and BNIP3 promoter hypermethylation of CRC cells with HIF-2α 
and CA9 related poor outcome.  
In a series of 195 CRCs, TP53 mutations in exons 5-8 were analyzed by direct sequencing and 
promoter hypermethylation of BNIP3 was determined by methylation specific PCR (MSP). 
Expression of HIF-2α, CA9, p53, BNIP3 and M30 were analyzed immunohistochemically.  
Poorer survival of HIF-2α and CA9 stromal positive CRCs was associated with wild-type TP53 
(p=0.001 and p=0.0391), but not with BNIP3 methylation. Furthermore, apoptotic levels were 
independent of TP53 status, but lower in unmethylated BNIP3 CRCs (p=0.004).  
It appears that wild-type TP53 in CRC cells favours progression of tumors expressing markers for 
hypoxia in their stroma, rather than in the epithelial compartment. Preserved BNIP3 function in 
CRC cells lowers apoptosis, and may thus be involved in alternative cell death pathways, such as 
autophagic cell death. However, BNIP3 silencing in tumor cells does not impact on hypoxia driven 
poorer prognosis.  
These results suggest that the biology of CRC cells can be modified by alterations in the tumor 
microenvironment under conditions of tumor hypoxia. 
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Introduction 
Hypoxia has been reported to influence tumor biology in opposing ways. It can 
directly induce cell death by activating apoptosis or autophagy, yet hypoxic 
zones in solid tumors also harbour viable cells resistant to treatment which 
contribute to poor patient outcome1. Hypoxia influences the expression of 
genes involved in cell death and energy homeostasis mainly by stabilization 
and activation of the Hypoxia Inducible Factor (HIF) family of transcription 
factors, influencing angiogenesis (VEGF), glycolysis (GLUT1), pH regulation 
(CA9), apoptosis (TP53, BNIP3) and autophagy (BNIP3)2,3.  
A common hallmark of solid tumors under hypoxic stress is an increased ATP 
requirement, which is supplied by induction of anaerobic glycolysis. This 
subsequently leads to a high production of intracellular lactate, requiring 
regulation of intracellular pH, a process mediated partly by HIF dependent 
upregulation of Carbonic Anhydrase 9 (CA9). CA9 catalyzes the extracellular 
trapping of acid by hydrating cell-generated CO2 into HCO3- and H+4. 
Consequently, CA9 expression may serve as a marker for metabolic adaptation 
during hypoxia.  
Upregulation of p53 and BNIP3 proteins, which stimulate cell death via 
apoptosis and/or autophagy, appears contradictory to the adverse association 
between tumor hypoxia and prognosis. However, it was suggested that through 
induction of cell death, hypoxia selects for cells with defective cell death 
regulators such as TP535. In non-selected cells hypoxia can induce expression 
of p53 and activate p53 mediated G0/G1 arrest or apoptosis, although 
secondary effects such as extracellular acidosis and glucose deprivation are 
necessary for p53 mediated apoptosis5-8. Over 50% of human tumors contain 
somatic mutations in the TP53 gene, resulting in a defective apoptotic 
response9,10. Therefore, TP53 mutations are expected to decrease the 
susceptibility of tumor cells to hypoxia induced cell death, as shown in vitro5,11. 
BNIP3 is a Bcl-2 family member, containing a single BcL-2 homology 3 (BH3) 
domain and a transmembrane domain localizing it to the outer mitochondrial 
membrane12,13. It is activated by HIF during hypoxia and initiates programmed 
cell death through apoptosis or autophagy14,15. Epigenetic silencing of BNIP3 
by promoter hypermethylation has been reported in several cancer types and 
contributes to resistance to hypoxia-induced cell death16-18. The role of BNIP3 
in CRC is unknown, although 66% of tumors show BNIP3 silencing by 
promoter hypermethylation19,20.  
Usually, the effects of hypoxia in solid tumors are studied within the tumor cells 
themselves, neglecting the hypoxic response in tumor associated stroma. In a 
previous study we found that hypoxia within the tumor associated stroma is 
indeed correlated with a poorer outcome in patients with colorectal cancer who 
are treated by surgery alone. In a multivariate model, stromal expression of 
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HIF-2α and CA9 both were independent adverse prognostic factors, whereas 
HIF-1α was not. Furthermore, expression of hypoxia related proteins HIF-1α, 
GLUT1 and CA9 in the tumor cells self was not associated with poorer patient 
survival21. 
Our previous findings indicate that hypoxic conditions may modulate the tumor 
stroma in such a way, that a more aggressive tumor behavior is facilitated, 
ultimately leading to decreased patient survival.   
The present study attempts to elucidate whether changes in the epithelial cell 
compartment of CRC, such as apoptosis and concomitant (epi-)genetic 
changes that are confined to the tumor cells, are related to hypoxia related 
changes in the stromal compartment. For this purpose, we correlated 
alterations of TP53 and BNIP3 in tumor cells with expression of hypoxia related 
proteins HIF-2α and CA9 in relation with patient outcome and apoptotic activity 
in CRCs. 
Patients and methods 
Patient population 
Patients were entered in two multi-center prospective clinical trials in the 
Netherlands, between 1979 and 1981. One trial was designed to compare 
patient survival after treatment of colon cancer by conventional surgery or the 
no-touch isolation technique22. The second trial was conducted to compare 
survival in rectal cancer patients with or without preoperative radiotherapy. In 
the current study, we included only the patients who did not undergo 
preoperative radiotherapy. At the time the trial was conducted, only surgical 
removal of the tumors was performed, and adjuvant chemotherapy was not yet 
standard practice. This study population therefore enables unbiased study of 
the influence of hypoxic conditions on tumor biology.  
Tumor tissues were fixed in buffered formalin, sectioned, and embedded in 
paraffin. Experienced pathologists documented the histopathological 
characteristics of the tumors (Table 8.1). Follow up took place every 3 months 
during the first three years and every 6 months between three and five years 
after initial diagnosis and surgery. Standard protocols were followed, with 
routine blood counts and chemistry studies (including CEA levels) at each visit 
and liver ultrasound, chest x-ray and colonoscopy annually, to evaluate 
recurrence of disease and disease-related death. After five year follow up 
period, only time and cause of death were registered. Follow-up was complete 
for all patients. Failure was defined as death due to recurrent disease, 
excluding postoperative mortality within 30 days and non-disease related 
death.  
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For immunohistochemical and molecular analysis, tumor tissues from 195 CRC 
patients were available. The distribution of age, gender, tumor stage, location 
and type of tumor, frequency of events and mean follow-up time of the patients 
in this study are representative for the patients in the trial (see Table 8.1).  
 
Table 8.1 TP53 mutation analyses, BNIP3 methylation and clinicopathological characteristics. 
 TP53  BNIP3  
 Wt Mutant  U M  
 No % No % P No % No % P 
Total patients 78 (50) 77 (50)  92 (47) 103 (53)  
Age     .297     .759 
  <69 years 
  >69 years 
35 
43 
(45) 
(55) 
41 
36 
(53) 
(47) 
 
 
44 
48 
(48) 
(52) 
47 
56 
(46) 
(54) 
 
Sex     .942     .788 
  Male 
  Female 
35 
43 
(45) 
(55) 
35 
42 
(45) 
(55) 
 42 
50 
(46) 
(54) 
49 
54 
(48) 
(52) 
 
Tumor location     .202     .016 
  Proximal 
  Distal 
32 
46 
(41) 
(59) 
24 
53 
(31) 
(69) 
 25 
67 
(27) 
(73) 
45 
58 
(44) 
(56) 
 
Tumor     .819     .967 
  Colon  49 (63) 47 (61)  61 (66) 68 (66)  
  Rectum 29 (37) 30 (39)  31 (34) 35 (34)  
Differentiation     .913     .959 
  Well 
  Moderate/poor 
8 
70 
(10) 
(90) 
8 
69 
(10) 
(90) 
 10 
82 
(11) 
(89) 
11 
92 
(11) 
(89) 
 
TNM     .471     .001 
  1 1 (1) 2 (2)  3 (4) 1 (1)  
  2 40 (51) 46 (60)  61 (66) 55 (53)  
  3 28 (36) 19 (25)  14 (15) 40 (39)  
  4 9 (12) 10 (13)  14 (15) 7 (7)  
Wt, Wild-type; U, Unmethylated; M, Methylated. Location: proximal or distal to splenic flexure. 
 
Genomic DNA Isolation  
Genomic DNA was extracted from CRC tissues using PureGene™ Genomic 
DNA Isolation Kit (Gentra Systems) based on the manufacturer’s protocol. 
TP53 sequencing 
Mutation analyses of TP53 exons 5-8 was performed using a semi-nested PCR 
approach, (see supplemental Table 8.1S for primer sequences). CaCo2 (exon 
6, codon 204 non-sense mutation) was included as a control. Direct 
sequencing of PCR products was performed using the BigDye Terminator 
v1.1 Cycle Sequencing Kit (Applied Biosystems) and analysed on the ABI 3730 
DNA Analyzer (Applied Biosystems). Mutation detection was performed using 
Mutation Surveyor DNA Variant Analysis Software v3.0 (SoftGenetics LLC, 
USA). The results of the mutation analyses are listed in Table 8.2. 
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Furthermore, we assessed whether TP53 missense-mutants were 
transcriptionally active or not, based on the IARC prediction models 
http://www.p53.iarc.fr/MutationValidationCriteria.asp). Missense mutations 
were classified as either transactivation incompetent or transactivation 
competent missense mutations. 
 
Table 8.2 Frequency and type of TP53 alterations. 
TP53 Mutation No % 
Wild type 72 (46) 
Tr-Incom. Missense  57 (37) 
Tr-Com. Missense 8 (5) 
Silent 4 (3) 
Non-sense 5 (3) 
Deletion 4 (3) 
Insertion 3 (2) 
Polymorphism 2 (1) 
Total 155 (100) 
Tr-Incom, Transactivation incompetent; miss-mutations, missense mutation; 
Tr-Com, Transactivation competent.  
 
BNIP3 Promoter methylation analysis 
BNIP3 promoter methylation was determined by sodium bisulfite modification of 
genomic DNA using the EZ DNA methylation kit (ZYMO research Co., Orange, 
CA). Methylation Specific PCR (MSP) was performed as described in detail 
elsewhere23,24. DNA was first amplified with BNIP3 flanking PCR primers that 
amplify bisulfite modified DNA but do not preferentially amplify methylated or 
unmethylated DNA. The resulting template was used as the template for BNIP3 
MSP. For primer sequences see supplemental Table 8.1S. All PCRs were 
performed with a control for unmethylated BNIP3 alleles (normal lymphocyte 
DNA) and a positive control for methylated BNIP3 alleles (Sssl 
methyltransferase (New England Biolabs) treated normal lymphocyte DNA) and 
a negative control without DNA. Each PCR reaction was loaded onto a 2% 
agarose gel, stained with Gelstar® (Cambrex Bioscience Rockland Inc, USA) 
and visualized under UV illumination. 
Immunohistochemistry 
Serial formalin fixed, paraffin-embedded tissues sections (4 µm) were stained 
for HIF-2α and CA9 as described previously21.  
Briefly, HIF-2α staining: Antigen retrieval was performed by microwave 
treatment (750 W for 20 min in 1mM TE buffer pH 8.0), followed by 30 min. 
cooling in buffer. Slides were blocked in 25% normal serum for 10 min. 
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Sections were incubated with primary antibody HIF-2α (1:500) for 100 min. 
(anti-HIF2 alpha monoclonal: ab8365  AbCam, UK). 
CA9 staining: Slides were blocked in 25% normal serum for 10 min.,  then 
incubated for 45 min. with primary CA9 antibody MoAb M75 (1:50) (anti-human 
CA9, kindly supplied by Dr. S. Pastorekova) at room temperature. 
In addition, serial sections were stained for p53, BNIP3 and M30, as follows: 
p53 staining: Antigen retrieval was performed by microwave treatment (750 W 
for 15 min. in Antigen Retrieval (Dako)), followed by 30 min. cooling in buffer. 
Slides were blocked in 25% normal serum for 10 min. Sections were incubated 
for 45 min at room temperature with primary antibody p53 (1:500) (anti-p53 
monoclonal (DO-7), M7001 DAKO, Denmark). 
BNIP3 staining: Antigen retrieval was performed by microwave treatment (750 
W for 15 min. in Antigen Retrieval (Dako)), followed by 30 min. cooling in 
buffer. Slides were blocked in 25% normal serum for 10 min. Sections were 
incubated for 180 min at room temperature with primary antibody BNIP3 
(1:400) (anti-BNIP3 monoclonal (Ana40): ab10433, UK).  
M30 staining: Antigen retrieval was performed by microwave treatment (750 W 
for 10 min. in Antigen Retrieval (Dako)), followed by 30 min. cooling in buffer. 
Slides were blocked in 25% normal serum for 10 min. Sections were incubated 
for 45 min at room temperature with primary Cytodeath antibody M30 (1:50) 
(mouse monoclonal (CloneM30), Roche Applied Science, Germany). 
Each staining protocol was started with pre-incubating in 0.6% hydrogen 
peroxide for 20 min to block endogenous peroxidase activity. Furthermore, as a 
negative control, TBS buffer instead of primary antibody was used. 
Visualization was performed using Dako Envision, Peroxidase, mouse System 
(K4001, DAKO, Denmark). Powerenvison Poly-HRP (50510-60307, 
Immunologic, the Netherlands) was used for M30 visualization. The slides were 
counterstained with hematoxylin.  
Evaluation of IHC  
Evaluation for HIF-2α and CA9 staining as described previously in detail21. 
Briefly, localisation (epithelial or stromal) was scored separately. For the 
category stromal staining only the stromal myofibroblasts were taken into 
account, not the tumor infiltrating inflammatory cells or the lamina propia of the 
normal mucosa. If nuclear staining was present in >5% of the tumor epithelial 
cells or stromal cells, the sample was considered positive for HIF-2α.  
If membranous staining occurred in >5% of the tumor epithelial cells or stromal 
cells, samples were considered positive for CA925. 
TP53 and BNIP3 staining were considered positive by the presence of nuclear 
staining for TP53 and cytoplasmic staining for BNIP3 respectively, in >5% of 
tumor cells.  
150Chapter 8 
M30 expression was documented as the number of positive M30 cells per 
square millimeter of tumor cells (counted in 10 high-power fields (×100) per 
tumor) (Figure 8.1A, B). Apoptosis was categorized as Low apoptosis when the 
number of M30 positive cells ≤10 (mean), and High apoptosis when the 
number of M30 positive cells >1026,27.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.1 (A) Nucleair expression of TP53 in colorectal tumor epithelial cells. (B) Cytoplasmic 
expression of BNIP3 in colorectal tumor epithelial cells. (C,D) Expression of M30 in 
colorectal tissue. (C) Expression of M30 in normal colon tissue. (D) Expression of M30 
in tumor epithelial cell. (A,B) Original magnifications × 20. (C-D) Original 
magnifications × 40. Black bar pictures A, B = 200 µm, C, D = 100 µm. 
 
Data-analysis 
Correlations between HIF-2α, CA9, BNIP3, TP53, M30 and  clinicopathological 
parameters were determined by the Pearson Chi-Square and Fisher’s exact 
test where appropriate. To evaluate the relationship between HIF-2α, BNIP3, 
TP53 and survival, Kaplan-Meier survival curves were calculated. Differences 
between groups were determined by using the Log-rank test. The endpoint for 
analyses was overall survival starting from the day of surgery. All p-values are 
two sided and p-values <0.05 were considered statistically significant. 
Correction for multiple comparisons was performed using the Bonferroni 
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procedure. Patients with unknown and unspecified scores have been omitted 
from analyses for that specific variable. SPSS 12.0 software was used for data 
analyses. 
Results 
TP53 mutations  
TP53 mutation analysis was successful in 155/195 (79%) of CRCs. CRCs were 
classified as having no TP53 mutations 72/155 (46%), silent mutations 4/155 
(3%) or known common polymorphism (exon 6, codon 213, CGA>CGG, R/R, 
refSNP rs1800372) 2/155 (1%) (Table 8.2). 37% (57/155) of CRCs were 
classified as transactivation incompetent missense mutations and 5% (8/155) 
of CRCs were classified as transactivation competent missense mutations. 
Correlations between TP53 and other variables did not change with respect to 
the predicted presence or absence of transcriptional activity of TP53 mutants. 
Therefore,  in further analyses CRCs were classified as TP53 wild-type when 
no mutations, silent mutations or a known common polymorphism were found, 
and as mutant TP53 when CRCs had either missense, nonsense or frame shift 
mutations. Using this classification, 77/155 (50%) of CRC’s showed TP53 
mutations (Table 8.1), which is in agreement with data published by others28-37.  
p53 protein expression was only observed in the nucleus of epithelial cells 
(Figure 8.1A). There was a significant correlation between the absence of p53 
protein expression and wild-type TP53 versus the presence of p53 protein in 
mutant TP53, p=0.029 (data not shown). No correlation between TP53 
mutation status and clinicopathological data was observed (Table 8.1).  
TP53 mutations, patient survival and apoptosis  
Overall no significant survival difference between TP53 wild-type and mutant 
CRCs was observed (data not shown). However, the previously reported 
association between HIF-2α or CA9 positive CRCs and poor prognosis was 
found to exist exclusively in TP53 wild-type CRCs (p=0.001 and p=0.0829 
respectively, Figure 8.2 A+B). Furthermore, there was a significant difference in 
survival between stromal CA9 expression (38% 5-years survival) versus 
epithelial CA9 expression (71% 5-years survival) within TP53 wild-type tumors, 
p=0.0391 (data not shown). Overall levels of HIF-2α or CA9 expression were 
not different between wild-type and mutant TP53 CRCs (Data not shown). 
Survival of TP53 mutant CRCs was not related to HIF-2α nor CA9 expression 
(p=0.9312 and p=0.8456, respectively, Figure 8.2 E+F). These data suggest 
that wild-type TP53 CRCs are less susceptible to the adverse effects of 
hypoxia. Since TP53 can induce apoptosis during hypoxia, we assessed the 
extent of apoptosis (M30 staining, Figure 8.1C+D). Overall we found no 
152Chapter 8 
differences in apoptotic levels between TP53 wild-type and TP53 mutant CRCs  
(Table 8.3), or between HIF-2α and CA9 positive or negative CRCs (data not 
shown). This was found regardless of TP53 mutation status. These results 
indicate that presence or absence of functional p53 protein is not decisive for 
determining the extent of apoptosis in CRCs.  
BNIP3 methylation  
BNIP3 promoter methylation analysis was successful in 195/195 CRC’s 
(100%). Overall 53% (n=103/195) of CRCs showed BNIP3 promoter 
hypermethylation (Table 8.1), which is in agreement with data published by 
others12,20.  
The relationship between protein expression of BNIP3 and BNIP3 promoter 
methylation status was analyzed in a randomly selected subset of patients 
(n=31). BNIP3 protein expression was only observed in the cytoplasm of 
epithelial cells (Figure 8.1B). BNIP3 promoter methylated CRCs less frequently 
demonstrated BNIP3 protein expression than unmethylated CRCs (25% vs. 
75%, respectively). 
BNIP3 methylation, patient survival and apoptosis 
Overall there was no significant survival difference between BNIP3 methylated 
and unmethylated CRCs (data not shown). Although in HIF-2α stromal negative 
CRCs, BNIP3 methylation occurred in 61% (33/54), and did not influence 
prognosis whereas in the HIF-2α positive tumors methylation was observed in 
almost equal frequency, 52% (68/132) but was associated with poorer patient 
survival (p=0.006, Figure 8.2G). Similarly, exclusively stromal (and not 
epithelial) expression of CA9 was an indicator of a poorer prognosis in both 
BNIP3 methylated and BNIP3 unmethylated tumors (p=0.0495 and p=0.0725, 
respectively, Figure 8.2D, H).  
This suggests that hypoxic CRCs with stromal expression of HIF-2α and CA9 
have a poorer prognosis, independent of BNIP3 methylation.  
Since BNIP3 has been reported to induce apoptosis in response to hypoxia, its 
methylation and associated down regulation might be expected to result in less 
apoptosis in the HIF-2α subgroup. However, a low apoptotic activity (low M30 
expression) was detected more frequently in BNIP3 unmethylated CRCs 68% 
(50/73) compared to BNIP3 methylated CRCs 46% (42/91, p=0.004, Table 
8.3). Although tumors with both methylated BNIP3 and stromal HIF-2α 
expression showed a poorer patient survival compared to HIF-2α negative 
tumors, this was not related to apoptosis (data not shown). Furthermore, we did 
not detect differences in apoptotic levels between tumors with or without CA9 
expression, regardless of BNIP3 methylation status. 
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Figure 8.2 Survival curves (A) HIF-2α expression in wild-type TP53 group, p=0.001 (n=75). (B) 
CA9 expression in wild-type TP53 group, p=0.0829 (n=72). (C) HIF-2α expression 
in BNIP3 unmethylated group, p=0.1712 (n=83). (D) CA9 expression in BNIP3 
unmethylated group, p=0.0725 (n=79). (E) HIF-2α expression in mutant TP53 
group, p=0.9312 (n=69). (F) CA9 expression in mutant TP53 group p=0.8456 
(n=71). (G) HIF-2α expression in BNIP3 methylated group p=0.006 (n=98). (H) CA9 
expression in BNIP3 methylated group p=0.0495 (n=95). U, Unmethylated; M, 
Methylated.  
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Table 8.3 Correlations between BNIP3 methylation and TP53 alteration vs. M30 expression  
 M30 
LOW 
       M30 
       HIGH 
 
 No % No % p-value 
BNIP3      
   Unmethylated 50 (68) 23 (32) .004 
   Methylated 42 (46) 49 (54)  
TP53      
   Wild-type 39 (56) 31 (44) .703 
   Mutation 36 (59) 25 (41)  
 
Discussion 
In a previous study on the expression of hypoxia related markers (HIF1α, 
HIF2α, CA9 and GLUT1) in colorectal adenocarcinomas, we found that in all 
tumors at least one of these proteins is immunohistochemically expressed. This 
indicates that hypoxia is an all but ubiquitous phenomenon in colorectal tumors. 
However, only expression of HIF2α and CA9 in the tumor associated stroma 
was correlated with a poorer prognosis, suggesting that tumors with this 
particular phenotype follow a more aggressive course21. These results are in 
contrast to some other studies in colon and rectum tumors, that can be 
summarized by the observation that HIF1α and GLUT1 expression in rectal 
cancer cells is of prognostic significance25,38-40. Our finding was relatively new, 
in the sense that others have mainly reported the relation between tumor 
prognosis and expression of hypoxia markers in cancer cells, without paying 
attention to stromal expression. The results in our study did not differ between 
tumors of the colon or rectum. 
So far, the biological basis of stromal expression of hypoxia related markers in 
CRC is unclear. It could either be a serendipitous finding, or a genuine 
indication of altered epithelial-mesenchymal interactions within a subset of 
tumors. In these tumors, hypoxia driven metabolic and cell biological changes 
could hypothetically alter the tumor stroma towards an environment that can 
facilitate cancer progression, along multiple routes, among which an enhanced 
proliferation or survival of tumor epithelial cells41. The tumor stroma under 
hypoxic conditions could select for the propagation of certain subclones of 
cancer cells that are optimally endowed for tumor progression. A recent study 
in breast cancer, on how changes in stromal gene expression affect epithelial 
tumor progression, showed that gene expression profiling of microdissected 
tumor stroma resulted in a set of stromal genes, that could predict clinical 
outcome. This set notably included enhanced stromal expression of hypoxia-
associated genes42.  
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The current study attempts to pinpoint specific genetic and epigenetic features 
of colorectal cancer cells, that are both associated with the observed more 
aggressive presentation of CRCs expressing HIF2α and CA9 in their 
surrounding stroma, and impact on one of the hallmarks of cancer, namely 
regulation of apoptosis under hypoxic conditions. 
Tumor hypoxia results in the induction of pro-death signals, mediated partly by 
TP53 and BNIP343. Therefore it could be envisaged that hypoxia provides a 
selective environment for outgrowth of cells in which these genes have become 
mutated or silenced. Loss of pro-death genes such as TP53 and BNIP3 may 
result in increased hypoxia tolerance and cross resistance to other death 
inducing stimuli associated with metabolic stress or treatment. Immuno-
histochemical staining showed that TP53 and BNIP3 expression are confined 
to the epithelial cell compartment in CRC, and are not present in surrounding 
mesenchymal cells, making these two genes interesting candidates to study 
the hypothesis of cancer cell selection under hypoxia driven modification of 
tumor-stroma interactions.   
Intriguingly, our results indicate that tumors expressing HIF-2α or CA9 in their 
stroma have a poorer prognosis in TP53 wild-type tumors compared to mutant 
tumors. It is unclear how wild-type TP53 might benefit this tumor subgroup, but 
several possibilities exist. Firstly, p53 is involved in a metabolic switch to 
glycolysis when oxidative phosphorylation is impaired during hypoxia44. Also, 
other means of adaptation to metabolic stress, such as an increased fatty acid 
β oxidation, have been shown to be present in tumor cells with intact p53. With 
respect to this, increased apoptosis was reported in p53-deficient HCT-116 
colorectal cancer cells as compared to wild-type p53 HCT-116 cells, when 
challenged by metabolic stress45. The second possibility is that wild-type TP53 
is not acting directly, but instead simply correlates with defects in another 
pathway such as the BNIP3 cell death pathway, that substitutes for TP53 loss 
in a similar fashion during carcinogenesis.  
With respect to apoptosis and hypoxia driven tumor progression, we did not 
find important effects related to the mutational status of TP53. However, 
apoptotic levels were lower in BNIP3 expressing tumors, compared to tumors 
with epigenetically silenced BNIP3 (p=0.004), which is somewhat surprising, 
given the fact that functional BNIP3 is thought to induce cell death downstream 
of hypoxia inducible transcription factors. Apparently, things are more 
complicated. BNIP3 may not be restricted to regulation of apoptosis, but could 
also regulate other pathways such as autophagy, in which there is a delicate 
balance between cell survival and cell death46. Conceivably, the lower 
apoptotic activity in tumors with functional BNIP3 might be due to autophagic 
rescue of the tumor cells. Furthermore, BNIP3 levels appear to modulate cell 
death not only via apoptosis or autophagy, but also by necrosis. Also, the net 
effect of BNIP3 is determined by the level of expression: too high BNIP3 
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expression will lead to autophagic cell death, while lower levels of BNIP3 
expression, as in cells where BNIP3 is silenced, will induce necrosis47. In our 
study we used the immunohistochemical marker M30, which exclusively 
measures apoptotic cell death,  and thus were not able to differentiate between 
other forms of cell death, such as autophagic death and necrosis48,49.  
Summarizing the results from the current study, levels of apoptosis do not play 
an important role in determining the poorer prognosis of hypoxic CRC’s, as 
defined by stromal expression of HIF-2α and CA9. However, the latter 
phenotype is correlated with the presence of wild-type TP53 in the tumor cells, 
and the presence of functional p53 does indeed appear to have an important 
impact on poorer prognosis. This prognostic effect is not established through 
regulation of programmed tumor cell death, but may rather be connected to an 
enhanced capacity for adequate adaptation to metabolic stress. As TP53 
mutations occur in a relatively early stage of colorectal carcinogenesis, the 
potential deleterious effects of hypoxia on colorectal cancer biology may 
already be programmed in a very early phase of tumor development.  
As opposed to TP53, functional or epigenetically silenced BNIP3 did not turn 
out to be of influence in determining tumor prognosis. Furthermore, 
preservation of BNIP3 function showed to decrease apoptotic activity, and may 
thus be involved in enhanced cell survival through autophagic rescue, or could 
be implicated in alternative cell death pathways, such as autophagic cell death 
or necrosis, which we were unable to measure in our experimental approach.  
The findings in this translational study, on the relation between expression 
patterns of hypoxia related markers in clinical samples of CRC and the 
functional status of genetically or epigenetically modified proteins involved in 
regulation of tumor cell death on the one hand and patient outcome on the 
other, opens up interesting new avenues for more fundamental studies on the 
mechanisms underlying tumor hypoxia induced changes in epithelial-
mesenchymal interactions. 
Understanding the mechanisms by which hypoxic tumors can overcome cell 
death signals and adapt through metabolic changes is critical for our 
understanding of tumor progression and development of effective therapeutics 
in CRC patients with adverse prognostic profiles. 
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Table 8.1S TP53 mutation analysis primers and BNIP3 MSP primer sequences. 
TP53 Primer Sequence  Product size 
5 exon Flank sense 
Flank antisense 
Inside sense 
5’ CTG TTC ACT TGT GCC CTG AC 3’ 
5’ AGC CCT GTC GTC TCT CCA G 3’ 
5’ TGC CCT GAC TTT CAA CTC TG 3’ 
268 bp 
 
257 bp 
6 exon Flank sense 
Flank antisense 
Inside antisense 
5’ GGC CTC TGA TTC CTC ACT G 3’ 
5’ ATA AGC AGC AGG AGA AAG CC 3’ 
5’ GAC CCC AGT TGC AAA CCA G 3’ 
240 bp 
 
164 bp 
7 exon Flank sense 
Flank antisense 
Inside antisense 
5’ CAT CTT GGG CCT GTG TTA TC 3’ 
5’ GAT GTG ATG AGA GGT GGA TGG 3’ 
5’ GGA AGA AAT CGG TAA GAG GTG 3’ 
261 bp 
 
230 bp 
8 exon Flank sense 
Flank antisense 
Inside antisense 
5’ GAT TTC CTT ACT GCC TCT TGC 3’ 
5’ CAT AAC TGC ACC CTT GGT CTC 3’ 
5’ TCC TCC ACC GCT TCT TGT C 3’ 
231 bp 
 
212 bp 
BNIP3 Primer Sequence  Product size 
 Flank Sense 
Flank  
antisense 
5’-TTY GTT TTG TTT TGT GAG TTT TTT-3’ 
5’-CCR AAC TAC AAA ATA TAC TTC AAC TAC-3’ 
129 bp 
 
 
 Unmethylated 
sense 
Unmethylated 
antisense 
5’-GGT TTT GTT TAG TTT GGG AGT G-3’ 
5’-CCT CAA CTA CAA ACA ATA AAA AAA CA-3’ 
 
74 bp 
 Methylated 
sense 
Methylated 
antisense 
5’-TTT CGT TTA GTT CGG GAG CG-3’ 
5’-CAA CTA CGA ACG ATA AAA AAA CG-3’ 
69 bp 
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General discussion and future perspectives 
Accurate staging of colorectal cancer (CRC) is of crucial importance for optimal 
management of the disease. The currently used classification system, the 
American Joint Committee on Cancer (AJCC) TNM classification system is 
based on three variables: the extent of penetration of tumor into the intestinal 
wall (T stage), nodal status (N stage) and the presence of distant metastasis 
(M stage). Although easy to implement, the survival for patients with the same 
TNM stage varies, which is caused by other factors that influence the 
prognosis. Therefore, the TNM classification is regularly being revised in order 
to improve the prediction of outcome. For example, a large study (n=128,000) 
including readily available patient characteristics such as age, sex, tumor 
differentiation/grade, and number of regional lymph nodes evaluated, better 
predicts survival than the currently used seventh edition of the AJCC system1. 
This study clearly indicates that adding additional factors influencing prognosis 
can be helpful in refining the staging system for CRC.  
Since the behavior of the tumor is determined by the underlying biology, 
inclusion of biological aspects of CRC carcinogenesis into the currently used 
classification system would be the next step. The last two decades it has 
become clear that CRC is a heterogeneous disease consisting of multiple 
molecular subtypes differentially influencing prognosis and response to 
therapy. The molecular subgroups most often used are MSI, CIN and CIMP, 
however only for MSI CRCs a consistent and accepted positive association 
with prognosis has been reported2. Moreover, in contrast to assessing KRAS 
mutations to predict response to anti-EGFR therapy3-5 and establishing the 
cause of MLH1 loss6 (biallelic MLH1 promoter CpG island methylation in 
sporadic CRC or mutations in mismatch repair genes in patients with Lynch 
syndrome) to determine disease management, this information is currently not 
being used routinely in the clinic. 
In addition to the molecular classification mentioned above, a revolution in the 
technologies to study the molecular alterations underlying the initiation and 
development of cancer, such as micro-array- and next generation sequencing 
approaches enabled a detailed exploration of the genetic and epigenetic basis 
of CRC. Thus, although the identification of subgroups and key molecular 
alterations in CRC are rapidly being unraveled, the majority of these alterations 
have not been confirmed and validated as biomarkers in large validation 
studies. Multiple reasons account for this. First, independent validation studies 
confirming the initial observation are often lacking. Second, data analyses are 
predominantly performed on a mixed group of CRCs, not taking into account 
specific subgroups. Third, the effect of treatment is not always accounted for.  
The aim of this thesis was to assess well characterized genetic and epigenetic 
alterations in a retrospective study, consisting of patients with CRC who were 
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entered in two multi-center prospective clinical trials between 1979 and 1981 in 
the Netherlands and were treated by surgery alone. We studied these 
alterations in relation with morphological features, hypoxia and prognosis. 
First we analysed a set of well characterized molecular parameters associated 
with CRC, e.g. MSI, CIMP, APC-, KRAS-, TP53-, and BRAF mutations in a 
series of 160 CRC cases. This study was based on a literature analysis by 
Jass et al.7 in 2007, concluding that five distinct molecular subgroups with 
differential clinicopathological and morphologic features can be identified in 
CRC. We tested this hypothesis by using computer assisted unsupervised 
hierarchical clustering of the markers described above. Interestingly, 
hierarchical clustering of colorectal adenocarcinomas showed that CIMP status 
is the principal classifier, and that both CIMP+ and CIMP- tumors are further 
classified on the basis of TP53 mutational status. Although it has been more 
than a decade since CIMP was first identified in CRC, controversy still exists on 
whether this subgroup of CRCs is an etiologically and clinically distinct group 
within the disease and to date, the cause of CIMP remains unknown8. Even 
more complexity is introduced by the fact that no gold standard with respect to 
gene panels, marker thresholds or techniques for detection of the altered DNA 
methylation used to define this phenotype exists8. Taking into account these 
considerations, it is surprising to observe that CIMP was identified as the 
principal classifier for CRC in this study and although these data need to be 
replicated, this observation underscores the significance and illustrates the 
need to establish the group of CRCs characterized by CIMP. Although the 
subgroups generated by the clustering algorithms did not show strong 
associations with clinicopathological parameters and therefore could not 
improve traditional staging with respect to identifying patients with a poorer 
survival in our first study, we did find an association with CIMP and prognosis 
in the validation series analysed in Chapter 4. We also observed that, in line 
with other publications7,9,10, CIMP+ CRCs appear to comprise two subsets, one 
localized in the right-sided colon, with MSI and mucinous differentiation, the 
other occurring in the rectum, being MSS7,9,10. This could reflect important 
differences in the underlying molecular biology of proximal and distal CRCs. 
For example, is was recently reported that anatomic location is a more 
significant predictor of progression than the histological type of CRC precursors 
like hyperplastic polyps, sessile serrated polyp or traditional adenoma11. One 
explanation for a difference in biology could be a difference in the availability of 
dietary factors important in promoter CpG island methylation such as folic acid, 
methionine and related vitamins B2, B6 and B12. Epidemiological evidence 
suggests that these nutrients are associated with risk of colorectal cancer and 
CIMP status12-15. Notably, methionine has been associated with a decreased 
risk of proximal colon cancer, whilst among women it was inversely associated 
with rectal cancer. Conversely, a strong positive association between vitamin 
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B6 and rectal cancer risk in women has been reported14. These results 
underscore that nutrients involved in promoter CpG island methylation are to 
some extent related to associated phenotypes such as CIMP and tumor 
location in the large intestine.  
Since we observed a strong effect of CIMP on the clustering in this series, we 
further investigated whether CIMP and 19 other genes reported to be 
functionally methylated and involved in a diversity of cancer related pathways 
in CRC, were associated with prognosis. Again, keeping in mind that prognosis 
is affected by biology of subgroups of cancer and treatment, we specifically 
analyzed data taking into account defined subgroups (based on MSI and 
BRAF-mutation status, other genetic alterations had no significant effect on 
prognosis) of CRCs in the population only treated with surgery.  
Although for CIMP no clear biological cause or definition exists and numerous 
methods and definitions are used in CRC to quantify CIMP8,16 we chose to use 
the Weisenberger panel17 for studying associations with clinicopathological 
variables. When analyzing all 19 (or 24 if including CIMP) genes, only APC and 
CHFR promoter CpG island methylation were associated with a worse 
prognosis in stage II MSS, BRAF wild-type CRCs. For stage III MSS BRAF 
wildtype CRCs, associations with a poorer prognosis were found for promoter 
CpG island methylation of RASSF1A, THBS1, CACNA1G. When analyzing a 
second, independent series of CRCs, we could only confirm the prognostic 
effect of CHFR methylation in stage II, MSS, BRAF wildtype CRCs. This last 
observation illustrates the importance of validating findings in independent 
series. Promoter CpG island methylation of CHFR is present in approximately 
43% of CRCs and is not a prognostic marker when assessed in a general 
population of CRCs consisting of all stages and all subgroups. Analyzing this 
gene in a specific subgroup of CRCs, namely the stage II MSS BRAF wildtype 
CRCs reveals the potential of this marker. Since we only observed this effect in 
two series of CRCs, we searched the literature for additional evidence for 
CHFR being a clinically relevant gene (Chapter 5). Interestingly, we found 
multiple lines of evidence for CHFR not only having prognostic significance but 
also predictive significance. CHFR is a E3 ubiquitin-protein ligase and functions 
as a mitotic stress checkpoint protein that delays mitotic entry in response to 
microtubule damage18. Although taxanes are not implemented in CRC 
treatment because they failed to demonstrate a significant clinical benefit in 
Phase II trials19,20, a specific subgroup of CRCs with CHFR promoter 
methylation might benefit from taxanes. Therefore additional studies comparing 
the outcome of stage II MSS BRAF wildtype CHFR methylated CRCs versus 
unmethylated stage II MSS BRAF wildtype CRCs and the effect of taxane 
treatment in CHFR methylated versus unmethylated CRCs is warranted. 
Although we found multiple lines of evidence, some inconsistent findings have 
166Chapter 9 
been reported as well. This clearly shows the need for large, well designed 
trials to test the clinical relevance of CHFR methylation in CRC. 
 
The first chapters of this thesis in detail address the genetic and epigenetic 
changes that occur during colorectal carcinogenesis, and their role in 
classification of the disease, notably the importance of promoter CpG island 
methylation in subcategorizing large intestinal tumors, which can further be 
characterized by certain genetic alterations, of which TP53 mutations and 
microsatellite stability status appear to be the most relevant. These studies also 
show that CIMP is a more complex entity than was previously anticipated, not 
only with respect to definition and mode of detection, but CIMP also represents 
a heterogeneous category of tumors, from which an unequivocal single 
prognostic or predictive role for the whole group cannot be derived. Rather, it 
turns out that methylation of invididual genes may play specific roles in the 
process of tumorigenesis and tumor progression, as exemplified by CHFR. In 
the second part of this thesis we therefore continued our search for additional 
individual candidate methylated genes, which not only could be applied in 
classification, prognostication and therapy of CRC, but might play a role in 
tumor biology as well. These studies depart from the notion that promoter CpG 
island methylation is an event that occurs early in neoplasia, and can even be 
demonstrated in pre-neoplasia, which in the colorectum is exemplified by gene 
methylation in adenomas21,22. As promoter CpG island methylation 
subsequently remains present during later evolutionary stages of malignancy, 
we presumed that this type of epigenetic change not just accompanies tumor 
progression, but might exert it’s influence on tumor progression as well. Apart 
from accumulation of genetic and epigenetic changes, tumor progression in a 
biological sense involves the concerted interaction of several important 
pathways, which have been defined as the so-called “hallmarks of cancer”23. In 
chapter 7, we therefore studied promoter CpG island methylation in a selection 
of multiple genes which individually can be attributed to every one of these 
tumor progression pathways. Furthermore, as tumors become increasingly 
dependent on oxygen and nutrients during progression, and upon outgrowing 
their supply become increasingly hypoxic, we correlated the methylation status 
of the selected genes with the occurrence of hypoxia in colorectal 
adenocarcinomas, defined by immunohistochemical expression of hypoxia 
related markers. We specifically chose to correlate epigenetic changes with 
such a complex phenomenon as hypoxia, because the latter has a major 
impact on cancer biology, not only underlying genetic, biochemical and 
metabolic changes in carcinoma cells, but also in a more integrative way, co-
ordinating cellular alterations and responses in the tumor micro-environment, 
and influencing the interaction between tumor cells and stroma. With respect to 
this, in our studies, we did not restrict our observations to the tumor epithelial 
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compartment, but also specifically addressed stromal changes. Finally, tumor 
hypoxia is important from a clinical perspective, driving tumor progression 
towards a more aggressive phenotype, with relative resistance to 
chemotherapy and radiotherapy.    
In the studies described in chapters 6 and 7 we found an important role for the 
tumor stroma (as opposed to tumor epithelial cells), with respect to both 
expression of hypoxia related markers, the relation of this expression pattern 
with a more aggressive tumor behavior, and the correlation with promoter CpG 
island methylation of selected genes involved in tumor progression pathways. 
This points to a potentially important role for the tumor micro-environment 
during tumorigenesis. It has already been well established that tumor 
development and -biology cannot be explained exclusively by studying tumor 
cells, but are modified to a considerable extent through the interaction with 
surrounding stromal cells. Work by other groups in recent years supports the 
somewhat underestimated role of the tumor stroma in determining the biology 
of a malignant tumor. With respect to this, in general, Pietras and Ostman 
review the role of tumor stroma and specific mesenchymal cell types in 
governing processes involved in the hallmarks of cancer24, while others 
describe the role of hypoxia in relation to these hallmarks25. Our results add to 
these, by linking tumor hypoxia, promoter CpG island methylation of selected 
genes, and the tumor stroma. Of course our studies are correlative in nature 
and do not allow any definitive conclusions on the underlying mechanisms. 
There are however more detailed studies reported in the literature, 
underpinning the relevance of stromal changes for tumor development and 
biology. Recently it was revealed that stromal cell signals could lead to 
silencing of tumor suppressor genes in tumor cells by promoter CpG island 
methylation26. It was shown that the epigenome of tumor cells is highly plastic 
and easily modified by the tumor microenvironment26-32. Similarly as within 
tumor cells, stromal cells also harbour unique aberrant epigenomes, relevant to 
clinical outcome and treatment choices33. Finak et al.34 supply evidence for the 
supplementary role of tumor stroma in governing tumor biology. In their study 
on breast cancer, they addressed stromal gene expression through a 
microdissection approach, separating tumor stroma from epithelium, and found 
an interesting set of specific stromally expressed genes, which have an impact 
on several tumor biological mechanisms, and which they combined into a new 
stroma derived prognostic predictor set. Interestingly, the stromal genes that 
were upregulated in their study included genes involved in immune responses, 
angiogenic and hypoxic responses. Also other studies report genomic 
alterations in stroma relevant to tumor development33. An interesting 
mechanistic and theoretical approach was presented by Lisanti et al.35, 
describing the role of hypoxia, oxidative stress and autophagy/mitophagy in the 
tumor microenvironment. In their so-called “Autophagic Tumor Stroma Model of 
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Cancer”, the theoretical basis is that during tumor growth cancer cells induce 
oxidative stress in surrounding stroma, which leads to production of reactive 
oxygen species in the stromal compartment. These subsequently give rise to 
upregulation of defense mechanisms in the epithelial compartment, which not 
only protects against oxidative stress, but also serves to prevent tumor cell 
apoptosis. Moreover, stromal production of reactive oxygen species can induce 
mutations and genomic instability in the tumor epithelium. Also, stromal 
autophagy and mitophagy increase, and this process of degradation gives rise 
to enhanced production of metabolites such as ketones, pyruvate and lactate in 
the tumor microenvironment, which in turn serves to fuel the tumor cells, 
enabling tumor growth. Naturally, intricate signaling and sophisticated cross-
talk between stromal cells and tumor epithelial cells take place during the 
course of tumor progression. In this respect, HIF transcription factors and their 
downstream effects play a central part, but it seems plausible and appealing 
that methylation and silencing of certain key regulatory genes connected to 
various tumor progression pathways are involved as well.  
As was presented and discussed in Chapter 7, we found an interesting 
correlation between tumor hypoxia, represented by stromal expression of 
hypoxia markers, and methylation of certain genes involved in essential tumor 
progression pathways. Whether the process of methylation is a cause or rather 
a consequence of hypoxia is still a matter of debate. We were interested in 
another aspect of gene methylation, namely the ability to protect tumor cells 
from the deleterious effects of tumor hypoxia. Hypoxia in theory induces cell 
death, and thus can render selective pressure on a tumor cell population, in 
which only the most resilient, apoptosis insensitive tumor cells would survive 
and continu to populate the tumor with the most aggressive cell fractions. We 
therefore chose to address one of the hallmarks of cancer, the evasion of 
apoptosis, in an attempt to clarify this issue. For this purpose, in chapter 8, the 
correlations of BNIP3 methylation and TP53 mutational status with levels of 
apoptosis and tumor behaviour were investigated. The idea being that silencing 
of pro-apoptotic BNIP3 in tumor cells could protect them from the occurrence of 
programmed cell death, and along similar lines, that mutations in TP53 would 
result in defective apoptotic machinery, and thus that both events would lead to 
lower apoptotic activity in a tumor. The hypothesis was that tumors with BNIP3 
methylation and/or TP53 mutations would have the lowest apoptotic activity, 
the most accelerated growth, leading to increased hypoxia, and show the most 
aggressive behaviour, as manifested by the poorest prognosis. However, it 
turned out that wild-type TP53 did not have an effect on apoptosis levels but 
was associated with the more aggressive tumors with stromal hypoxia, 
whereas conversely, tumors with unmethylated and thus preserved BNIP3 had 
lower apoptotic levels, and this on the other hand did not have an impact on 
tumor prognosis. It was reasoned that functional p53 could act in other ways to 
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protect cells from the selective pressure exerted by hypoxic stress, such as 
metabolic adaptation of tumor cells to hypoxia. As BNIP3 is also known to be 
involved in autophagy, perhaps alternative causes of cell death come into play 
in tumors unmethylated for this gene, which could still account for the lack of 
correlation with tumor aggressiveness and poorer prognosis. These results in 
Chapter 8 once again show that there is a considerable gap between 
theoretical models and hypotheses, the data derived from descriptive studies 
using patient materials, clinical data and statistical analysis on the one hand 
and the ability to explain important tumor biological processes on the other. 
Nevertheless, the data presented in the current thesis will hopefully form a 
theoretical basis for further mechanistic studies to clarify the precise relations 
between epigenetic changes, tumor hypoxia and the role of tumor stroma 
during the process of tumor progression. 
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Summary 
Colorectal cancer (CRC) is one of the most common cancer types worldwide 
and approximately 50% of patients with CRC die due to the disease. The 
histology based Tumor Node Metastasis (TNM) system is currently the best 
tool to provide information on prognosis and to determine treatment protocols 
in CRC. Although this anatomical based staging system predicts the survival 
accurately, variation in the course of the disease and response to treatment 
among individuals within the same stage exists. Therefore the identification of 
new prognostic and predictive markers for CRC to determine prognosis and to 
identify patients that need adjuvant therapy respectively is urgently needed. 
Understanding the underlying biology of CRC will provide novel molecular 
markers to accurately predict prognosis and improve treatment options besides 
the traditional histological staging system.  
The aim of this thesis was to study genetic and epigenetic alterations in 
relation to morphological features and hypoxia in CRC, providing insight in the 
underlying biology of CRC and possibly yielding relevant novel prognostic 
information.  
 
In chapter 1 we introduce the (epi)-genetic alterations that underlie the process 
of cancer development and discuss the molecular phenotypes of CRC: 
chromosomal instability (CIN), microsatellite instability (MSI) and the CpG 
island methylator phenotype (CIMP). Furthermore, the importance of hypoxia 
within solid tumors like CRCs is pinpointed, by explaining the cellular 
responses during hypoxia, with special emphasis on the tumor associated 
stroma. 
 
In chapter 2, we review the current knowledge on the epidemiology, diagnosis, 
treatment and the prognostic and predictive value of (epi)genetic markers in 
CRC. 
 
In the first experimental study (Chapter 3) we classified CRCs by computer 
assisted unsupervised hierarchical clustering, based upon well described 
markers in the genesis of CRC including: CIMP, MSI, APC-, KRAS-, TP53-, 
and BRAF mutation status, in a series of 160 CRCs. Subsequently, we 
investigated in which way this classification was related to patient data, 
including clinicopathological parameters, morphological features (differentiation 
grade, mucinous differentiation, dirty necrosis, circumscribed tumor growth, 
tumor budding and lymphocyte infiltration) and biological behavior in terms of 
patient prognosis. 
These analyses revealed that for molecular clustering of colorectal 
adenocarcinomas, CIMP status was the principal classifier, and that both 
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CIMP+ and CIMP- tumors were further classified on the basis of TP53 
mutational status. Hierarchical clustering was only modestly related to 
morphology and outcome, which appeared to be dependent on additional 
factors such as microsatellite stability and localization in the intestine. Although 
molecular clustering provided insight in the underlying biology of CRC, it did not 
improve traditional staging with respect to prognostic value.  
 
Data on the prognostic significance of promoter CpG island methylation in CRC 
are conflicting, possibly due to associations between methylation and other 
factors affecting survival such as genetic alterations and use of adjuvant 
therapy. Therefore in chapter 4 we examined the prognostic impact of promoter 
methylation of 19 tumor suppressor- and DNA repair genes and CIMP, as 
defined by Weisenberger et al., in CRC patients treated with surgery alone in 
the context of MSI, BRAF- and KRAS mutations. Our study failed to 
demonstrate a consistent prognostic effect of CIMP, however we identified 
promoter CpG island methylation of CHFR as a prognostic biomarker in stage 
II, MSS, BRAF wild-type CRCs in two independent populations of CRCs.  
 
Chapter 5 reviews the evidence for CHFR as a prognostic and predictive 
biomarker in a diversity of solid malignancies including CRC.  
 
In CRC, the importance of hypoxia has been demonstrated by clinical studies 
in which hypoxia predicts for worse outcome and resistance to chemotherapy 
and radiotherapy. Therefore, in chapter 6 we studied the role of protein 
expression of hypoxia-inducible factor (HIF)-1α, HIF-2α, carbonic anhydrase 9 
(CA9) and glucose transporter 1 (GLUT1) in patients with colorectal 
adenocarcinomas. Expression of these hypoxia markers was detected in the 
epithelial compartment of the tumor cells as well as in tumor associated stromal 
cells. Although epithelial tumor cells frequently showed expression of one or 
more of the investigated hypoxia markers, no correlation among these markers 
or with clinical response was found. In contrast to this, within the tumor stroma, 
expression of HIF-2α and CA9 were both associated with a significantly 
reduced overall survival. In the Cox proportional hazard model, stromal HIF-2α 
expression was an independent prognostic factor for survival. Our study 
suggested that tumor hypoxia may influence tumor associated stromal cells in 
a way that ultimately contributes to patient prognosis. 
 
Since epigenetic silencing might play a role in the cellular responses to 
hypoxia, in chapter 7 we investigated whether hypoxia in CRC is associated 
with promoter CpG island methylation of genes involved in important tumor 
biological processes such as: MGMT, CHFR, HLTF, MLH1, RASSF1A 
(genomic instability), p14ARF, p16INK4A (limitless replication potential), 
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ADAM23, TFPI2 (tissue invasion and metastasis), APC (insensitivity to anti-
growth signals), SOCS1 (self-sufficiency in growth signals), THBS1 (sustained 
angiogenesis), and BNIP3, NEURL, RUNX3, RAB32 (evasion of apoptosis). 
This study showed that stromal expression of hypoxia regulated proteins HIF-
2α and CA9 was associated with promoter CpG island methylation of genes 
involved in important tumor biological processes. Tumors with hypoxic features 
did not show increased overall CpG island promoter methylation, but rather 
harboured specific methylated cancer biology related genes, which could 
contribute to the more aggressive behaviour of these tumors.  
 
Finally in chapter 8 we studied whether tumor cell death, regulated by a 
hypoxic stromal microenvironment could be of importance in the observed 
poorer prognosis in CRC with stromal expression of HIF-2α and CA9. 
Therefore, we correlated apoptosis, TP53 mutational status and BNIP3 
promoter hypermethylation (both genes involved in regulation of apoptosis) of 
CRC cells with HIF-2α and CA9 related poorer outcome. Our study showed 
that the effect of HIF-2α as an indicator of a poorer prognoses was dependent 
on wild-type TP53 and not methylation status of BNIP3. It appeared that wild-
type TP53 in CRC cells favors progression of tumors expressing markers for 
hypoxia in their stroma, rather than in the epithelial compartment. We also 
showed that preserved BNIP3 function in CRC cells lowers apoptosis, and may 
thus be involved in alternative cell death pathways, such as autophagic cell 
death. Our study suggested that the biology of CRC cells can be modified by 
alterations in the tumor microenvironment under conditions of tumor hypoxia.  
 
In conclusion, this thesis demonstrated the importance of CIMP in 
subcategorizing CRC’s, which could further be characterized by TP53 
mutations and microsatellite stability status. It turned out that methylation of 
individual genes may play a specific role in the process of tumorigenesis and 
tumor progression, as exemplified by the validated prognostic value of CHFR. 
Besides methylation of individual genes, hypoxia related protein expression of 
HIF-2α and CA9 in the tumor associated stroma was associated with a poorer 
patient survival compared to expression of these markers in epithelial tumor 
cells. We have reasons to believe that promoter CpG island methylation and 
mutations of crucial cancer genes are involved in the observed more 
aggressive behaviour of these hypoxic tumors. Future studies are needed to 
unravel the pathways involved and establish the role of (epi-)genetic markers 
for treatment stratification of patients in addition to the traditional staging 
method.  
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Samenvatting 
Colorectaal carcinoom (CRC), ook wel kanker van de dikke darm en endeldarm 
genoemd, is een veelvoorkomende vorm van kanker en ongeveer de helft van 
patiënten met CRC sterft als gevolg van de ziekte. Op basis van het ‘Tumor 
node Metastasis’ systeem, een histologisch stadiërings systeem, worden de 
prognose en de behandelingskeuze van patiënten met CRC bepaald. Ondanks 
dat dit histologisch stadiërings systeem de overleving van groepen van 
patiënten accuraat voorspelt, bestaat er binnen eenzelfde stadium van CRC 
een variatie in het beloop van de ziekte en respons op adjuvante therapie. Dit 
illustreert dat er een dringende behoefte is aan nieuwe, additionele moleculaire 
merkers, die de respons op adjuvante therapie en de prognose van patiënten 
met CRC beter kunnen voorspellen. De verwachting is, dat met het verrichten 
van onderzoek naar de moleculaire ‘pathways’, die ten grondslag liggen aan 
deze ziekte, nieuwe moleculaire merkers ontdekt kunnen worden. Deze 
nieuwe, moleculaire merkers zouden, naast het huidige histologische 
stadiërings systeem, de prognose van patiënten beter moeten kunnen 
voorspellen en mogelijk nieuwe therapeutische opties voor patiënten kunnen 
identificeren. Het doel van dit proefschrift was het bestuderen van genetische 
en epigenetische afwijkingen in relatie met morfologische kenmerken en 
hypoxie in CRC, om met behulp hiervan, nieuwe inzichten in de biologie van 
CRC te verwerven en mogelijke nieuwe bruikbare prognostische merkers voor 
patiënten met CRC te ontdekken. 
 
In hoofdstuk 1 wordt een introductie gegeven over de bestaande (epi)-
genetische afwijkingen die de ziekte CRC in drie verschillende moleculaire 
subgroepen verdelen: chromosomale instabiliteit (CIN), microsatelliet 
instabiliteit (MSI) en het CpG-eiland methylerings fenotype (CIMP). Tevens 
wordt er in dit hoofdstuk een overzicht gegeven van de rol van hypoxie in CRC; 
de cellulaire paden die hierbij betrokken zijn, en in het bijzonder de rol van het 
tumor geassocieerde stroma hierin. 
 
Hoofdstuk 2 geeft een overzicht van de epidemiologie, diagnose, behandeling,  
prognostische en voorspellende waarde van (epi)-genetische merkers in CRC. 
 
De eerste experimentele studie (hoofdstuk 3) beschrijft de resultaten die 
gevonden werden met het ‘unsupervised’ hiërarchisch clusteren van 160 CRCs 
op basis van genetische en (epi)-genetische afwijkingen waaronder: CIMP, 
MSI, APC-, KRAS-, TP53-, en BRAF mutaties. Vervolgens werd er onderzocht 
in hoeverre de verkregen moleculaire clusters, correleerden met klinisch 
relevante patiënten gegevens, morfologische tumorkenmerken (differentiatie 
graad, mucineuze differentiatie, necrose, circumscripte tumorgroei, tumor 
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budding en lymfocytaire infiltratie) en overleving van patiënten. Uit deze 
analyse bleek dat CRCs in eerste instantie op basis van CIMP onderverdeeld 
werden in CIMP+ en CIMP- tumoren en vervolgens op basis van TP53 
mutaties verder onderverdeeld werden. Hiërarchisch clusteren was slechts in 
geringe mate gecorreleerd aan morfologische tumorkenmerken en patiënten 
overleving. Deze correlaties bleken afhankelijk te zijn van andere factoren 
zoals microsatelliet instabiliteit en de locatie van de tumor in de darm. Onze 
moleculaire cluster analyse geeft nieuwe inzichten in de onderliggende biologie 
van CRC, echter de clusters bezitten geen toegevoegde prognostische waarde 
in vergelijking met het traditionele, histologisch gebaseerde stadiërings-
systeem. 
 
Hoofdstuk 4 richt zich op het bestuderen van de prognostische waarde van 
CIMP, (gedefinieerd door Weisenberger et al.) en promoter CpG-eiland 
methylering van 19 andere tumor suppressor- en DNA reparatie genen in 
patiënten met CRC. Omdat dit soort studies vaak wordt verstoord door factoren 
die een invloed hebben op het ziektebeloop, zoals genetische afwijkingen en 
chemotherapie, werd in onze studie de prognostische waarde bestudeerd 
onafhankelijk van MSI, BRAF, KRAS mutaties en tumor stadium in een 
populatie van patiënten met CRC die uitsluitend behandeld werden middels 
chirurgie. Uit deze analyse kwam naar voren dat niet CIMP, maar promotor 
CpG-eiland methylering van een individueel gen, het CHFR gen, een 
prognostisch effect toonde in stadium II, microsatelliet stabiele, BRAF wildtype 
CRC; in twee onafhankelijke studie populaties van CRCs. 
 
Hoofdstuk 5 geeft een literatuur overzicht over veranderingen die optreden in 
de expressie van het CHFR-gen in verschillende kanker soorten waaronder 
CRC en de mogelijke rol van CHFR als een biomerker.  
 
Een belangrijke rol voor hypoxie in CRCs is gebleken uit studies die laten zien 
dat hypoxie gerelateerd is aan een slechtere overleving van patiënten met 
CRC en resistentie voor chemo- en radiotherapie. Vandaar dat we in hoofdstuk 
6 de expressie bestuderen van de hypoxie gereguleerde eiwitten HIF-1 alpha, 
HIF-2 alpha, CA9 en GLUT1 in patiënten met CRC. Hieruit bleek dat in CRC de 
expressie van deze hypoxie gereguleerde eiwitten zowel in de epitheliale 
tumorcellen als in de tumor geassocieerde stromale cellen voorkwam. Echter, 
in tegenstelling tot expressie in epitheliale tumorcellen, was de expressie van 
hypoxie gerelateerde eiwitten HIF-2 alpha en CA9 in stromale cellen 
gerelateerd aan een slechtere overleving van patiënten met CRC. Dit 
onderzoek suggereert dat hypoxie in tumoren stromale cellen dusdanig 
beïnvloedt dat dit uiteindelijk resulteert in een slechtere prognose voor CRC 
patiënten. 
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Het is bekend dat promoter CpG-eiland methylering betrokken is bij de 
cellulaire respons van tumoren tijdens hypoxie. Vandaar dat er in hoofdstuk 7 
onderzocht is of de expressie van hypoxie eiwitten in CRC geassocieerd is met 
promoter CpG-eiland methylering van genen die een rol spelen in belangrijke 
kanker gerelateerde processen waaronder: MGMT, CHFR, HLTF, MLH1, 
RASSF1A (genoom instabiliteit), p14ARF, p16INK4A (ongelimiteerde 
celdeling), ADAM23, TFPI2 (invasieve groei en metastasering), APC 
(ongevoeligheid voor groeiremmende signalen), SOCS1 (zelfvoorzienend in 
groeifactoren), THBS1 (onbeperkte angiogenese), en BNIP3, NEURL, RUNX3, 
RAB32 (voorkomen van apoptose). Onze resultaten toonden aan dat niet de 
expressie van hypoxie eiwitten in de epitheliale tumorcellen, maar juist in de 
stromale cellen geassocieerd was met promoter CpG-eiland methylering van 
diverse genen die een belangrijke rol spelen in kanker gerelateerde processen. 
Dit onderzoek suggereert dat genmethylering in hypoxische tumoren niet een 
willekeurig proces betreft, maar juist gekenmerkt wordt door methylering van 
specifieke kanker gerelateerde genen, waardoor deze hypoxische tumoren in 
staat zijn zich agressiever te gedragen.  
 
Ten slotte is in hoofdstuk 8 onderzocht of tumorcel dood en hieraan 
gerelateerde (epi-)genetische afwijkingen in de epitheliale tumorcellen, 
geassocieerd zijn met de geobserveerde slechtere overleving van CRC 
patiënten met expressie van hypoxie eiwitten in stromale cellen. Hiervoor werd 
er in epitheliale tumorcellen gekeken naar afwijkingen in apoptose regulerende 
genen zoals TP53 en BNIP3 , en onderzocht of deze gen afwijkingen 
gecorreleerd waren met de slechtere overleving van CRC patiënten met 
stromale expressie van hypoxie eiwitten HIF-2α en CA9. Uit dit onderzoek 
bleek dat de geobserveerde slechtere prognose van CRC patiënten met 
expressie van HIF-2α in stromale cellen, gecorreleerd was met wild-type TP53 
en onafhankelijk van de methylerings status van BNIP3. Kennelijk draagt 
ongemuteerd TP53 ertoe bij, dat tumoren met stromale expressie van hypoxie 
eiwitten progressie laten zien, in tegenstelling tot tumoren met expressie van 
hypoxie eiwitten in de epitheliale tumorcellen. Verder bleek dat een behouden 
functie van het BNIP3 gen resulteerde in minder apoptose, en dus mogelijk 
betrokken is bij een alternatief tumorcel dood mechanisme, zoals ‘autofagie’ 
gereguleerde tumorcel dood. Onze studie laat zien dat de biologie van CRC 
cellen gemodificeerd wordt door hypoxie in het tumor geassocieerde micro-
milieu. 
 
Concluderend leveren de resultaten van dit proefschrift nieuwe inzichten in de 
ontstaanswijze van colorectale tumoren. Men kan op basis van 
(epi-)genetische afwijkingen zoals CIMP, TP53 mutaties en microsatelliet 
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instabiliteit, CRCs onderverdelen in aparte subgroepen, waarbij individuele epi-
genetische merkers zoals CHFR methylering, een onafhankelijke en 
gevalideerde prognostische merker bleken te zijn. Naast DNA promotor 
methylering van individuele genen, was de expressie van hypoxie eiwitten HIF-
2α en CA9 in stromale cellen gerelateerd aan een slechtere overleving van 
CRC patiënten en aan methylering van specifieke kanker gerelateerde genen. 
Toekomstige studies zullen de betrokken celbiologische processen moeten 
ophelderen en het potentiële belang van epigenetische merkers voor het 
bepalen van de therapie in CRC patiënten moeten aantonen. 
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Dankwoord 
Het dankwoord is het meest frequent gelezen hoofdstuk van een proefschrift. 
Gek genoeg bedankt de gemiddelde promovendus in dit dankwoord zijn 
vrienden, opa, oma en de buren, en nog net niet zijn cavia of diepzeeschildpad. 
Waarvoor? Hetzelfde principe dat je op je eigen verjaardagsfeest rond rent met 
bitterballen, mosterd en lege flesjes bier voor vrienden, opa, oma en de buren! 
Daarbij komt dat deze vrienden, opa, oma en de buren, je voor gek verklaren 
tijdens je promotie en de wederkerende vraag stellen: “Wanneer is het nu eens 
af?” of deze: “Waarom maak je het niet gewoon af?” of deze: “Loopt alles 
volgens de planning?”  
Dat is een goede in wetenschapsland waar het principe ‘Tomorrow never dies!’ 
zegeviert. Tijdens een promotietraject zit je in een spannende, eeuwig durende 
treinreis op je werk, na je werk, op vakanties, ga zo maar door. Als je wilt, kun 
je ook aan je onderzoek werken tijdens 30 min. fietsen in de fitnessclub. Terwijl 
andere zwetende medeburgers tijdschriften lezen zoals: Privé, Linda en de 
Telegraaf, lukte het mij om gemiddeld 1 artikel uit: JAMA, JNCI, CCR of JCO te 
lezen. Uiteindelijk na al het gefitness zegt de conducteur: “Meneer Cleven, u 
heeft uw bestemming bereikt.” Je stapt na alle hoogtepunten en ontberingen uit 
te trein waarin je jaren hebt gezeten; een tijd waarin relaties werden gewisseld, 
baby’s geboren, banen gewisseld, er vielen zelfs doden! Ik heb nog net geen 
oorlog meegemaakt. Plotseling sta je dus op het pad in de Minderbroedersberg 
4-6, en dat doet me denken aan een scène uit ‘Monty Python and the Holy 
Grail’. Een ridder ligt op een eenzaam zandpad met afgehakte onderste en 
bovenste extremiteiten en schreeuwt vervolgens tegen zijn opponent: ”Come 
on, tis but a scratch- A scratch? Your arm’s off.- I’ve had worse, come here I’ll 
bite your legs off!” 
  
Na deze korte introductie m.b.t. het promotietraject, moet ik toegeven dat onze 
volksheld Lee Towers gelijk heeft met zijn lied vanaf de Rotterdamse haven 
‘You never walk alone!’.  
Vol enthousiasme en een hoop wetenschappelijke bagage, dacht ik, startte ik 
aan een nieuw onderzoeksproject met als doel uiteindelijk te promoveren. Ik 
klopte aan bij mijn promotor prof. dr. Adriaan de Bruїne.  
Beste Adriaan, hoe kan ik nu in godsnaam formuleren wat jouw rol is geweest 
in het tot stand komen van dit proefschrift? Aangezien god niet bestaat, zal ik 
proberen het chronologisch in verhaalvorm uit te leggen.  
Na ons eerste gesprek op de afdeling, nam je mij op sleeptouw in de 
wetenschappelijke wereld van de afdeling pathologie te Maastricht. Bij het 
eerste onderzoeksvoorstel dat ik schreef, kan ik mij nog herinneren dat je zei: 
“The sky is the limit meneer Cleven”.  
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Na een jaar in vitro werk met cellijnen onder hypoxische omstandigheden, 
zonder bruikbare resultaten, bleek er inderdaad een ‘sky’ te zijn. Jij maakte 
snel de beslissing om het onderzoek te concentreren op in vivo werk in een 
serie van dikke darm tumoren dat uiteindelijk geresulteerd heeft in het huidige 
proefschrift. Tijdens deze lange periode nam je mij mee naar verschillende 
congressen waarbij ik nieuwe onderzoeksdata mocht presenteren. Naast het 
leerzame aspect hiervan, was het altijd ontzettend gezellig: je regelde leuke 
hotels, heerlijke etentjes en minstens een ‘City-tour’ per vreemde stad. Deze 
gezelligheid resulteerde in de beruchte: ‘The flying burito with a  lot of sour 
cream’ op het nieuwe driedelig pak van een perifere patholoog in Brighton; tot 
de bratwurst met curry om zes uur ‘s ochtends in hartje Berlijn. We waren om 
vier uur vertrokken vanuit Maastricht en eenmaal aangekomen in Berlijn 
hadden we geen muntgeld voor een treinkaartje. Het kopen van een bratwurst 
resulteerde in muntgeld, maar je was volgens mij blij en ik overigens ook, nadat 
de bratwurst met curry om zes uur in de ochtend in de prullenbak belandde.  
Naast het leren om belangrijke details te signaleren uit een wereld van 
resultaten, heb ik door jou geleerd snel te lezen, met behulp van het boek 
‘gebruik je hersenen’. Dit boek lag op een ochtend op de bijrijderstoel in onze 
carpool sessie naar Venlo. Een stille hint! 
Af en toe was ik ongeduldig, ik vuurde dan simpelweg een kruisraket met 
kernkop af. Bij de aanblik van dit projectiel aan de horizon, brommelde jij je tot 
een kolonel in het kaliber van ‘Apocalypse now’ William Kilgore: “Charlie don’t 
surf, but I love the smell of napalm in the morning”. Het resultaat was, dat de 
kernkop terugkwam op mijn eigen grondgebied en vervolgens ontplofte. Dat 
was verhelderend, aangezien ik na zo’n Hiroshima momentje, weer door de 
weinige bomen het bos kon zien! 
Adriaan, ik denk dat ik mijn achternaam ‘Cleven’ waar heb gemaakt!  
Jij bent de grondlegger van dit boekje en ik wil je bedanken, niet alleen voor de 
goede en langdurige begeleiding, maar ook voor de inhoudelijke vrijheid die je 
mij gegeven hebt en de ontzettend gezellige tijd die hiermee gepaard ging.    
 
Voor mijn promotietraject had ik mijn hobo al lang ingewisseld voor een stevige 
elektrische gitaar met versterker. Dit heeft mijn promotor prof. dr. Manon van 
Engeland vaak moeten ervaren.  
Beste Manon, laat me beginnen te zeggen dat het niet raar is dat wij elkaar nog 
ontmoet hebben in de prachtige wereld van de wetenschap. Jaren geleden 
mocht ik, als broertje samen met mijn vader mijn zus en haar 
discovriendinnetje ’s avonds met de auto ophalen. Jij bevond je ook onder 
deze discovriendinnetjes. Op de terugweg naar city Susteren zagen alle 
inzittenden rondom middernacht een schotelvormig object met rode lampen in 
een verlaten Susters weiland. We dachten allemaal dan nu eindelijk een UFO 
gespot te hebben in de achtertuin van de Hommele Hei. Slechts één 
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discovriendinnetje trok deze hypothese in twijfel en ging op onderzoek uit. Bij 
thuiskomst volgde er een telefoontje: “Ja, hier met Manon. Neen, het is geen 
UFO maar een bietenwagen van een boer die daar zo stond te blinken.” Jaren 
later kwam ik je weer tegen in het onderzoekslaboratorium waar jij leiding 
geeft. Ideeën en plannen waren er genoeg, maar wat zonder onderzoeksgeld? 
Manon, jij hebt meerdere bietenwagens vol met euro’s in mijn onderzoek 
gepompt. De reagentia, een analist, high throughput sequencing; zonder jouw 
investering had er geen letter geschreven kunnen worden. Je hebt me alle do’s 
en dont’s uitgelegd in de wereld van de epigenetica, het stappenplan bij het 
schrijven van een helder hoofdstuk en als vrouw heb je mij ook weten te 
overtuigen dat een lay-out essentieel is. Terugkomend op de gitaar, Jimi 
Hendrix introduceerde zichzelf tijdens zijn eerste concert in Europa met het 
doormidden breken van zijn gitaar en het vervolgens in brand steken van zijn 
schitterend solo-instrument. Dit soort sessies hield ik af en toe ook in jouw 
Headquarter. Je keek ernaar, je luisterde ernaar en met een symbolische 
emmer koud water bluste je het vuurtje, waardoor ik onbeschadigd verder kon 
gaan met mijn wetenschappelijke carrière. Manon, bedankt voor alles. 
 
Een lotgenoot! Net zo goed als moeder Theresa de lotgenoot is van Gandhi, 
had ik tijdens mijn promotietraject ook een lotgenoot.  
Beste dr. Sarah Derks, mijn co-promotor. Sarah, wat ik bedoel met lotgenoot is 
dat het prettig was te weten dat ik niet de enige idioot was die op een vrije dag 
een agarose gel stond op te dweilen. Dit nadat deze omslachtig voorbereide 
gel had besloten na de eerste sequence run, de polonaise te nemen tussen de 
glasplaten door tot op de grond; terwijl ander vrije collega’s verkleed de 
polonaise liepen op het Vrijthof. Beiden waren we zeer kritisch naar elkaar toe, 
wat vaak verhitte discussies opleverden die meestal eindigden met: “Ja, ik 
begrijp wat je bedoelt, maar ik heb gelijk!” Daarnaast konden we als buren 
samen goed dineren, met Joep en mij als wijn- en whiskydeskundigen: 
prachtige tijden! 
Laat me eindigen te zeggen dat er meer artsen zouden moeten zijn zoals jij, 
die hun wetenschappelijke ideeën zo plannen, dat ze een klinisch toepasbare 
relevantie hebben. Ik ga ervan uit dat ik op de hoogte blijf van je carrière en 
eventueel een Tweede Kamerdebat met je voer! Sarah, bedankt voor de hulp 
en het fantastische stuk over CHFR.  
 
Het lab: Ingrid, bedankt voor het uitleggen van de IHC en cellijn basisprincipes, 
jij hebt mij mijn eerste labboek gegeven, dat ik kon vullen met allerlei 
experimenten. De Mark en de Mork, bedankt Margriet en Leentje voor het 
openstellen van jullie IHC faciliteiten. De eerste TP53 en APC   
mutatieanalyses, ga zo maar door, een DNA vrije kamer, soep en de 
ingrediënten. Bedankt Guido, Andrea en Angela. Rik, de verloren zoon, 
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bedankt voor de HIF-1-alpha oplossing, de pH-waarde van de wasbuffer was 
zeer essentieel! Peter en Joep, bedankt voor jullie mannelijkheid! 
Charlies Angels: Sandra, Kim en Kathleen, mega bedankt voor al die primer 
sequencies, epjes vol met reagentia, pipetpunten en pipetten. Onderzoek is 
onmogelijk zonder jullie voortdurende back-up!  
Beste Angela, je hebt veel werk uit mijn handen weggenomen en je hebt me 
uitgelegd wat een logische sample codering is. Ik heb je uitgelegd waar “Der, 
Die, Das Party-zone is in Maastricht”, en welke mannelijke tube “Der, Der, Der 
Falsche ist!”  
Andere lotgenoten: Veerle, Ingrid, Iris, Femke, Coen, Kim (Survival of the 
Fittest) en Debbie. We zijn allemaal goed terecht gekomen, maar Debbie de 
meeste dromen zijn bedrog! 
 
Nu aangekomen bij een ander lotgenoot, paranimf en patho-collega: Marjolein 
Lentjes-Beer. Beste Marjolein, wat heb ik vaak met jou kunnen lachen op de 
wetenschapskamer. We hadden op vrijdagmiddag ons verdiende you-tube 
halfuurtje: “Hi my name is Veronique, but recently I changed my name in 
REFLEX, REFLEX, I like to put the tip of my tong into your earhole, you sick 
b….”, Gunter. En nu op zijn Duits! 
Over patho-land gesproken, daar zal ik zeer zeker een aantal zwaargewichten 
van moeten bedanken. Collega arts, u bent gewaarschuwd: zodra er tegen u 
gezegd wordt dat uw proefschrift klaar moet zijn voordat de opleiding begint, is 
het al te laat! Vergelijk het met het medisch anticipatie krediet van de ABN-
AMRO na het behalen van uw propedeusediploma! 
Het geweldige team uit Venlo, ik kon bij jullie een half jaar van mijn perifere 
stage lopen. Naast het leren van het vak op zijn pragmatisch en degelijk 
perifeers, gaven jullie meteen aan dat er tijd was voor onderzoek. De 
dieselmotor van Venlo, ook wel Siep Wouda genaamd, hield in zijn eentje de 
fabriek in Venlo draaiende terwijl Adriaan en ik in een afgesloten kamer zonder 
telefoontjes van de kliniek, werkten aan een wetenschappelijk hoogtepunt. Jij 
beste Siep, kwam om half vijf met je jas aan polsen hoe het was in 
wetenschapsland, 80 coupes lichter en 2 obducties rijker verliet je tevreden het 
pand! Bedankt voor de tijd die jij letterlijk voor mij en Adriaan creëerde. Dat 
geldt tevens voor het andere teamlid uit Venlo, Ariënne van Marion. Ariënne, 
bedankt voor de uitleg over het beenmerg, de kleine lymfkliercelletjes en de 
fles Champagne. Tja, ik zal hem zelf moeten betalen, hopelijk kom je naar de 
Domkeller in Aken, dan toosten we samen! 
 
Het kloppende team uit Heerlen, een heel jaar lang onder de hoede van jullie 
deskundigheid! Jullie hebben mij onder de loep genomen en flink bijgeschaafd 
wat mijn vorming tot patholoog heeft bespoedigd. Ongelooflijk wat ik bij jullie 
allemaal heb kunnen leren! Het stellen van de diagnose folliculair lymfoom 
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zonder immuno’s (Paul Theunissen), “een microscoop is ouderwets”, “dicteer 
wat je ziet en concludeer ondubbelzinnig” (Marius Nap). Ik begrijp alle 
afkortingen in de gynaecologiewereld: CIN, VIN, VAIN, EIN, CGIN (Nathalie 
Vandevijver). En ja, ik weet dat Bier belangrijk is, dat de kassa rinkelt na een 
send rapport en wat het verschil is tussen boven en onder, voor en achter, als 
je op de aardbol van de prostaat staat (Ruud Clarijs). Jullie alle vier, enorm 
bedankt voor de goede opleiding in de baas zijn tijd, wat dus inhield dat ik mijn 
boekje in de weekenden en avonduren eindelijk eens kon gaan afschrijven! 
 
Het grootste team uit Maastricht: de assistenten (van Mitch, Lance, Branda tot 
mister en misses Lover Lover) en stafleden, ik bedank jullie, als jullie samen 
met mij feesten op 1 juni in de Domkeller! Laten we er een feestje van bouwen, 
dan kunnen we op maandag weer soepel de weefsels snijden met een mes 
zonder mes! 
 
De stafdames en assistenten van divisie drie, vier en nog meer? Bedankt voor 
the Holiday!  
 
Het management: Cor, Elly, Audrey en Tiny Wouters, bedankt voor het werk 
achter de schermen. Het hele secretariaat, bedankt! 
 
De opleider: dr. Ann Driessen, beste Ann, bedankt voor de soepele planning 
van de wetenschap in mijn eerste jaar en de soepele planning rondom 1 juni! 
 
Prof. dr. Fré Bosman, U heeft nagenoeg mijn hele proefschrift gereviewed en 
voorzien van praktische tips, enorm bedankt voor dit alles! 
 
Prof. dr. Mat Daemen, ik kreeg een ‘go’ op mijn ‘no go-gesprek’ en de ware, 
dankbare tip: “Blijf realistisch in je doelstellingen en behoud in alles wat je doet 
plezier!” 
 
Talking about ‘Pulp Fiction’, It’s been a while prof. dr. Brad Wouters, many 
thanks for our productive collaboration! 
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Thanks for editing this chapter mister Granda: “In love there are no buts!” 
 
Het ‘bystander-effect’, ja, schwessie Anouk, daar weet jij alles van als 
afgestudeerd psychologe werkzaam in Brazilië samen met je lieve man Markie 
Mark! Geweldig dat we deze dag samen gaan vieren. 
 
Lieve Mutti, ik weet dat je trots bent op mij, ik ben ook trots op jou en laten we 
genieten van alle goede dingen die het leven ons te bieden heeft. Bedankt voor 
de spellingscontrole en de op lange termijn zo belangrijke, elementaire sturing 
die je mij in mijn leven gaf als onwetende, middelbare scholier puber!  
 
Mijn spudselhaze, lieve, lieve Annette. Bij onze eerste treffen in Berlijn, 
verkondigde ik nonchalant dat ik zo goed als klaar was met promoveren. Dat 
was in 2008! Jij bent de enige die mij nooit gevraagd heeft wanneer het nu 
eens af was. Je regelde een super appartement in Lissabon, waar ik niet alleen 
kon werken, maar waar we tegelijkertijd konden genieten van een vakantie. Je 
faciliteerde vaak genoeg een continue werkomgeving in het vliegtuig, uit het 
vliegtuig, in de trein, uit de trein, in de stationhal, uit de stationhal; en dit met 
behulp van meerdere laptops, USB-sticks en een hoop koffie en lekker eten. 
Ja, ook ik verheug me enorm op de komende vakantie, welteverstaan zonder 
PhD laptop! Tenslotte, Bono zingt voor jou: “A woman needs a man like a fish 
needs a bicycle, but a man needs a woman!” 
 
Arjen Cleven 
Aachen, maart 2012                         
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Curriculum vitae 
Arjen Cleven was born in Rinteln in Germany on January 13th, 1977. After 
completing Athenaeum at the Serviam Lyceum in Sittard in 1997, he started 
studying Biological Health Sciences (1997) and Medicine (2000). He performed 
research for his master thesis at the department of General Practise, 
Epidemiology and Statistics at Maastricht University under supervision of Dr. 
H.E.J.H. Stoffers. In 2002 he received his master degree in Biological Health 
Sciences on the topic: Prediction of the outcome of peripheral arterial disease 
using the ankle-brachial pressure index. After his graduation in 2002 he started 
as a research assistant in the cancer pathology laboratory of Prof. dr. M. van 
Engeland and Prof. dr. A.P. de Bruїne at the department of Pathology of 
Maastricht University Medical Center. In 2003 he continued his research and 
started his Ph.D. program by studying the prognostic implications of hypoxia 
and promoter CpG island methylation in colorectal cancer, which resulted in 
this dissertation.  
In 2006 he completed Medical School and in 2008 he started his residency 
training Pathology at the Maastricht University Medical Center, Maastricht. 
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